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ABSTRACT 
Human embryonic stem (hES) cells have great therapeutic potential for the 
treatment of degenerative conditions such as Parkinson's disease, cardiac failure and 
type I diabetes. This potential is based on the ability of hES cells in vitro to self-renew 
and also differentiate to cells of all three germ layers; ectoderm, mesoderm and 
endoderm. Type I diabetes is due to an autoimmune disease destroying the insulin- 
a, secreting cells of the pancreas (P-cells) that regulate plasma glucose concentration. The 
pancreas develops from the endoderm lineage. To find a cure for type I diabetes based 
on the use of hES, it is essential to understand the differentiation process of ES cells 
into the endodermal, P-cell lineage. The aim of this study was to investigate the 
generation of insulin-secreting cells using hES cells in vitro and to compare such cells 
with those in the developing pancreas of the foetus. 
The differentiation of hES cells was induced by their aggregation in culture to 
form embryoid bodies (EBs) using various combinations of growth factors. Peptide (C- 
peptide, insulin) and protein expression markers of cells were analysed by 
histochernical (dithizone stain) immunolocalisation, and immunosorbent assay (ELISA). 
mRNA expression (RT-PCR) was used to confirm the expression of some early and 
mature P-cells markers including Pancreatic duodenal homeobox 1 (PDX-1), 
Neurogenin 3 (NEUROG 3; NGN3), Glucokinase (GCK, GK), Glucose Transporter 
(GLUT) I and 2 (SLC2,41 and SLC2.42) and insulin (IDDM2). Comparisons were made 
with pancreas recovered from human foetus between 8- 12 weeks gestation and 
subjected to immunolocalisation and proteornic analysis. 
The number of cells expressing markers of insulin-secreting cells in EB colonies 
varied with different growth factor/s combinations. Medium supplemented with 
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nicotinamide and activin A was the most successful in generating P-cell-like cells. 
However, EBs failed to secrete the pro-insulin peptide, C-peptide, in culture. 
Immunocytochemistry of foetal pancreas indicated that islet P-cell development 
initiated at about week 10 of gestation and that consistent C-peptide secretion measured 
by ELISA was apparent in cells recovered from week 12 fbetuses and cultured in vitro. 
The protein profile of the pancreas from week 10 and 12 foetuses revealed significant 
differences by proteomic analysis. 
I conclude that in vitro culture processes of hES cells need to be further 
improved to achieve a higher efficiency and a full differentiation towards insulin- 
secreting cells that mimic those of foetal or mature islet P-cells. 
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Chapter I 
INTRODUCTION 
1. Diabetes 
Introduction 
Carbohydrates are broken down to sugars and absorbed during digestion 
and when this sugar (mainly glucose) enters the bloodstream it can provide the 
body with energy for metabolic processes. Excess amount of glucose, which is not 
needed, is stored short-term in the liver or for long-term as fat deposits. Levels of 
sugar in the bloodstream are closely regulated by the hormone insulin, which is 
produced by the pancreas (Edlund, 2001; Ono, 2006). Insulin is synthesized and 
secreted by the P-cells, which reside in the pancreatic islet; the functional unit of 
specialized endocrine cells (Edlund, 200 1; Peck et al, 2004; Gabrielle et al, 2005). 
Diabetes is a chronic disease characterised by abnormally high levels 
(hyperglycemia) of glucose in the bloodstream (Baertschiger et al, 2006; Yang et 
al, 2006). Excessive amounts of free glucose can cause blindness, kidney failure, 
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heart disease, stroke, neuropathy and amputations (Efrat, 2002; Baertschiger et al, 
2006; Yang et al, 2006). 
There are two types of diabetes, type 1, insulin-dependent, and type II, 
non-insulin dependent (Docherty, 2001; Edlund, 2001). Type I diabetes is 
characterised by loss of 0-cells of the pancreas, generally as a result of an 
autoimmune reaction. That is, the body's own immune system destroys 90% or 
more of islet cells (in which P-cells reside) of the pancreas by attacking them as 
foreign bodies (Docherty, 2001; Peck et al, 2004; Trucco, 2006). In the absence of 
insulin, glucose accumulates in the blood creating the condition known as type I 
diabetes and patients must have regular insulin injections to control blood glucose. 
This condition is also referred to as juvenile diabetes as the disease often strikes 
the young (Efrat 2002; Peck et al, 2004). Although the exact cause of type I 
diabetes is not known, it is thought that genetic and environmental factors (e. g. 
viral infection, vitamin D levels) are involved. Recently, large-scale genetic fine 
mapping and genotype-phenotype associations implicated polymorphism in the 
interleukin 2 receptor alpha gene (IMA) as being important in whether 
individual developed type I diabetes (Lowe et al, 2007) 
Type 11, or adult-onset diabetes is the most common form of diabetes and 
occurs when the body either cannot use the insulin effectively because of the 
dysfunction of P-cells resulting in an inability to produce and secrete sufficient 
amounts of active insulin (Docherty, 2001; Edlund, 2001), or the cells of the body 
do not use insulin properly; 'insulin resistance'. In this case, more insulin than 
usual is required to keep the blood glucose levels at non-nal levels. Type 11 
diabetic patients can usually control their blood glucose levels by regular diets, 
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exercises and oral medication. In type 11 diabetics the P-cells of the pancreas 
remain present in large numbers. 
Binding of insulin to its specific receptor on the cell membrane, leads to 
the activation of the receptor and a phosphorylation of intracellular signaling 
pathways, which activate glucose absorption and utilization by the cell. Most cells 
have the insulin receptors on their cell membranes and are termed insulin- 
dependent. But some cells such as brain cells, kidneys cells, cells lining the 
digestive tract and red blood cells lack insulin receptors and are insulin- 
independent. These cells can absorb and utilize glucose without insulin 
stimulation (Rhodes et al, 1994; Dodson et al, 1998). 
2. Islet Transplantation 
Transplantation of whole pancreas or pancreatic islets is used as a 
fundamental treatment for type I diabetic patients by replacing the cells lost by 
disease. A pancreas transplant is surgery to implant a healthy pancreas from a 
donor into a patient thereby giving this person the chance to become independent 
(or less dependent) of insulin injections. However pancreas transplant is only 
offered to people who have severe diabetes due to the risks attached to the 
procedure. Since severe type I diabetes is often associated with chronic renal 
(kidney) failure, a person who needs a pancreas transplant also might need a 
kidney transplant. Therefore, three kinds of pancreas transplant operations are 
undertaken. These are (1) a combined kidney-pancreas transplant; (2) "pancreas 
after kidney" transplant, in which the pancreas is transplanted some time after a 
kidney has been transplanted; (3) pancreas transplant alone, for patients with 
functioning kidney (Peck et al, 2004; Pileggi et al, 2004; Ono, 2006; Urban et al, 
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2006). The first attempted transplant of both kidney and pancreas was carried out 
in 1967 by Kelly and her colleagues (Kelly et al, 1967 Hayek et al, 1997). Over 
the recent years, long-term success has improved and risks have decreased. One 
year after transplantation more than 95% of all patients are still alive and 80-85% 
of all pancreases are still functional. However, besides the surgical risks, there are 
other potential complications and transplantation patients need lifelong 
immunosuppression which increases the chances of acquiring various infections 
and cancer. The biggest restriction to the use of pancreas transplantation is the 
lack of suitable immune (histocompatibility) matched donors. 
Sachs and Bonner-Weir considered that transplantation of pancreas as a 
single organ is complicated, and more effort was needed to find alternatives to 
insulin injections (Sachs et al, 2000). A more experimental treatment was 
therefore introduced which is the transplantation of purified pancreatic islets 
rather than the whole pancreas organ. This procedure reduces the need for the 
long and complicated surgery. The first successful islet transplantation was 
performed in 2000 by Shapiro and his colleagues for type I diabetic patients 
(Hayek et al, 1997; Amiel, 2001; Mathieu, 2001; Shapiro et al, 2006). Shapiro's 
group at the University of Alberta in Edmonton, Canada, have continued to use 
and refine the procedure called the Edmonton Protocol although there are still 
considerable problems with the technique. 
In islets transplantation, the islets are isolated from the donor pancreas by 
using protease and collagenase enzymes. Because islets are fragile and cannot be 
preserved, transplantation must occur soon after they are removed. Usually a 
patient receives at least 10,000 islet "equivalents" per kilogram of body weight, 
extracted from two donor pancreases. Patients often require two transplants to 
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achieve insulin independence. The transplant of cells is often performed by a 
radiologist, who uses X-rays and ultrasound to guide a catheter (small plastic 
tube) through the upper abdomen and into the portal vein of the liver. The islets 
are then infused slowly through the catheter into the liver (Figure 1) (Hayek et al, 
1997; Sachs et al, 2000; Mathieu, 2001; Shapiro et al, 2006). Some studies on 
mice, by Hayek and Beattie in 1997, showed that fetal endocrine islet-like cells if 
compared to adult islets are richer in generating insulin-producing cells (Hayek et 
al, 1997). After transplantation of adult islets, some P-cells were selectively lost 
but the reason for this is not clear (Hayek et al, 1997; Miszta-Lane et al, 2006). 
The limited supply and low yield of islets from donor's pancreas prevents 
the wide-sprcad use of islet transplantation therapy (Ackermarm et al, 2007) at 
present. In 2005, a 5-year follow-up of results for 65 patients who received 
transplants indicated that only about 10% of the patients remained free of the need 
for insulin injections. Most recipients returned to using insulin because the 
transplanted islets lost their ability to function over time. The researchers noted, 
however, that many transplant recipients were able to reduce their need for insulin 
and achieve better glucose stability. Like pancreas transplantation, patients require 
life long immunosuppression and therefore the procedure is not suitable for young 
patients. However, islet transplantation indicated that if alternative sources of 
insulin-producing cells could be generated then this approach might be a practical 
method of treatment for diabetic patients as the cell infusion was relatively simple. 
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Figure IA diagram illustrating the principles of the islet transplantation 
process; the Edmonton Protocol. islets are recovered and purified 
from one or two pancreases and then infused into recipient patient 
via the portal vein where the cells embed in liver (after Shapiro el 
al, 2001 ). 
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3. Embryonic Stem Cells 
introduction 
One can define a stem cell as a special kind of cell, from the embryo, 
foetus or adult, that has the ability to proliferate, renew itself, and differentiate to 
give rise to specialised cell types that make up the tissues and organs of the body 
(Donovan et al, 2001; LO et al, 2007). Stem cells can be divided into two main 
categories: adult or somatic stem cells and embryonic stem cells. 
Embryonic stem (ES) cells were first derived from the pluripotent inner 
cell mass, ICM, of the pre-implantation blastocyst stage of the early embryo, and 
were shown to be capable of unlimited and undifferentiated proliferation and 
initially maintained a stable diploid and normal karyotype in vitro (Thomson et al, 
1998; Pera et al, 2000; Donovan et al, 2001; Amit et al, 2002; Gepstein, 2002). 
In 1981, Evans and Kaufman isolated the first embryonic stem cell lines 
from the mouse blastocyst. At the same time, but independently, the same work 
was done by Martin and her colleagues (Evans et al, 1981; Martin, 1981). When 
ES cells were injected into blastocysts, which were then implanted in foster mice, 
the tissues of the offspring had some of the genetic composition of the ES cells 
(chimeric animals) indicating that the ES cells were pluripotent. ES cells therefore 
differ from all other types of cells in that they have the ability to retain their 
potential to generate derivatives of all the three germ layers, endoderm, mesoderm 
and ectoderrn, and proliferate without differentiation in culture under appropriate 
conditions (Pera et al, 2000; Amit et al, 2002; Gepstein, 2002; UI et al, 2007). 
Mouse ES cells were shown to differentiate, in vitro, into a variety of cell 
types including cardiomyocytes, skeletal and smooth muscle cells, neural and glial 
cells, hernatopoietic progenitor cells, adipocytes, endothelial cells, pancreatic cells 
(P-cells) and several other tissue types (Gepstein, 2002). However, the cells 
7 
Chapter I Introduction 
remained undifferentiated in vitro if they were grown with leukaemia inhibitory 
factor, LIF, or if they were seeded on an inactivated feeder layer of cells of 
embryonic fibroblasts (Roche et al, 2005). A study was done by Williams and 
colleagues that demonstrated the importance of leukemia inhibitory factor, a 
member of the interleukin-6 related family of cytokines, in the maintenance of 
mouse ES cells from differentiation, in vivo and in vitro without the need of feeder 
cells (Williams et al, 1988). 
Isolation of ES cells from the primate, thesus and marmoset monkeys, 
were reported in 1995 by Thomson and coworkers where these cells remained 
undifferentiated in continuous passage for more than one year, and maintained 
their morphology, normal karyotype and expression of specific cell surface 
markers (Thomson et al, 1995; Reubinoff et al, 2000). 
The first human embryonic stem (hES) cell lines were derived in 1998 
(Thomson et al, 1998). In the human embryo, a hollow sphere of cells is formed 
4-6 days after fertilization. This blastocyst, contains an outer cell layer and an 
inner cluster of cells which is known as the inner cell mass, ICM (Gepstein, 
2002). The outer cell layer, the trophectoderm, forms part of the placenta and 
other supporting tissues, while the ICM creates all tissues of the developing foetus 
as well as foetal sacs. If the ICM is placed in culture then these cells can change 
their characteristic to become ES cells with indefinite self-renewal. In culture, it 
was found that hES cells like mouse ES cells required a feeder layer, to maintain 
the cells in an undifferentiated phenotype (Draper et al, 2003). On the other hand, 
experiments indicated that undifferentiated hES cells could not be maintained by 
LIF alone (Thomson et al, 1998). Xu and colleagues indicated that there were 
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undefined soluble factors released from the feeder layer which were important in 
maintaining an undifferentiated hES cell (Xu et al, 2003). 
The similarities between human and rhesus ES cells, has allowed rhesus 
ES cells to provide an accurate model for developing strategies to prevent immune 
rejection of transplanted cells and for demonstrating the safety of ES cell- based 
therapies (Thomson et al, 1998; Furuya et al, 2003). 
Since undifferentiated ES cells can be differentiated in vitro and in vivo to 
a specific cell lineage of ectoderm, mesoderm or endoderm potentially any disease 
resulting from the failure of specific cell types can be treated through the 
transplantation of differentiated cells derived from ES cells (Thomson et al, 1995; 
Meivar-Levy et al, 2006; Urban et al, 2006). Moreover, hES cells can be used for 
new drugs tests, such as in new medications tests, or for screening anti-tumor 
drugs for cancer (Meivar-Levy et al, 2006; Urban et al, 2006). The disadvantages 
of using ES cells for transplant therapy include tumors formation as 
undifferentiated ES cells are mitotically active and may result in the formation of 
teratomas (Draper et al, 2002). Also as hES cells produced from a blastocyst will 
not match the genetic composition of the patient a transplant with these cells will 
be rejected by the immune system unless immunosupression is used (Draper et al, 
2002; Ono, 2006). To avoid immune rejection, derivation of the patient ES cell 
line by the use of somatic nuclear transfer technology has been suggested 
(Donovan et al, 200 1; Gepstein, 2002). 
In culture ES cells can form cluster of cells called an embryoid body (EB) 
which can then develop with differentiated cell types. The selection of a specific 
cell type from the mixed population of cells in an EB is important to have a 
relatively homogenous, pure, cell population (Gepstein, 2002; Calafiore et al, 
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2006). To do so, a tissue specific promoter can be utilized to derive a selectable 
marker as was used by Klug and coworkers (Klug et al, 1996) to obtain 
cardiomyocyte. An appropriate antibiotic and selection process of in vitro 
differentiated ES cells carrying a fusion gene resulted in 99% purity of cultured 
cardiomyocytes (Klug et al, 1996). A similar strategy was used to produce 
purified cultures of neurons and insulin secreting pancreatic P-cells that derived 
from murine ES cells (Gepstein, 2002). 
ES cells can be used as a source of insulin-producing donor cells in type I 
diabetes cell therapy (Jiang et al, 2007). Derivation of insulin- producing cells 
from mouse ES cells was performed in 2000 by Soria's group (Soria et al, 2000). 
They used a simple genetic approach to generate insulin-producing cells, that 
normalizes blood glucose when transplanted into streptozotocin (STZ)-induced 
diabetic mice, which are able to maintain a stable glucose in vivo. Lumelsky, 
2001, reported the successful differentiation of mouse ES cells into insulin- 
secreting structures, with similar topology and function as the pancreatic islets, by 
using an ES cell-based system (Lumelsky et al, 2001). 
The derivation of human ES cells which differentiated into insulin- 
secreting cells, via EBs formation, was first performed by Assady and his 
colleagues in 2001 (Assady et al, 2001). They used undifferentiated hES cells to 
produce cells with the characterization of insulin producing P-cells (Assady et al, 
2001). 
Different researchers have tested different ways to produce P-cells from 
ES cells to be used for the transplantation purposes. The importance of the 
differentiation process of P-cells in vitro is summarized in the sensitivity of the 
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cells to the blood glucose and the quality and quantity of the insulin secreted from 
them (Ackermann et al, 2007). 
Embryonic genn (EG) cells are another pluripotent type that have the 
ability to proliferate and differentiate to multiple types of somatic cells derived 
from all the three embryonic germ layers (Shamblott et al, 1998; Clark et al, 
2007). These cells derived from primordial germ cells in the genital ridges of the 
developing embryos (Gepstein, 2002; Clark et al, 2007). EG cells, are like ES 
cells, and have the ability to differentiate in vitro to form embryoid bodies 
composed of mature cell types as well as proliferating progenitor cells. The first 
human embryonic germ (hEG) cells were isolated from a 5-10 week embryonic 
gonadal ridges in 1998 (Shamblott et al, 1998; Draper et al, 2002). Recently, 
glucose responsive insulin cells were produced from human embryonic germ (EG) 
cell derivatives (Clark et al, 2007). 
Stem cells are also present in many tissues of adult animals (Donovan et 
al, 2001). Adult stem (AS) cells are undifferentiated cells that are found in a 
specific tissue or organ and have the ability to proliferate and differentiate to 
produce the specific cell types of the tissue that they are derived from; but they 
show limited proliferation in vitro compared to ES cells (Jonathan et al, 2003). 
The main function of AS cells is involved in tissue repair, in which they are 
found, and homeostasis (Donovan et al, 2001). 
Expansion and differentiation of progenitor cells that might be derived 
from adult human pancreas, liver, spleen and bone marrow may help in producing 
insulin-secreting cells which can be used in the replacement therapies for diabetes 
and avoid immunorejection and formation of pluripotent cells (Gao et al, 2007; 
LO et al, 2007). AS cells have been used to generate P-cells. AS cells from old 
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patients are likely to have less potential for differentiation and growth (Winston, 
2001; Meivar-Levy et al, 2006; Urban et al, 2006). The advantage of using AS 
cells in transplantation is their histocompatibility with the donor for 
autotransplantation and this will not cause any rejection problems by the immune 
system (Miszta-Lane et al, 2006). 
However, AS cells are very rare cells and hard to identify and it is not 
clear, to date, if they are present in all organs or only restricted to some specific 
organs. Furthermore, they are few in numbers and difficult to extract and grow in 
laboratory cultures (Williams et al, 1988; Winston, 2001). Some unexpected cells 
in the body were found producing insulin such as fat cells and liver in both (I and 
11) diabetic mice, but the number of cells and the amount of insulin produced were 
very small (Baylor College of Medicine, 2004). 
In addition, some studies showed that insulin-producing cells can be 
generated from the mouse and human ductal cells, which form the tubes that carry 
the digestive enzymes from the pancreas to the duodenum (Bonner-Weir et al, 
2000). However, the number of cells producing insulin in this experiment was too 
small for transplantation therapy in the future (Bonner-Weir el al, 2000). 
Hence, stem cell biology is a new field that holds the promise for mass 
production of pancreatic P-cells if efficient methods can be devised for generating 
functional cells in vitro (Soria, 2001). This requires an understanding of the 
normal development of the human pancreas. 
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4. The Development of Human Pancreas 
4.1 General Anatomy and Morphology 
The pancreas is a gland situated in the upper part of the abdomen, 
posterior to the stomach, and connected to intestine by a fine tube called the bile 
duct (Figure 2) (Grapin-Botton et al, 2001; Fishman et al, 2002). It has two major 
functions. The first is the production of digestive enzymes, which are secreted by 
exocrine acinar cells which make up most of the organ, and the second is in the 
regulation of blood sugar, which is carried out by the endocrine cells of the islets 
of Langerhans (St-Onge et al, 1999; Grapin-Botton et al, 2001; Fishman et al, 
2002; Murtaugh, 2007). Pancreas morphology was first described by Paul 
Langerhans in his thesis in 1869 (see Volk et al, 1985). At that time, the main 
function of the pancreas was not determined but it was suggested that it had a 
close connection with the nervous system (see Volk et al, 1985). The pancreas is 
innervated by sympathetic and parasympathetic fibres, in which the nerves in the 
islets of Langerhans follow the blood vessels and terminate within the 
pericapillary space (Felig et al, 2001). Moreover, the pancreas is composed of 
four different parts. The head which is a disc-shaped structure lying in the 
concavity of the second and third parts of the duodenum. The neck which is 
narrower than the head, connecting between the head and the body. The body 
which is triangular in shape with a flat posterior surface and finally the tail 
(Rogers, 1992). 
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Figure 2A diagram showing the gross morphology of the human pancreas 
and a micrograph histology section of the endocrine and exocrine 
regions (based on diagrams from www. Lil'espan. org). 
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There are two types of secretory cells (Volk et A 1985). About 99% of the 
pancreatic volume consists of clusters of gland cells, pancreatic acini, which are 
connected to the intestine through a highly branched ductal network (Rogers, 
1992). The acinar cells form small lobules adjacent to the ducts (Soria, 2001). 
Both the gland and the duct cells secrete large amounts of digestive enzymes and 
bicarbonate mixture that reaches the lumen of the digestive tract through the 
secretory ducts and bile duct (Volk et al, 1985). The other cell types are endocrine 
cells, which are in the islets of Langerhans, which are scattered through the central 
regions of the organ (Figure 3) (Murtaugh, 2007) between acini lobules. The 
endocrine pancreas regulates the glucose level by production of insulin in the 
blood stream as well as producing other hormones (St-Onge et al, 1999; Soria, 
200 1; Habener et al, 2005). 
4.2 Differentiation and Growth 
The mammalian pancreas controls nutrient resorption and glucose 
metabolism by the various cell types in the islets, the exocrine acinar tissue and 
the ductules (Peter et al, 2000; Ramiya et al, 2000; Habener et al, 2005). 
Although all of the three structures have the same origin they differ in their 
functions (Peter et al, 2000). 
The pancreas develops from the foregut of embryonic endoderm (Peters et 
al, 2000; Gu et al, 2002). During embryogenesis two pancreatic lobes arise as 
thickenings along the dorsal and ventral surfaces of the posterior foregut followed 
by the foregut development in later stage (Gradwohl et al, 2000; Murtaugh, 2007). 
These two lobes evaginate into the surrounding mesenchyme as dense epithelial 
buds, which then expand, branch and differentiate to a fully functional organ 
system prior to birth (Murtaugh, 2007). However, the two buds fuse together to 
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Figure 3A low power section of adult human pancreas tissue showing the 
pancreatic islet of Langerhans surrounded by acinus cells and 
closer to the pancreatic intralobular duct (from www. udel. edu). 
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make a functional organ (Gradwohl et al, 2000; Grapin-Botton et at, 2001; 
Habener et al, 2005). 
In the mouse which has been investigated the most, the pancreas firstly 
appears as an evagination on the dorsal surface of the primitive gut endodenn at 
early cmbryogencsis stage (Figure 4) (Docherty, 2001). Shortly after that, the 
ventral pancreatic bud arises. Rapid growth then takes place where the epithelial 
cells branch forming a network surrounded by mesenchymal tissue. Epithelial 
cells then develop into endocrine, ductal and acinar cells (Docherty, 2001). 
Pancreas development requires signals originating from the notochord and 
pancreatic mesenchyme, where these signals are important in inducing 
proliferation and differentiation of pancreatic epithelial cells into islet cells as well 
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Figure 4 Diagram of early development of mouse pancreas. Definitive 
endoderni cells (at E 12.5 gestation) develop from the primitive gut 
tube to invaginate and then produce pancreatic endoderin at tile 
posterior foregut. Ductal cells start to express P-cell markers and 
migrate into the mesenchyme to then aggregate and form the islets 
of Langerhans at gestational age E13.5 (from Horno-Delarche, 
2004). 
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as determining the ratio of the exocrine and endocrine cells in the pancreas (St- 
Onge et al, 1999; Docherty, 2001; Soria et al, 2001; Habener et al, 2005). 
Exocrine and endocrine cells have the same progenitor (Fishman et al, 2002; 
Murtaugh, 2007). They both originate from ductal cpithelial cells during 
development (Gu et al, 1994; Soria, 2001). However, the proliferation 
morphogenesis and the differentiation of the exocrine pancreatic epithelium are 
stimulated by fibroblast growth factors (FGFs), which are produced by the 
adjacent mesenchyme (Edlund, 1999; Habener et al, 2005; Ackermann et al, 
2007). Follistatin, also found in mesenchyme, promotes the differentiation of 
exocrine cells but reduces the differentiation of endocrine cells (St-Onge et al, 
1999; Peter et al, 2000; Docherty, 2001). 
4.3 Islets of Langerhans 
Islets of Langerhans are considered to be the pancreas endocrine 
functional unit (St-Onge et al, 1999). During development the endocrine cells, 
emerge as small aggregates to forrn about 1% of the total pancreatic tissue, 
migrate from the duct system network into the surrounding mesenchyme and 
aggregate around capillaries to form isolated clusters of cells, known as islets of 
Langerhans, which are scattered throughout the exocrine glandular tissue (Peter et 
al, 2000; Young, 2000; Docherty, 2001; Soria, 2001; Bertuzzi et al, 2006). In the 
human, each islet consists of about 930 cells (Bonner-Weir et al, 2000). 
They are rounded clusters of cells condensed together particularly in the 
tail region of the pancreas (Figure 5; Stevens et al, 1997). Individual cells within 
the islets are smaller, paler than the exocrine cells and spherical in shapes 
(Stevens et al, 1997). Each islet is surrounded by a capillary network that contacts 
with each cell in the islet and carries hormones into the blood stream (Figure 5) 
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Figure 5A diagram showing (A) the islet of Langerhans embedded in the 
exocrine region of the pancreas (B) the proximity of P-eells to blood 
vessels to enable a rapid secretion of insulin (National Institute of 
Health, USA). 
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(Stevens et al, 1997). Thus, the association of the pancreatic tissues with blood 
vessels is probably important for the formation of the insulin secreting cells 
(Fishman et al, 2002). 
Each islet of Langerhans contains five different types of endocrine cells. 
These cells include P-, cc-, 8-, e-cells and pancreatic polypeptide, pp, producing 
cells (Table 1) (Murtaugh, 2007; Docherty, 2001; Gradwohl. et al, 2000; Ord, 
1982). 
P-cells represent the majority of the endocrine cell population (St-Onge et 
al, 1999; Murtaugh, 2007). They form clusters connected by gap-junctions and 
respond to high blood glucose by producing insulin hormone which helps in 
lowering the blood glucose levels by increasing the rate of glucose uptake and 
glycogen synthesis in skeletal muscles and liver (St-Onge et al, 1999; Soria, 
2001). Furthermore, these cells were also found to secrete amylin polypeptide 
hormone which lowering the glucose level in the blood by suppressing glucagon 
secretion and slowing gastric emptying (Singh-Franco et al, 2007). 
a-cells are the next most common cell types. These cells produce glucagon 
which raises the blood glucose levels by increasing the rates of glycogen 
breakdown and glucose release by the liver (Murtaugh, 2007; Singh-Franco et al, 
2007). They are silent at higher glucose concentrations but active when P-cells are 
silent (Soria, 2001). 
B-cells are cells produce somatostatin peptide hormone that suppresses the 
release of glucagon and insulin and slows the rates of food absorption and enzyme 
secretion along the digestive tract (Murtaugh, 2007). Finally, the pancreatic 
polypeptide cells that producing pp hormone which inhibits the gallbladder contr- 
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Table I The different cell types in the endocrine pancreas (Ross cf al. 1995, 
Stevens ef al, 1997, K16ppel ci al, 2001 ý Toshinai ef al, 2006). 
Characteristic cl-cells 11-cells 6-cells IIP-cells 1: -cells 
Features 
Peptide I lornione Glucagion In su Ii [I Somalostatill Pancreatic Ghrelin 
Polypeptide 
Location 
In the III tile islet In the III posterior III the isk 
periphery centre periphery of lobe of centre, 
of tile the islets pancreas, acinar eel 
islets [lead, neck .1n (I (I II c t': 
regions and cpitheliul 
scattered in 
duct wall 
Appearance Uniform I lave Have larger 
in size polyhedral granules 
and have c0 re a 11 (1 than u- & 11- 
dense pale cells 
granules matrix 
compared 
to P-Cells 
Molecular weight 3500 58011) 1500 4200 3314 
Numhcr of'aiiiiiiio 
ac 1d.,, 29 51 14 36 28 
Total olume "o 
in adult 15-20 70-80 5-110 15-25 20 
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actions and regulates the production of some pancreatic enzymes and help in 
controlling the rate of nutrient absorption by the digestive tract (Murtaugh, 2007). 
Recently, c-cells were identified as an endocrine cells found in the islets 
(Murtaugh, 2007). These cells produce ghrelin which is a gastric hormone 
synthesized in the epithelial cells lining the stomach, placenta, kidney, pituitary 
and hypothalamus (Shuto et al, 2001; Lugar et al, 2004; Toshinai et al, 2006; 
Murtaugh, 2007; Rindi et al, 2007). Ghrelin works as a stimulator of the growth 
hormone secretion, food metabolism, suppressor of fat utilization in the adipose 
tissue, stimulate gastric emptying and increase cardiac output (Shuto et al, 2001; 
Lugar et al, 2004; Toshinai et al, 2006; Rindi et al, 2007). 
The distribution of endocrine cells in the islets is nonrandom. However, 
rodent P-cells are found in the core of the islets surrounded by the other three cell 
types a, 8 and pp that containing glucagon, somatostatin and pp hormone 
respectively (Figure 6) (St-Onge et al, 1999). In contrast human and primate islet 
appearance (Brissova et al, 2005). Islets are surrounded by fibroblasts and 
collagen fibres in an incomplete capsule (Felig et al, 2001). 
All endocrine cells are derived independently during ontogeny from the 
foregut endodermal progenitors (Gradwohl et al, 2000; Herrera, 2000). The islets 
O-cells appear to be close to the duct-like structures during embryogenesis which 
indicates that they arise from the pancreatic duct (Edlund, 1999; Bonner-Weir et 
al, 2000). After a few weeks the primordial islets separate from the ducts where 
the non P-cells surround the P-cells. Later, the non P-cells start to extend to the 
centre of the islets forming the postnatal islets (Peter et al, 2000). 
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Figure 6 Distribution of u-cells and P-cells in the human islets of 
Langerhans. (A) glucagon secreting cells, cells stained brown, were 
found to be in the periphery of the islet, where as (B) insulin 
secreting cells, dark red stained, aggregated to the centre of the 
islet. Note capillary bed surrounding islet (University ofMadison, 
Medicine). 
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The final stage of islet formation involves the migration of the endocrine 
progenitor cells out of the endodermal epithelium (Docherty, 2001). After birth 
there is a period during which the neonatal islet undergoes remodeling by P-cell 
replication and apoptosis, to balance the number of P-cells in the islets. Islet cells 
continue their growth to mature after birth, and with growth the islet mass of the 
organism may change according to the demands of the insulin (Docherty, 2001). It 
was found that human P-cells have low replication rate in late foetal and adult 
pancreas (Bonner-Weir et al, 2000). 
Experiments to grow the islets of Langerhans in culture have not been 
successful, (Docherty, 2001). An understanding of the differentiation pathway of 
P-cell in vivo is requiredto increase the number of insulin-secreting cells 
successfully in vitro (Ackermann et al, 2007). 
5. Transcription Factors 
There are many homeodomain transcription factors that control and 
regulate the development of islet cells at different stages in mammals such as, 
Pdx-1, ngn3, IsM, Pax4, Pax6, Neurol), Nkx2.2 and Hlxb9 (Table 2) (Edlund, 
1999; Gradwohl et al, 2000). NeuroD, Nkx2.2, Pax4, Pax6 and lsl-l are often 
referred to as a second group of regulatory genes because ngn3 regulate their 
function (Gradwohl et al, 2000). They are involved in pancreas morphogenesis, 
pancreatic endocrine cell proliferation, survival and differentiation and are found 
to be express during early stages of pancreas development (Edlund, 1999; 
Gradwohl et al, 2000). 
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Table 2 
I III I (OLIC I iý I I) 
Some of the main transcription I, actors that are involved in 
pancreas development (revised from SI-Onge el al, 1999). 
Transcription Factor Expression in 
adult pancrea! 
Pancreatic duodenal ji-Cells 
homeohox I (PDX-1 ) 
Isl lim homeobox I (Isl- 1 6-, pp- cells 
dorsal mesench)mc 
Paired box gene 4 (11ax4) P, 6-, pp- cells 
Paired box gene 6 (Pax6) ji-, u, 6-, pp- cells 
NK2 HOMEOBOX 2 ji-, (x-. pp- cells 
(Nkx2.2) 
NeuroDI (NeuroD/Beta2) ji-. (1-, 6, pp- cells 
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Several transcription factors are expressed in specific regions of the 
endoderm prior to organogenesis (Grapin-Botton et al, 2001). Some of the main 
transcription factors are discussed below. 
5.1 Pancreatic duodenal horneobox I (PDX-1) 
PDX-1, is the earliest gene expressed in the developing pancreas and a key 
transcriptional factor of pancreatic development and differentiation (Gu et al, 
2002; Habener et al, 2005; Shiroi et al, 2005). It is proposed to be the master 
regulator of the pancreas at different development stages (Grapin-Botton et al, 
2001). All the three types of pancreatic tissue arise from PDX-1 progenitor cells 
(Gu et al, 2002). PDX-I plays an important role in pancreas formation in early 
embryonic stages as well as initiating islet cell differentiation, but does not 
complete it (Grapin-Botton et al, 2001; Noguchi, 2006). Pdx-I is known also as 
insulin promoter factor, IPF-I, somatostatin transactivating factor 1, STF-I, or 
islet duodenal homeodomin protein, IDX-I, (Soria, 2001). 
As the organogenesis progresses, Pdx-I was found to be expressed during 
formation of the pancreas, stomach and duodenum (Gu et al, 2002). It acts at a 
later stage in pancreatic development in both dorsal and ventral regions of the 
pancreas but not for the evagination and initial bud formation (Edlund, 1998; 
Edlund, 1999). Deficiency of Pdx-I in mice pancreas causes development 
blocking at the bud stage (Docherty, 200 1; Gu et al, 2002). 
After birth, Pdx-I expression is found to be restricted to P-cells within the 
endocrine islets of pancreas, dorsal side of the stomach and all the mucosa cells in 
the duodenum (Gu et al, 2002; St-Onge et al, 1999). Furthermore, Pdx-I is 
required for both regionalization. of the primitive gut endoderm and in the 
maturation of the P-cells that produce insulin (Edlund, 1998; Grapin- Botton et 
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al, 2001). It seems to be a key factor in insulin gene expression in the adult 
pancreas (Grapin-Botton et al, 2001; Soria, 2001; Noguchi, 2006). Pdx-I is 
required for maintaining the hormone producing phenotype of the P-cells (Edlund, 
1998; Habener et al, 2005). Thus, the expression of insulin and somatostatin was 
found to be regulated by Pdx-1 but not expressed in glucagon cells (Edlund, 1998; 
Soria, 2001; Habener et al, 2005). 
Over expression of Pdx-I leads endocrine cells to lose their elongation 
shape and enhance the ductal cells to secrete insulin instead of P-cells. In contrast 
cells expressing low level of Pdx-I remain in the epithelium (Grapin-Botton et a/, 
2001; Noguchi, 2006). It has been shown that Pdx-I regulates the expression of 
other islet-specific genes such as Glut-2, islet amyloid polypeptide and GK 
(Habener et al, 2005). Low activity of Pdx-I may contribute with type 11 diabetes 
by causing stopping the expression of insulin (Edlund, 1998; Habener et al, 2005). 
5.2 Neurogenin 3 (Neu rog 3; Ngn3) 
Ngn3, is a transcription factor that is considered as a competence factor 
involved in the determination of neural precursor cells (Gradwohl et al, 2000; 
Shiroi et al, 2005). It can be found in a specific region in the nervous system as 
well as scattered within the embryonic pancreas (Gradwohl et al, 2000). However, 
it is first expressed in the developing pancreas (Edlund, 1999). 
Ngn3 is a basic helix-loop-helix protein which is expressed in the 
developing pancreas specifically islet cell progenitors but not present in mature 
islets (Docherty, 2001; Gu et al, 2002; Habener et al, 2005). It is found within or 
adjacent to pancreatic ducts and was identified as a potential initiator of endocrine 
differentiation (Gradwohl et al, 2000; Grapin-Botton et al, 2001). It is expressed 
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in the islet precursor cells that have not start producing honnones and used as a 
marker for these cells (Gradwohl et al, 2000; Habener et al, 2005). 
Moreover, this transcription factor is important for the survival of 
differentiated endocrine cells as well as for the generation and differentiation of 
endocrine and exocrine progenitor cells (Docherty, 2001; Gradwohl et al, 2000; 
Gu et al, 2002). In mouse, for example, it founds that Ngn3 is required for 
differentiation of all pancreatic endocrine lineages but when expressed alone 
before the formation of the bud, under the control of Pdx-I promoter, it does not 
induce insulin cell differentiation (Grapin-Botton et al, 200 1). 
The inactivation of Ngn3, in mice, prevents all endocrine cells in the 
pancreas from differentiation as well as the islets of Langerhans which results in 
diabetes (Gradwohl et al, 2000; Habener et al, 2005). In contrast, over expression 
of Ngn3, in mice, may accelerate the differentiation of pancreatic endocrine cells, 
while decrease the pancreatic precursor cells (Edlund, 1999; Habener et al, 2005). 
Pdx-I acts with Ngn3 to form the endocrine cells of the pancreas, in the islets of 
Langerhans (Fishman et al, 2002; Habener et al, 2005). Pax 6, Isl-l, NeuroD and 
Nkx2.2 are endocrine cell markers induced by Ngn3 (Grapin-Botton et al, 2001). 
Hesl is an inhibitor of the endocrine cell differentiation which is promoted by 
Ngn. 3 and it plays a role in the maintenance of the pancreatic precursor cells 
during development (Habener et al, 2005; Soria, 200 1). 
5.3 Neurodifferentiation 1 (NeuroDl; NeuroD) 
Neurol) is a basic helix-loop-helix late transcription factor promoted by 
Ngn3, that induces its expression (Docherty, 2001; Soria, 2001; Ilabener et al, 
2005). The expression of NeuroD is important in regulating both P-cells of adult 
islets, as well as for the differentiation and maintenance of all endocrine cells, and 
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terminal differentiation of neurons (Edlund, 1998; Docherty, 2001; Soria, 2001; 
Habener et al, 2005). Loss of NeuroD expression occurs during endocrine cell 
differentiation (Docherty, 2001; Soria, 2001). 
5.4 Isl lim homeobox I (Isl-l) 
Isl-I is a late expressed transcription factor of LIM-homeodomain protein, 
homeobox gene, which is expressed in all types of islet cells in the adult pancreas 
but in low level in P-cells (Edlund, 1998; Peter et al, 2000; Docherty, 2001; 
Habener et al, 2005). During early embryogenesis the expression of Isl-I is 
important to determine which region of the gut endoderm that will form the 
pancreas (Edlund, 1999; Docherty, 2001). This homeodomain appears around the 
dorsal pancreatic bud only and it is important, later, for the differentiation of the 
islet cells (Edlund, 1998; Docherty, 200 1; Peter et al, 2000; I-labener et al, 2005). 
Isl-I has two functions. The first is in the development of the exocrine 
cells of the pancreas from the dorsal mesenchyme, whereas the second function is 
in differentiation of islet cells from the epithelial cells (Docherty, 2001; Soria, 
2001). All endocrine cells depend on Isl-I for their terminal differentiation 
(Edlund, 1998). Furthen-nore, Isl-I acts upstream of Pax6 during pancreatic 
endocrine differentiation (Edlund, 1998). 
5.5 Paired box gene 4 (Pax4) and Paired box gene 6 (Pax6) 
These two homeobox genes are restricted to nervous system and endocrine 
cells in the developing pancreas (Gradwohl et al, 2000; Habener et al, 2005). 
They are a late expressed transcription factors (Docherty, 2001). Both genes 
expressed in the dorsal and ventral buds of the developing pancreas (11abener et 
al, 2005). They are essential for the generation of different cell types (Soria, 
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2001). In addition, Pax4 and Pax6 require Ngn3 for their expression (Gradwohl et 
al, 2000). 
Pax4 is expressed in both buds of the pancreas but later in development it 
becomes restricted to 0-cells (Edlund, 1998; Habener et al, 2005). However, PaA 
is important for the differentiation of insulin producing P-cells and somatostatin 
producing 8-cells (Edlund, 1998; Soria, 2001; Habener et al, 2005). On the other 
hand, Pax6 is required for the generation of glucagon producing a-cells (Peter et 
al, 2000; Soria, 2001; Habener et al, 2005). Furthermore, Pax6 is expressed in all 
endocrine cells during development (P-, 8-, a- as well as pp) (Edlund, 1998; 
Habener et al, 2005). Cells expressing both, PaA and Pax6, will develop into 
mature insulin producing P-cells (Peter et al, 2000; Soria, 2001). However, 
inactivation of both of them lead to the absence of mature P-cells (Gradwohl et al, 
2000). 
5.6 NK2 Homeobox 2; (NKX2-2; Nkx2.2) and 
NK Homeobox 6 (NKX6-1 Nkx6.1) 
Nkx2.2 and Nkx6.1 are homeodomain genes that expressed in early 
pancreatic cells as well as the progenitor cells (Docherty, 2001; Shiroi et al, 
2005). They are regulators of the differentiation of pancreatic endocrine cells 
(Habener et al, 2005). 
Nkx2.2 is an important transcription factor that expressed in early 
development of pancreas and later in differentiation of P-cells. It was firstly found 
in the dorsal bud of the pancreas during early embryogenesis of mouse embryo 
(St-Onge et al, 1999; Habener et al, 2005; Shiroi et al, 2005). As differentiation 
proceeds scientists found that Nkx2.2 expression restricted to the P, a and pp-cells 
but not mature B-cells (Edlund, 1998; St-Onge et al, 1999; Docherty, 2001; 
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Habener et al, 2005). Mutants of Nkx2.2 lead to hyperglycernia because of the 
lack of P-cells that produce insulin (Habener et al, 2005; Shiroi et al, 2005). 
Nkx6.1 lies downstream of Nkx2.2 (Docherty, 2001). It is expressed in 0- 
cells of adult islets (Edlund, 1998; Docherty, 2001; Habener et al, 2005). 
Moreover, Nkx6.1 is required for the tennination of differentiation of P-cells to 
produce functional hormone producing cells (Edlund, 1998; St-Onge et al, 1999). 
5.7 Homeobox HB9 (Hlxb9) 
Hlxb9 is a homeobox transcription factor gene which expressed in the 
notochord and the gut endodcrm (Edlund, 1999; Docherty, 2001). It is present 
also in P-cells of mature islets, where it is responsible for terminal differentiation 
and maturation of P-cells (Edlund, 1999; Docherty, 2001; Soria, 2001). Hlxb9 
function is expressed in both early and late stages of pancreatic differentiation 
(Edlund, 1999). It controls the earlier step in morphogenesis of the dorsal 
pancreas (Edlund, 1999; Soria, 2001). Furthermore, Hlxb9 is found in regions of 
endoderm that give rise to the respiratory and digestive tubes as well as the dorsal 
and ventral pancreatic buds, before Pdx-I (Edlund, 1999; Soria, 2001). 
5.8 p48 (P48) 
P48 is the first exocrine transcription factor that has been discovered that 
controls the expression of genes in the exocrine pancreas (Edlund, 1998). This 
subunit factor is located downstream of Pdx-1 (Edlund, 1998). It is required for 
differentiation and proliferation of the exocrine cell lineage (Edlund, 1998). The 
expression of p48 mRNA is observed in both pancreatic buds (Edlund, 1998). 
A number of other transcription factors are important in the field. 
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5.9 Octamer-binding Transcription Factor 4 (Oct 4) POU 
Domain, Class 5, Transcription Factor (POU5FI) 
qct4 is a transcriptional binding factor that is found in undifferentiated 
high proliferative cells (Gu et al, 2005; Tondreau et al; 2005). The expression of 
Oct 4 is important for maintaining the ICM and pluripotency of ES cells (Gu et 
al, 2005). It is specifically expressed in the germ line and pluripotent stem cells 
that play a role in the normal development of cells (Gu et al, 2005; U et 01,2005; 
Marikawa et al; 2005). 
Oct4 expression is regulated by proximal enhancer and promoter in the 
epiblast and distal. enhancer and promoter in pluripotent cell lineage (Gu et al, 
2005). Low expression of Oct4 indicate the initiation of differentiation of ES cells 
(Gu et al, 2005). 
5.10 Glucose Trasporter I and 2 (Glut-I and Glut-2) 
Glucose transporters, Gluts, are membrane proteins that facilitate glucose 
uptake into cells. Gluts are important molecules for normal carbohydrate 
metabolism (Matsutani et al, 1990). 
Immunolabeling techniques of pancreatic P-cells sectioned from human 
foetal and adult pancreas were used, by Richardson and colleagues, to identify the 
presence of Glutl, Glut2 and GK (Richardson et al, 2007). No expression of 
Glutl was observed during early development of pancreas but it was detected in 
development, after 15 weeks gestation, when insulin positive cells increased. In 
contrast, Glut2 expression was detected during early development of the pancreas, 
at about 7 weeks gestation (Richardson et al, 2007). 
Glut2 expression is regulated by transcription factors Pdx-I and 
hepatocyte nuclear factor 1, Hnf-la (Cerf et al, 2007). The early loss of Glut2 
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expression causes hyperglycemia, and low insulin expression that leads to diabetes 
(Cerf et al, 2007). 
High fat diet also causes reduction in the expression of Glut2 that inhibit 
glucose stimulation insulin secretion and affect P-cell mass and function (Cerf, 
2007). 
Humans differ from rodent in glucose transporter gene expression in the 
adult pancreas which is predominantly Glut-I instead of Glut-2. The 100-fold 
lower glut 2 abundance in human versus rat P-cells is associated with a 10-fold 
slower uptake of alloxan, explaining their resistance to this rodent diabetogenic 
agent (De Vos et al, 1995). 
5.11 Glucokinase (GCK, GK) 
Glucokinase (GK) is a key enzyme that plays a role in glucose 
homeostasis which secretes from the liver (de la Iglesia et al, 1999; Cuesta-Munoz 
et al, 2000; Slosberg et al, 2001). However, mRNA of GK was first found in the 
I iver parenchyma of neonatal rats (Moorman et al, 199 1). 
GK gene transcription initiates in the P-cells of the pancreatic islets, gut, 
and brain from promoter sequences upstream the liver sequences (Moates et al, 
2003). 
In P-cells, the expression of beta GK is controlled by Pdx-I (Moates et al, 
2003). Moreover, GK in the pancreatic 0-cells functions as the glucose sensor 
detennining the threshold for insulin secretion, while in liver it is essential for the 
regulation of glucose-responsive genes as well as facilitates the hepatic glucose 
uptake during hyperglycemia (Postic et al, 2001). 
Mutations in the GK gene cause two different diseases: diabetes type 11 
and hyperinsulinernic hypoglycernia of infancy (Postic et al, 2001; Cuesta-Munoz 
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et al, 2004). However, mice lacking GK in the pancreatic P-cell die within 3 days 
of birth with hyperglycernia. On the other hand, mice lacking hepatic GK are 
viable but are mildly hyperglycernic when fasted (Postic et al, 2001; Cuesta- 
Munoz et al, 2004). Glucokinase polymorphism is not a major determinant of type 
11 diabetes (Laurino et al, 1994). 
5.12 Notch Signaling 
Notch signaling is an intercellular signaling molecule (Docherty, 2001). It 
is a transmembrane receptor that is stimulated by Ngn3 (Docherty, 2001). In the 
human, notch signaling is important for pancreatic development, in controlling 
both endocrine and exocrine fates (Edlund, 1999; Habener et al, 2005). The notch 
signaling pathway controls the differentiation of endocrine cells as well as the fate 
of endocrine and exocrine cells (Edlund, 1999). Lack of notch signaling results in 
high levels of Ngn3 which promote the differentiation of endocrine cells. On the 
other hand, cells with active notch signaling promote the differentiation of 
exocrine cells and keep the progenitor cells undifferentiated (Edlund, 1999). 
6. Insulin Chemistry 
Insulin is the polypeptide hormone produced by P-cells when glucose 
levels exceeded in blood more than the normal level of 4-7mmol/L, and regulates 
the metabolism of glucose, fats and proteins. Secretion of insulin is also 
stimulated by elevated levels of some amino acids, including arginine and leucine 
(Dodson et al, 1998). It was the first human gene to be cloned and the one of the 
first proteins to be isolated crystallized and sequenced (Bell et al, 1980). 
Insulin has been found in all vertebrates and has a highly conserved 
structure (Dodson et al, 1998). It consists of two polypeptide chains, A and B, 
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connected by two disulfide bridges (Dodson et al, 1998). Another disulfide bridge 
is found within the A chain between the sixth and eleventh amino acids residues 
(Figure 7). In human there is a single copy of the insulin gene located on the short 
arm of chromosome 11 (Docherty et al, 1996). The complete insulin molecule 
contains 51 amino acids 21 amino acids in A chain and 30 amino acids in B chain 
with a 5,800 molecular weight (Dodson et al, 1998). 
The insulin gene is composed of three exons and two introns, among 
different species (Dodson et al, 1998). Exon one is located in the translated region 
of the gene, while exon two contains sequences coding for the signal peptide, B 
chain and part of the C-peptide and exon three encodes the remainder of the 
insulin sequence (Bell et al, 1980). The N-terminal and C-terminal regions of the 
A chain and the hydrophobic residues of the B chain are highly conserved 
(Dodson et al, 1998). 
Human insulin promoter region regulates the transcriptional response to 
glucose and other nutrients and limits transcription of the gene to the pancreatic 
cells (Docherty et al, 1996). 
Insulin, like most secretory proteins, is synthesized as a precursor molecule, called 
preproinsulin that carries a single peptide (Rhodes et al, 1994). By the interaction 
of the signal recognition peptide with the signal recognition peptide receptor on 
the ribosome ensures that preproinsulin. enters the secretory pathway in the rough 
endoplasmic reticulum. (Rhodes et al, 1994). However, preproinsulin is a single 
polypeptide chain of 110 amino acids that permits correct alignment of the three 
pairs of disulfide bonds and with molecular weight of 11,500, as shown in figure 
7, (Rhodes et al, 1994). 
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The diagram shows the active structure of insulin as processed. 
The two polypeptide chains of insulin, A and B, connected by two 
disulfide bridges. The other disulfide bridge is found within tile A 
chain between the sixth and eleventh amino acids residues (Beta 
cell consortium, 2004). 
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Tertiary structure of the insulin, the active form, is derived from the 
proinsulin which is about 86 amino acids by cleavage of 31 amino acids of the C- 
peptide structure from the centre. This is brought about by the action of 
proteolytic enzymes, known as prohormone convertases (PCI and PC2), as well 
as the exoprotease carboxypeptidase E. In the secretory granules of the P-cells, the 
presence of zinc ions favors the formation of insulin hexamers made up of three 
dimers arranged around an axis with two atoms of zinc (Dodson et al, 1998). 
The effect of insulin on the cellular metabolism is in a series of steps that 
begins when insulin binds to receptor proteins on the cell membrane (Dodson et 
al, 1996). This leads to the activation of the receptor which functions as a kinase, 
attaching phosphate groups to intracellular enzymes. Phosphorylation of enzymes 
then produces primary and secondary effects in the cell, where then glucose 
absorption and utilization is the most important effect (Dodson et al, 1998). 
Insulin receptors are present on most cells which are called insulin dependent cells 
(Dodson et al, 1998). Brain and kidneys cells, cells lining the digestive tract and 
red blood cells lack insulin receptors, and are called insulin independent. These 
cells absorb and utilize glucose without insulin stimulation (Dodson et al, 1996). 
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7. Aims of this Study 
In the present study, the goals were: 
1. To induce insulin-secreting cells in vitro using ES cells (H7 cell line), derived 
from human embryonic stem cells, using different growth factors, and compare 
these cells with those produced by the foetal pancreas during early development. 
2. To assess the functional output of any insulin-secreting cells generated from ES 
cells by measuring C-peptide secretion and gene expression. 
3. To relate findings to development of the human pancreas during early 
organogenesis. 
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1. INTRODUCTION 
Tissue Culture 
The unique nature of hES cells to either self-renew or differentiate into most 
cell types, suggests that these cells could potentially supply an unlimited source of 
transplantable islet cells in the future. As discussed previously, the pancreatic islets of 
Langerhans originate from definitive cndoderm and therefore the primary 
differentiation step that ES cells must undertake in vitro is along an endodermal 
pathway. However, the path from definitive endoderm to a mature hormone- 
producing islet cell phenotype is complex and involves sequential cell fate decisions, 
which include the formation of pancreatic endoderm, endocrine progenitors, and 
hormone-producing islet cell types, including P-cells that secrete insulin. Embryonic 
development of the pancreas is the result of several interacting mechanisms involving 
growth factors, epithelial-mesenchymal interactions and extracellular matrix that 
eventually regulate the expression of diverse transcription factors and genes (see 
chapter 1). However, it is still unclear as to the nature of the initial signals in the 
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cascade of events that enables gut endoderm to develop to pancreas. Much remains to 
be learned about the extracellular cues that might be given in culture to specify, 
maintain, expand, and differentiate these endocrine progenitor cells. Thus, to control 
the differentiation of undifferentiated hES cells into functional effective pancreatic 
cells will be a challenging task. 
As a first step we need to establish whether insulin-secreting cell types can be 
generated from hES cells in sufficient numbers for experimental investigation. Under 
non-adherent culture conditions embryonic stem cells can differentiate into 
aggregates called embryoid bodies (EBs). These EBs can be composed of different 
proportions of cells from all three layers, endoderm, mesoderm and an ectoderm, 
(Roche et al, 2005; Trucco, 2005) and thereafter form a microenvironment for 
spontaneous embryonic development which may include endodermal-pancreatic 
developmental processes. 
Studies have shown that insulin cells can be generated from mouse and human 
ES cells by the use of different experimental strategies (Keller, 1995; Klug et al, 
1996; Soria et al, 2000; Assady et al, 2001; Amit et al, 2002) but mostly using EBs. 
The approach used most frequently is based on the findings that similar mechanisms 
operate to control the development of both the central nervous system and the 
pancreas. Specifically, embryonic stem cells have been induced to differentiate 
initially into nestin-producing neural precursors that are then expanded and exposed 
to conditions, which result in clusters of insulin-containing cells. 
In the early steps of neural differentiation from mouse ES cells, some cells 
express nestin as a protein found in normal neuronal precursor cells (Lendahl et al, 
1990; Lumelsky et al, 2001). Nestin was also found in immature, hormone negative 
pancreatic cells in culture, which produce glucagon initially and then insulin after 
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maturation (Lumelsky et al, 200 1; Zulewski et al, 200 1). For this reason, nestin was 
used as an early identifier of the differentiation of ES cells towards insulin-secreting 
cells (Lumelsky et al, 2001). However, it has also been found that nestin positive 
cells contribute to the intra- and extramicrovascular environment of the islet rather 
than directly to the hormone producing cells of the pancreas (Selander et al, 2002; 
Treutelaar et al, 2003) and therefore may only be a temporary marker. Thus, 
immunocytochemistry to localise nestin was used in this study to identify the putative 
progenitors cells for later identification of the insulin positive cells among the 
differentiated hES cells. Lumelsky (2001) used a working protocol that started with 
the enrichment of the nestin positive cell population derived from mouse EBs to 
generate cells expressing insulin and other pancreatic hormones (Lumelsky, 2001). 
Nicotinamide has been used in a number of experiments to direct the 
differentiation of hES cells into insulin producing cells (Soria et al, 2000; Houard el 
al, 2003; Roche el al, 2005; Trucco, 2005). Nicotinamide can slow down the 
progression of type 11 diabetes by improving insulin and C-peptide secretion as well 
as preventing the death of O-cells in type I diabetes (Gale, 1996; Greenbaum et al, 
1996; Hoorens et al, 1999; Kolb et al, 1999; Polo et al, 1998; Li et al, 2006). 
However, the activity of nicotinamide as a growth factor is not well understood, 
although it is thought to play a role in stimulating endocrine differentiation in the 
early development of the pancreas. 
In two separate experiments, Soria and co-workers found that after incubation 
of mouse ES cells with nicotinamide for two weeks, or with nicotinamide in low 
glucose medium for five days, the differentiating cells increased their insulin 
secretion level (Soria el al, 2000; Roche et al, 2005). Thus, the Soria group indicated 
that addition of this growth factor played an important role in directing the 
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differentiation of ES cells into insulin secreting cells in all their protocols (Roche et 
al, 2005). In addition, Beattie and coworkers (1996) used nicotinamide to direct the 
differentiation and proliferation of progenitor cells from foetal pancreatic cells into 
EBs expressing insulin (Beattie et al, 1996; Trucco, 2005). 
On the other hand, Schuldiner and co-workers. succeeded in directing the 
differentiation of hES cells in culture into different cell types (ectoderm, mesoderm 
and endoderm) by using eight different growth factors, including FGF2 and activin A. 
These experiments indicated the importance of FGF2 in directing the differentiation 
of ES cells towards ectodermal and mesodermal cells, but not necessarily into 
endodermal cells after a ten day incubation period of hES cells in medium containing 
FGF2 (Schuldiner et al, 2000). However, Soria's group also used both FGF2 and 
activin A, with mouse ES cells to generate insulin-secreting cells (Schuldiner et al, 
2000; Soria, 2001). It was also found that the insulin secretion from the cultured EBs, 
derived from mouse ES cells, remained stable from day seven until day 21 (Soria et 
al, 2000; Houard et al, 2003). Hart and co-workers (2000) have suggested that FGF2 
signalling may be involved in P-cell maturation, terminal differentiation, and post 
natal expansion (Hart et al, 2000). 
While growth factors have different effects on the differentiation of hES cells, 
none have the ability to direct the differentiation of ES cells into a single specific cell 
type (Schuldiner et al, 2000; Amit et al, 2002). From the literature it has been shown 
that most of the experiments used growth factors with EBs rather than using the ES 
cells directly in monolayer culture. Tbus, growth factors were added to the EBs from 
the time of the earliest investigations (Perkins, 1998; Itskovitz-Eldor et al, 2000; 
Soria et al, 2000; Assady et al, 2001 Feraud et al, 200 1; Lumelsky, 200 1; Segev et al, 
2004). 
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Other groups have derived insulin secreting cells in vitro from mouse ES cells 
by using the three step differentiation method: direct differentiation, cell lineage 
selection and maturation. The resulting cells were shown to express P-cell specific 
genes, but they could not respond to increased glucose concentration (Soria et al, 
2000; Assady et al, 2001). 
A number of markers have been used to detect insulin-secreting cells 
including the detection of insulin secretion into medium. However, the presence of 
insulin in many culture media as a growth factor complicates the interpretation of 
results. An alternative marker is C-peptide (connecting peptide), an active peptide 
hormone but which is also important for the synthesis of insulin, where it links the 
two chains of insulin, A and B, in the correct way that allows the formation of 
disulfide bridges between them (Figure 1) (Ido el al, 1997; Rigler et al, 1999; Wahren 
et al, 2000). 
The structure, chain length and amino acid sequence of C-peptide varies in 
different species (Ohtomo et al, 1998). Human C-peptide, for example, has 31 amino 
acids with a molecular weight of 3020, but those of different species show differences 
in their physiological and biochemical structures (Ido et al, 1997; Rigler et al, 1999; 
Wahren et al, 2000). 
Another marker which has been used in this study is dithizone (DTZ), which 
is a zinc chelating agent used as a marker that selectively stains the P-cells in the 
pancreas with a crimson red colour (Jiao et al, 1991; Fiedor et al, 1996; Shiroi et al, 
2005; Priel el al, 2006). The depolarisation of P-cells lead to the influx of zinc into 
the P-cells through the L-type calcium channels (Priel et al, 2006). Zinc is required in 
secretory granules of pancreatic P-cells for packaging insulin (Figure 2) but needs to 
be chelated to prevent zinc toxicity (Priel. et al, 2006). The Zinc transporter, ZnT8, is 
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Figure 2 Tertiary structure of pro-insulin molecules (green) chelated with zinc 
(purple) in secretory granule of P, -cell (beta cell consortium, 2004). 
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a major component for providing zinc to insulin during maturation and storage 
processes in P-cells (Fabrice et al, 2005). It is localised in the secretion vesicle 
membrane and enables accumulation of zinc into the vesicles from the cytoplasm 
(Fabrice et al, 2005). 
Zinc is secreted to the out side of the cell during insulin secretion (Priel et al, 
2006). 
Pancreatic islets from such animal species as mouse, dog, pig and human are 
all known to be stained crimson red by its treatment, because of their much higher 
zinc contents compared with other tissues (Clark et al, 1994). In the present study 
DTZ was used to detect the presence of insulin-containing cells in EBs, which were 
derived from hES cells, grown using different growth factors and their combinations 
for two weeks in vitro. 
In this chapter the aim is to investigate the generation of insulin secreting P- 
cell- like cells in culture using hES cells and identify them with immunofluorescent 
localisation. 
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11. MATERIALS & METHODS 
1. Materials 
Tissue Culture 
All chemicals and media were from Sigma Aldrich (Poole, UK) or Invitrogen 
(Paisley, UK) unless otherwise stated. Culture flasks and other plastieware were from 
NUNC Germany (Thermofisher, UK) unless otherwise stated. 
1.1 Glass Bead Preparation 
The beads (3mm, Phillip Harris Scientific) were covered with concentrated 
HCI overnight in a beaker. The medium was neutralised by adding drops of IOM 
NaOH. The beads were rinsed copiously with tap water and then with sterile water, 
autoclaved and dried. 
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1.2 Preparation of stock medium 
1.2.1 DMEM/FCS Medium Used for Mouse 
Embryonic Feeders 
Dulbecco's Modified Eagle Medium (DMEM), with 4.5gAL D-Glucose, L- 
Glutamine without sodium pyruvate (DMEM) was prepared and supplemented with 
10% foetal calf serum (FCS) and 0.6% (v/v) of gentamycin solution. 
1.2.2 Human Embryonic Stem Cell (hES) Medium 
To prepare hES medium, (80%) knockout DMEM was mixed with (20%) 
knockout SP, serum replacement ImM L-glutamine, O. ImM P-mercaptoethanol 
solution, (1%) non-essential amino acid solution, 4ng/ml basic FGF (FGF2) and 0.6% 
gentamycin. The mixture was filtered in a 250ml 0.2gm cellulose acetate filtering 
unit. Medium was stored at 4'C and used within two weeks. 
1.2.3 Embryoid Bodies (EBs) Medium 
Prepared as hES, in section 1.2.2, but without the addition of basic FGF. 
1.2.4 Mitomycin C Medium (10pg/ml) 
Mitomycin C powder was dissolved in DMEMIFCS medium for a final 
concentration of 1099/ml. The solution was sterilized by passing it through a 0.2gm 
cellulose acetate filtering unit and stored in a refrigerator, 4'C, for up to one month. 
1.2.5 Ice Cold Freezing Medium 
10% Dimethylsulfoxide (DMSO) was mixed with 90% FCS. The mixture was 
stored at 4*C. 
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1.2.6 RPMI 1640 Mix Medium 
RPMI 1640 with L-glutamine was mixed with RPMI 1640 with L-glutamine 
without glucose in a ratio of 1: 1, to have a final glucose concentration of 5.5g/L, and 
0.6% gentamycin solution ( v/v) added and the medium filter sterilized. 
1.3 Preparation of Stock Solutions 
1.3.1 Trypsin/EDTA Solution 
Trypsin 0.25% (w/v) was mixed well with ImM EDTA dissolved in 8-59/1, 
NaCl. The solution was stored at 40C. I OX trypsin/EDTA solution was also used after 
dilution (IX). 
1.3.2 Gelatin (0.1 %) Solution 
Gelatin powder (0.2g) was dissolved in 200ml sterile (autoclaved) dH20, 
mixed well and stored at room temperature. 
1.3.3 Nicotinamide (IOmM) Solution 
A I. OmM solution was prepared by dissolving 0.1221g of nicotinamide in 
100ml EB solution. The mixture was sterilized by passage through a 0.2grn syringe 
filter (Nalgene) and stored for no more than two weeks at 4'C. 
1.3.4 Activin A (5ng/pl) Solution 
Activin A (5gg) was diluted in I ml autoclaved PBS. The solution was mixed 
by vortex and stored at -20'C. From this stock solution 501d was added to 50ml EB 
medium, filter sterilized and stored at 4"C. 
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1.3.5 FGF4 (25nWml) Solution 
FGF4 (Img) was added to stock 0.1% bovine serum albumin solution mixed 
well by vortex, filter sterilized and stored at -20'C. From this stock solution 50gl was 
added to 50ml of EB medium. 
1.3.6 bFGF (4ng/ml) Solution 
Basic FGF (IOgg) was dissolved in 5ml 0.1% BSA in PBS without Ca+2 and 
Mg+2 . 400gi aliquots were placed into 0.5ml Eppendorf tubes and stored at -20T. 
1.3.7 Collagenase IV Solution 
Collagenase Type IV from Clostridium histolyticum was dissolved in 
DMEM/FCS and a lmg/ml solution prepared. The solution was filter sterilized, 
stored at 4*C and used within two weeks. 
1.3.8 Bovine Serum Albumin (BSA, 0.1%) Solution 
BSA powder (0.1g) was dissolved in 100ml sterile PBS without Cd+2 and 
Mg+2 . The solution was stored at 41C. 
1.3.9 Antibody (Ab) SoIution 
Goat serum (10lig) was added to 0.1% Triton and dissolved in sterile PBS 
without Ca+2 and Mg+2. The solution was incubated at 37*C to dissolve the Triton 
completely then stored at 4*C. 
1.3.10 Stock Solution for Dithizone Staining 
A stock solution of dithizone (DTZ) was prepared by mixing 50mg of DTZ 
with 5ml dimethylsulphoxide (DMSO). The mixture was stored at -80*C. 
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2. Methods 
2.1 Mouse Embryonic Fibroblast Feeder 
Layers (MEFs) 
Mouse embryonic fibroblast feeder layers (MEFs) were grown in culture on 
untreated tissue culture plastic flasks. MEF cells were passaged every 3-4 days, 
where cells in each flask were divided into 2-3 new untreated flasks until passage 
five. After passage five, MEF cells were inactivated by lopg/ml mitomycin C 
(section 1.2.4) or with gamma irradiation (35 gray, Medical School secure source 
facility). 
2.2 Passaging MEFs 
Cells were washed once with PBS without Ca 12 and Me 2 and incubated with 
trypsin/EDTA for 3-5 minutes in an incubator at 37*C in 5% C02 in air. DMEM/FCS 
medium was added and centrifuged at 10OOrpm (400g) for 5 minutes at 4*C. The 
pellet was resuspended in DMEM/FCS medium, the cells divided between T25 
flasks, at a concentration of 1.5 -2x 106 cells/flask and incubated at 37*C in 5% C02 
in air. 
2.3 Inactivation of MEFs 
The inactivation process of MEFs was started by removing the DMEMIFCS 
medium (section 1.2.1) and covering the cells with 8ml mitomycin C medium. The 
cells were incubated with mitomycin C medium for about 2-3 hours at 37*C in 5% 
C02 in air. The cells were washed three times with IX PBS and then covered with 
0.25% trypsin (w/v): I mM EDTA (section 1.3.1) and incubated for 3 minutes at 37*C 
in 5% C02 in air. Each flask was flicked to dissociate the clumps of cells into single 
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cells. Trypsin/EDTA was inactivated by DMEM/FCS and the whole solution 
centrifuged for 3 minutes at 400g. Medium was removed and the pellet dispersed and 
10ml of fresh DMEM/FCS added. The number of cells was determined by 
haemocytometer with 7gl being taken from the cells and placed under the coverslip 
on the haernocytometer. Cells were reseeded on T25 tissue culture flasks pre-treated 
with 0.1% (w/v) gelatin solution (section 1.3.2) for about I-2 hours. Inactivated cells 
were finally seeded at about 106 cells/ flask and used within two weeks. 
2.4 Freezing MEFs 
MEF cells were washed with PBS without Ca+2 and Me 2 and incubated with 
0.25% trypsin (w/v): ImM EDTA solution (section 1.3.1) at 37*C in 5% C02 in air 
for 3 minutes. The solution was neutralised by adding DMEMIFCS and the mixture 
centrifuged at 400g for 3 minutes, the pellet resuspended in ice cold freezing medium 
(section 1.2.5) and finally transferred to cryovial tubes. The cryovials containing the 
cells were immediately immersed in ice and stored at -80*C. The next day cryovials 
were transferred to a liquid nitrogen tank for long term storage. 
2.5 Thawing MEF Cells 
The cryovial containing MEF cells was removed from the liquid nitrogen and 
thawed by immersing the bottom half of the cryovial in a 37'C water bath. After 
thawing, cryovials were cleaned from outside with alcohol to reduce contamination 
and cells immediately transferred to 10ml DMEM/FCS. Cells were centrifuged at 
400g for 3 minutes, the supernatant removed and the pellet dispersed by flicking the 
tube. Fresh 10ml DMEM/FCS was added to the pellet, mixed well and transferred to 
an untreated T75 flask. The flask was incubated at 37*C in 5% C02 in air. 
53 
Chapter 11 Tissue Culture 
2.6 Inactivation of FCS 
Foetal calf serum (FCS) was defrosted by putting it in a 37*C water bath and 
then incubated for 30 minutes in a 57*C water bath. The inactivated FCS was then 
ready to use. 
2.7 Maintenance of Cell Lines 
2.7.1 Passaging Human ES Cell Lines 
Human ES cell lines H7 S6 and H7 S14 (WiCell, and obtained from Professor 
Peter Andrews, Centre for Stem Cell Biology, University of Sheffield) were cultured 
in hES medium (section 1.2.2). To maintain their undifferentiated status, ES cells 
were harvested by treatment with 2ml of lmg/ml collagenase IV solution (section 
1.3.7), for eachT25 flask for 8- 10 minutes at 37*C. ES cells were then dispersed by 
scraping with 3mm glass beads (section 1.1), centrifuged at 300g for 3 minutes, the 
supernatant removed and the pellet dissociated by flicking the tube and finally cells 
were seeded onto fresh MEFs which had been washed once with IX PB S. 6mI of hES 
medium was added to each T25 flask and incubated at 37*C in 5% C02 in air. 
Various passages number where used in this study from each cell line. For H7 
S 14 passages number 16,18 and 20 were used, while H7 S6 passages number 37,4 1, 
44,83,88,90,92,94,95,96 and 98 were used. 
2.7.2 Freezing hES Cells 
The hES cells were covered with collagenase, IV solution (section 1.3.7) and 
incubated at 37*C in 5% C02 in air for 8 -10 minutes. The flask was gently scraped 
with sterile glass beads and transferred to a 15ml falcon tube, centrifuged at 400g for 
3 minutes and the pellet washed by resuspending in hES medium and then replacing 
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the hES medium with ice cold freezing medium (section 1.2.5). The cells were 
transferred to cryovials, where one T25 flask of cells was divided into 2 cryovials, 
kept on ice and then transferred to a -80*C freezer. The following day all cryovials 
were transferred to liquid nitrogen. 
2.7.3 Thawing hES Cells 
The same method was used in thawing as for MEFs (section 2.5). 
2.8 Differentiation of Human Embryonic 
Stem Cells 
2.8.1 Formation of Embryoid Bodies (EBS) 
Human H7 S6 and H7 S14 ES cells were differentiated after formation of 
embryoid bodies (EBs). hES cells were washed with (IX) PBS without Ca+2 and 
Mg12 . Cells were incubated with collagenase IV solution at 37*C in 5%CO2in air for 
10 - 15 minutes, the cells scraped with sterile 3mm glass beads and transferred to a 
falcon tube. The tube was centrifuged at 400g for 3 minutes, the pellet resuspended in 
10ml hES medium and finally transferred to a sterile 10cm diameter non-treated 
bacterial grade Petri dish (Sterilin). 
To induce insulin-secreting cells in the lab, both H7 S6 and H7 S14 cells were 
used and grown on MEFs as a feeder layer in hES medium. The EBs were grown 
using different growth factor media (see sections 1.3.3,1.3.4,1.3.5 and 1.3.6 of this 
chapter) and their combinations (Nicotinamide only, Nicotinamide + Activin A, 
Nicotinamide + FGF4, Nicotinamide + FGF2, Nicotinamide + Activin A+ FGF4 + 
FGF2, Activin A only, Activin A+ FGF4, Activin A+ FGF2, FGF4 only, FGF2 
only, FGF2 + FGF4 and Control) for the first week and normal EB medium for the 
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second week. The medium was changed every two days for each dish for the two 
weeks. 
After the first week, some EBs from each Petri dish were plated out in a 
twelve - well culture plates, three wells for each sample, and left at 37'C in 5% C02 
in air for two days with RPMI 1640 medium without FCS to spread out the EBs 
colonies to a monolayer making them easier to fix and undertake immunolocalisation 
analysis. At the end of the second week, the remaining EBs were spread out in twelve 
well plates. After the attachment and spreading of EBs in wells, some of them were 
stained for dithizone (section 1.3.10) while others were fixed and immunostained 
with different antibodies for C- peptide, insulin, glucagon and nestin. 
These experiments were repeated fifteen times to assess reproducibility and 
consistency of the results obtained. To confirm the expression of insulin producing 
cells immunocytochemistry was obtained in parallel with dithizone staining. 
2.9 Immunocytochemistry 
HES cells were assessed regularly using stem cell specific markers [Tra-1-60, 
SSEA3, SSEA4 (undifferentiated cells positive) and SSEAI (undifferentiated cells 
negative)]. Cells were washed three times with IX PBS then once with 100% cold 
(50C) methanol for 5-10 minutes at room temperature then washed twice with 1% 
antibody (Ab) solution (section 1.3.9). For EBs this was performed after attachment 
to culture plate. 
To optimise the primary and secondary antibodies various dilution ratios were 
used (1: 50,1: 100,1: 200 and 1: 500) all with a 1% Ab solution. The different dilutions 
of primary antibodies used in this study are listed in the table below. 
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Primary antibody 
II ra- 1 -60 IIIOLI SC 
monoclonal IgM 
SSEA4 JIIOLISC monoclonal 
IgG 
SSEA I 111OLISC monoclonal 
Mouse anti-liuman insulin 
monoclonal antibody 
Rabbit anti-hunlan 
glucagon 
Goat anti-human pro- 
insulin C-peptide 
Rabbit polyclonal to 
human nestin 
I 1, -, [lc ( killillk: 
Dilution Supplier, Cat # 
1: 10 CSCB, 
hybridoma supn 
1: 10 CSCB, 
hybridoma sLipn 
1: 10 ('S(*13, 
Ilybridoma sup 
1: 200 Abcam, ab7760 
1: 100 Dako, 0 10 1A 
1: 200 ALIIOgC[Illioclear, 
A1194 
1: 100 Abcam, ab7659- 
100 
The selected cells were covered %Nith the primary antibody and incubated 
overnight at 4T. The cells were "ashed twice with 1% Ab Solution then twice ý%ith 
IX PBS before secondarý antibod) %% as added. 
The fluorescent conjugated secondary antibodies (us ing 1% Ab solution) used 
in this studý and their dilutions arc listed in the tahic bcl()NN 
Secondary antibody Dilution Supplier, Cat 
Anti-i-nouse polyvalcm 1: ý00 I-, Igrna, F-1010 
inimunoglobulin lg(-i+M (Fl VC or 
I m-l-C) 
Anti-rabbit IgG (, A hole) (TRITC) 1: 500 Signia, T6778 
Ariti-mouse 1(-, (i (Fc specific) (1: 11'(') Lý00 Signia, F-5387 
, N1111-MOLISC (, ()at 0ý hole)- 3 1: 500 Sigma, A5324 
Anti-guinea pig IgG (whole inoleCLIle) 1: 500 Signia. F-6261 
(1: 1,1-c) 
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Cells were covered with the secondary antibody and incubated for two hours. After 
the incubation time cells were washed twice with IX PBS and examined under the 
microscope with UV optics. Sometimes double immunostaining was undertaken. No 
first antibody (PBS) and undiluted culture supernatant of the mouse myleoma P3X63 
Ag8 were used as negative controls. 
2.10 Transmission Electron Microscopy 
This was done in conjunction with the Electron Microscope Facility 
(Department of Biomedical Sciences, University of Sheffield). EBs were fixed in 
2.5% glutaraldehyde in OAM sodium cacodylate buffer and centrifuged at 10OOg to 
form a pellet of aggregated EBs. This was then prepared for electron microscopy by 
post-fixation in 1% osmiurn tetroxide, dehydration through graded ethanol solutions 
and propylene oxide and embedding in epoxy resin. Ultrathin sections were stained 
with lead citrate and examined by transmission electron microscope (Phillips). 
2.11 EBs Cells Stained for Dithizone 
For staining cells, 10ttl of the stock solution of DTZ were mixed with Iml of 
serum-free RPMI 1640 mix medium. The staining solution was syringe filtered. Cells 
were covered with DTZ staining solution and incubated at 37*C for 3-4 hours. Cells 
were rinsed 3 times with IX PB S and then examined under the microscope. 
2.12 Determination of Dithizone Stained Cells 
The total number of stained cells obtained after DTZ treatment was 
determined by counting the number of cells stained a red colour in each colony after 
trypsinisation of an EB with 0.25% trypsin (w/v): I mM EDTA solution for about 7 
minutes in a small Petri dish (3-5cm). The EBs stained with DTZ were selected as 
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being approximately the same size, with the biggest EB having about 4800 cells and 
the smallest about 3200 cells. Using a fine black marker pen, the dish lid was divided 
into four equal quarters. A mark was put on the dish bottom to align the lid. To 
determine the number of cells, the dish was scanned from the middle of each quarter 
outwards. The marks on the lid were out of focus but could still be clearly observed. 
Stained cells were determined in one quarter then multiplied by four to obtain the 
total number of stained cells on each plate. 
The proportions (%) of red stained cells were calculated using the following 
fonnula: 
%of stained cells The number of stained cells X 100 
Mean total number of cells of the (small/large) colony 
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III. RESULTS 
1. Preparation of Mouse Embryonic Fibroblast 
Feeder Layers (MEFs) 
Tissue Culture 
The inactivated MEF cells, which were prepared prior to co-culture with hES 
cells were confluent, forming as a feeder layer and ready to passage hES cells on 
them the next day (Figure 3 A). They were pre-washed once with IX PBS and 
covered with 6ml of hES medium in each T25 flask about one hour before seeding 
the hES cells. MEFs have to be used within a maximum of two weeks as they start 
dying after that and become unsuitable for passaging hES cells on them. 
2. Maintenance of Cell Lines 
2. assaging Human ES Cell Lines 
To maintain the hES cell lines H7 S6 and H7 S14 in an undifferentiated state, 
hES cells were seeded onto fresh MEFs every 4-5 days (Figure 3B). 
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Figure 3 (A) Inactivated mouse embryonic fibroblast feeder layers (MEFs). (B) 
undifferentiated human ES cells H7 S6 maintained on inactivated 
mouse feeders. 
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Immunolocalisation with specific cell surface markers (Figure 4 Tra-1-60, SSEAI) 
was performed regularly to demonstrate characterisation. 
3. Differentiation of Human Embryonic 
Stem Cells 
3.1 Formation of Embryoid Bodies (EBs) 
Both cell lines H7 S6 and H7 S14 were grown in Petri dishes, in the absence 
of MEFs, using different growth factor media (sections 1.3.3,1.3.4,1.3.5 and 1.3.6) 
and their combinations. When hES cells were cultured in suspension for two weeks 
they aggregated forming EBs (Figure 5). The EBs were three dimensional structures. 
Small, almost spherical and transparent EBs formed first but over time, these became 
more irregularly shaped, and darker in colour. It was therefore assumed that when 
observing cultures at any one time, recently formed EBs were small and clear while 
older mature EBs were irregular and large. The EBs which were differentiated from 
human H7 ES cells, S6 and S14, had normal karyotypes. 
All ES cell lines in the laboratory were regularly karyotyped by a 
cytogeneticist (Mr Duncan Baker, Sheffield Children Hospital) using the G-banding 
technique. Both S6 and S14 had non-nal karyotype at passage number 44 and passage 
number 96 (end) of the study. Where as, S14 had normal karyotype at end of the 
study (passage 20). 
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'I ISSLIC Culturc 
Figure 4 Immunolocallsation ot'liLS cell mai-kcrs \\ith 117 cells in culan-c altcr 
5 days. (A) phase-contrast of' colony surrounded by differentlating 
cells, (B) Tra-1-60 localisation (TRITC sccondary antibody) of' 
undifferentiated cells. (C) SSEAI localisation (IATC secondary 
antibody) of differentiated cells; (D) combined image. 
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A 
l. 
B 
Figure 5 Embryoid bodies cultured in 1713 medium for about one week. The 
micrograph shows both types of EBs. (A) The recently formed EBs are 
almost spherical in shape and transparent compared to (B) which are 
more irregularly shaped, darker in colour and with outgrowth cells. 
Phase contrast. Scale bar = 300grn 
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4. Immunocytochemistry 
4.1 The Expression of Nestin and Glucagon in 
Human EB Cells 
Spread EBs cells showed positive nestin and glucagon immunolocalisation 
after both 7 and 14 days in EBs medium indicating the presence of potential 
pancreatic progenitor cells (Figures 6 and 7; Table 1). The bright field images show 
the cells without the effect of the fluorescent dye, while the immunoreactant cells 
stained red or green under the effect of the fluorescent dye due to the use of Cy3 as a 
secondary antibody for nestin and TRITC as a secondary antibody for glucagon. 
Negative control samples were incubated with myeloma supernatant (non-specific 
binding) and Cy3 (red) or TRITC (green) secondary antibodies for nestin or 
glucagon, respectively. Table I show the presence or absence of positive stained EB 
cells for nestin, glucagon, insulin and C-peptide. However, this was determined 
according to the stain density in EB colony grown with different growth factor/s, 
where +ve indicate slightly positive result obtained for stained cells, +++ve indicate 
the highly positive results, where most of cells in the EB colony were stained 
positive, and ++ve indicate the presence of some positive cells in the EB colony but 
less than .. vc EB colonies. 
5. The Expression of Insulin and C-Peptide 
on Human ES Cells 
To be sure of the presence of some insulin containing cells among the 
differentiated human EBs in vitro, anti-insulin and anti C-pcptide antibodies were 
used (Table 1). When EBs cells, grown with different growth factors, were stained 
for insulin, a proportion of cells were stained and showed some immunoreactivity 
when examined under the fluorescent microscope (Figure 8). The brightfield image 
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Figure 6 Immunolocalisation of' nestin with spread human VB celis allter 14 
days in culture. (A) Phase-contrast. (13) Nestin localisation in 
monolayer cells from EB. (C) and (D) Phase-contrast and Iluorescent 
low magnification image of control (Cy3). 
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FISSUC CLIKII-C 
Figure 7 Immunolocalisation for gluý-. agon with spread hurnan EBs after 14 
days in culture. (A) lmmunfluorescent/phase-coiitrast-, (B) Immuno- 
fluorescence alone. 
Table 1 indicating the presence or not of the positive stained 1113 cells lor 
nestin and glucagons according to the staiii density in each growth 
flactor/s. +ve: slightly positive result, +++ve: highly positive result and 
ý-+ve: in between. 
Growth 
Factors 
Nestin 
7 days 
Glucapon Insulin Cqwplide Nestin 
14 (lays 
Clucagon Insulin C-peplide 
Nicotinamide +ve -ve ++ve -ve +++Ve ++ve ... ve ++Ve 
Nicotinamide -Ve -ve ++VC -ve ++Ve +ve ... ve ++VC 
+ Activin A 
Nicotinamide -ve -ve ++ve -ve ++Ve ++Ve ... ve ++ve 
+ FG F2 
_ 
Activin A+ -ve +ve +ve -ve ++,., e +ve ++ve ++ve 
FCF2__ 
Activin A -Ve -ve -ve -ve ++%, e +ve +ve +%, e 
Control -ve -ve +ve -ve +ve -Ve +%, e -ve 
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Figure 8 Immunolocalisation lor insulin with spread human LBs after 14 days, 
in culture. (A) Phase-contrast, (13) Immunolluorescence, (C and D) 
Phase-contrast and fluorescent low magnification of control. 
II ISSLIC Culturc 
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the cells on day 14 without the effect of the fluorescent dye, while the 
immunoreactant cells stained green on day 14 under the effect of the fluorescent dye 
from the use of FITC as a secondary antibody for insulin. On the other hand, control 
samples did not show any reaction from incubation of the cells with FITC only (as a 
secondary antibody for insulin) after the second week in culture. 
In addition, the results obtained from C-peptide immunostaining were found 
in small cell batches, positively stained, scattered throughout the EB colonies grown 
for 14 days with differcnt growth factors and thcir combinations such as, 
nicotinamide, nicotinamide + activin A, nicotinamide + FGF2 and activin A+ FGF2. 
These results indicate the presence of potential insulin containig cells 
especially with cells grown in the presence of nicotinamide + activin A (Figure 9). 
From figure 9 some cells, in B and D, in human EBs were stained green for C- 
Peptide on day 14 using FITC secondary antibody, which indicated the presence of 
putative insulin producing cells. 
6. EBs Cells Stained for Dithizone, (DTZ) 
Human EBs which were outgrowths from human ES H7 cells spread into a 
monolayer and after differentiation with growth factors in their various combinations 
some cells stained with DTZ. Most DTZ positive cells were found in clusters 
scattered throughout the colony rather than as isolated cells (Figure 10). The stained 
cells, were scattered within or outside the EBs colonies indicating the presence of 
some putative insulin producing cells in different proportions in each colony 
according to the growth factor used. In the control samples, the number of cells 
apparently stained faintly red with DTZ was minimal (0.1%) when compared with 
samples treated with various growth factors. 
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Figure 9 Immunolocalisation for C-Peptidc with spread hUrnan 1.13s after 14 
days in culture. (A) Phase-contrast, (B) Immuno-I'luorescence for LBs 
supplernented with nicotinamide + activin A, (C) 11hase-contrast, (D) 
Immunofluorescencc for EBs supplemcnted with activin A+ FGF2. 
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Figure 10 Human EBs cultured in different growth factor/s stained for DTZ. EBs 
were grown with growth factors for one week followed by another 
week with normal EBs medium and then stained with DTZ. (A) 1`113 
grown with Nicotinarnide + Activin A; (B) EB grown with 
Nicotinamide + FGF4; (C) EB grown with Activin A+ I-'Gi-'2, (D) FB 
grown with Nicotinamide; (E) EB grown with Nicotinarnide + FGF2 + 
Activin A+ FGF4 (F) EB grown with Nicotinarnide + FGF2 (G) 
Control. (E -G next page). (11) High magnification of DTZ stained 
aggregate (Nicotinamide + Activin A) from EB after 14 days in 
culture. Note morphology and resemblance to islet morphology in 
foetal pancreas. Scale bar I 00j, 1111. 
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Figure 10 continued (see previous page). 
Chapter 11 Tissue Culture 
When cells were incubated with DTZ after the long incubation time (of about 
two hours) in the absence of serum, the proportion of cell death increased as assessed 
subjectively under phase contrast microscopy (i. e. no bright halo). Thus, when cells 
were re-incubated with EB medium they did not show any obvious response. 
The experiment was repeated eight times for each growth factor/s, four times 
for the small sizes EB colonies and four times for the large sizes EB colonies. 
7. Determination of Dithizone Positive 
Stained Cells 
The number of DTZ staining positive cells was counted after trypsinising the 
EB colony with 0.25% (w/v) trypsin for seven minutes to yield single cells (Figure 
1) in small (3.5cm) Petri dish. 
In addition, the percentage of positive cells, stained for DTZ, for different 
growth factors and their combinations, are listed in Table 2. The percentage of cells 
stained with DTZ in selected EBs varied among different growth factors and 
according to the size of EBs under examination. The highest percentage was obtained 
from the combination of nicotinamide + FGF2, about 31%, while the lowest, about 
10%, resulted from the combination of both activin A+ FGF2. Human EBs which 
were grown with activin A only and those grown with normal EBs medium in the 
control samples showed about 1% and 0.1%, respectively, which means that almost 
none of the cells in these EBs were producing insulin as assessed by this method. 
The mean percentages, standard deviations (SD) and p values of the cells 
grown with different growth factors and stained positive for DTZ were determined. 
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Figure II Phase-contrast micrograph of EB cells after trypsinisation with 0.25% 
(w/v) trypsin f(--)r seven minutes to make single Cells. 11 'he arrow shows 
cells assessed to be stained red with dithizone. This was approximate 
magnification used when counting. 
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Table 2 The percentages of stained cells with Dithizone (DTZ) in EBs grown 
with different growth factors for 14 days. The number of positively 
stained cells was counted after trypsinisation of the selected EBs with 
25% (w/v) trypsin for seven minutes in the plate to yield single cells. 
The proportion of stained cells was determined using the mean value 
for the total number of cells in a small (3200 cells) or large (4800 
cells) colony. #= number and SD = standard deviations. 
Growth Factors 0 of Cells Approximati Mean % of P value 
Stained for Colony Size on of % of Cells against 
DTZ Cells Stained Stained for Control 
for DTZ DTZ + SD 
802 25 
483 Small 15 
450 Colonies 14 
Nicotinarnide 600 (3200 cells) 19 18+4.6 <0.05 
815 17 
1189 Large 25 
620 Colonies 13 
800 (4800 cells) 17 
420 13 
901 Small 28 
660 Colonies 21 
Nicotinarnide + 615 19 22+4.9 <0.05 
Activin A 1090 5 
1110 Large 23 
998 Colonies 21 
1345 28 
1200 38 
993 Small 31 
805 Colonies 25 
Nicotinamide + 1150 36 31+ 5.5 <0.05 
FGF2 1010 21 
1500 Large 31 
1583 Colonies 33 
1594 33 
220 7 
435 Small 14 
210 Colonies 7 
Activin A+ 108 3 10+4.9 < 0.05 
FGF2 480 10 
500 Large 10 
910 Colonies 19 
340 7 
19 1 
10 Small 0 
24 Colonies 1 
Activin A 13 0 1+0.4 <0.05 
38 1 
66 Large 1 
7 Colonies 0 
19 0 
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2 0 
0 Small 0 
0 Colonies 0 0.1+0.07 
Control 4 0 
9 0 
6 Large 0 
2 Colonies 0 
0 
-- 10 
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8. Data Analysis 
Tissue Culture 
T-tests, univariate analysis of variance and post-hoe tests were applied to the 
data from all cells stained with DTZ from EBs grown with different growth factors 
(appendix tables 3 A-F for T-test and table 4 for analysis of variance and post-hoc 
tests). 
9. Transmission Electron Microsocopy (TEM) of EBs 
This was carried out in conjunction with Dr Chris Hill, Department of 
Biomedical Sciences. 
TEM was undertaken on EBs cultured with nicotinamide + FGF2. Generally, 
the majority cells showed a polarised morphology with many vacuoles. Cells were 
connected by tight junctional complexes, and extracellular matrix was present 
(Figure 12). However there were some cells containing secretory granules. These had 
a halo appearance characteristic of P- cell insulin granules but did not show a dark 
core (Figure 13). 
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Figure 12 (A) Ultrastructure of polarised epithelial cells of EBs showing 
vacuoles. (B) higher magnification showing granules and tight 
junctions between cells. 
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Figure 13 
2 %6 
(A) Ultrastucture of cell of EB showing many secretory granules. (13) 
higher power ot'granuies showing halo and contents. 
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IV. DISCUSSION 
Tissue Culture 
Human embryonic stem cells (H7) could be cultured and passaged so they 
remained undifferentiated using inactivated mouse embryonic fibroblast feeder cells 
(MEFs). Immunolocalisation with specific markers (Tra-1-60, SSEA4 and SSEAI) 
were used to regular assess the quality of the cultures so that they retained 
undifferentiated pluripotent cells. While it is quite difficult to keep hES cells growing 
in culture at the same rate continually, the proportion of colonies showing Tra-1-60 
staining in undifferentiation conditions (about 70%) was fairly consistent throughout 
this study indicating that the cells used for experiments were probably of the same 
characteristics for all the batches produced (over 15 months period). 
It was decided at the start of the project to only use one cell line to reduce 
variation in the starting cells. Although two subclones were used, there was no 
apparent difference. However, hES cell lines do show some variation in their 
characteristics as demonstrated by the comparing of lines (Adewuni et al, 2007). 
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1. Insulin Producing Cells 
Tissue Culture 
Edlund, in 2001, showed the importance of different growth factors at 
different stages of pancreatic development and especially those of P-cell function. 
She showed the role of FGF/s in the development of the ventral part of the pancreas 
(Edlund, 2001). Additionally, nicotinamide has been used as a growth factor to treat 
human foetal pancreas to increase the number of endocrine cells and consequently 
the insulin content (Hori et al, 2002). 
Mouse ES cells were directed to differentiate into insulin producing cells by 
inhibiting the phosphoinositide 3-kinase, which is a member of a kinase enzyme 
superfamily involved in major signalling events in the cell including hES cells and 
that also mediates the effects of insulin on glucose and lipid metabolism. The cells 
produced accumulated in a way similar to that which occurs in pancreatic islets 
producing insulin when transplanted into diabetic mice (Shepherd et al, 1998; Fry, 
2001; Hori et al, 2002). 
In the present study, positive immunostaining was obtained for nestin and 
glucagon indicating the potential presence of progenitor immature insulin containing 
cells that differentiated from hES cells and with longer incubation period these cells 
in culture might have expressed mature insulin. The method used to direct the 
differentiation of human ES into insulin containing cells using different growth 
factors showed positive immunolocalisation, indicating the presence of some insulin 
containing cells in culture even although the amounts were relatively low in most 
cases. 
Immunostaining cells for insulin have been shown to be a problem and 
subject to artefact because culture medium contains insulin which might be absorbed 
by cells. Rajagopal and coworkers (2003) reported that insulin expression in cells 
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derived from hES cells was due to insulin uptake by the cells rather than new 
synthesis (Rajagopal et al, 2003). Therefore, several methods need to be used to 
establish that true insulin production occurs. C-peptide localisation is particularly 
useful as this peptide is not part of the mature insulin molecule and therefore should 
discriminate between cells absorbing insulin from the culture and cells producing C- 
peptide as part of the pro-insulin molecule. Cells in some EBs were positive for C- 
peptide indicating probable insulin synthesis. Interesting, glucagon 
immunolocalisation was also obtained in some EBs suggesting a-cell development as 
well. 
The different growth factors used in this study to direct the differentiation of 
hES cells towards insulin containing cells arc listed as follows: nicotinamidc, 
nicotinamidc + FGF2, nicotinamidc + activin A, nicotinamide + activin A+ FGF2, 
nicotinamide + activin A+ FGF4, activin A+ FGF2, activin A, nicotinamide + 
FGF4, nicotinamide + FGF2 + FGF4, activin A+ FGF4, activin A+ FGF2 + FGF4, 
FGF4, FGF2, FGF2 + FGF4 and nicotinamide + activin A+ FGF2 + FGF4. These 
growth factors were selected based on their importance in the process of the 
development of islets of the pancreas. 
Experiments were repeated several times for each growth factor to check 
consistency, reproducibility and reliability of the results obtained from them. Some 
growth factors and their combinations have been avoided due to the negative results, 
by immunostaining or DTZ staining, they showed when they applied on the EBs 
samples. 
From this study, it was noticed that some of the growth factors slowed the 
aggregation of cells to form EBs. These were nicotinamide + FGF4, nicotinamide 
FGF2 + FGF4, activin A+ FGF4, activin A+ FGF2 + FGF4, FGF4, nicotinamide 
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activin A+ FGF2, nicotinamide + activin A+ FGF4 and nicotinamide + activin A+ 
FGF2 + FGF4. Therefore, FGFs may effect the rate of developmental process. 
However, there was always some cell death after hES transfer to non-treated Petri 
dishes in which cells were first single. If cells had not aggregated within a few days 
then they progresscd to cell death. FGF2, FGF2 + FGF4 and FGF4 may have 
inhibited aggregation of cells leading to apoptosis. On the other hand, most of the 
positive results for putative insulin producing cells were obtained from the following 
growth factor combinations: nicotinamide, nicotinamide + FGF2, nicotinamide + 
activin A and activin A+ FGF2. This suggests that nicotinamide with activin A had a 
positive influence. 
2. EBs Cells Stained for Dithizone 
As mentioned insulin immunolocalisation can give artefactual results due to 
insulin absorption from culture medium. Several studies showed that DTZ is a good 
tool to use for monitoring and identifying viable transplanted pancreatic islets. They 
showed the reliability of DTZ and that it fades quickly leaving islets cells undamaged 
(Jiao et al, 199 1; Fiedor et al, 1995; Fiedor et al, 1996). Another group in China used 
DTZ to stain viable islets cells without damaging them (Jiang et al, 2002). Clark and 
his colleagues showed that prolonged exposure of islets to DTZ reduced insulin 
secretion and produced cell death (Clark et al, 1994). In a study in 1994, three 
different concentrations of DTZ, 2,10 and 1001tg/ml, were used on human and rat 
islets to evaluate the effect of DTZ on the islet secretion. However, the lowest 
concentration of DTZ, 21tg/ml, and the shortest period of incubation of the cells with 
DTZ were the best at maintaining the function of pancreatic islets (Conget et al, 
1994). 
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Thus, because of the specificity and reliability of DTZ in staining islet cells, it 
was used in the present study to identify putative insulin-containing cells from EBs 
grown in culture from human ES cells. The different percentages of cells stained red 
in human EBs colonies were determined for all cells cultured with all growth factors 
and their combinations. Staining was quite clear after 2 hours although longer 
staining (6 hours) tended to kill the cells. Although liver and intestinal cells contain 
detectable levels of zinc, when assessed with immunostaining then the most likely 
phenotype is an insulin secreting P-cell type. In fact some outgrowths from EBs at 14 
days of culture showed very similar morphology to an early fbetal islet cluster with a 
group of DTZ stained cells surrounded by cpithelial-like cells (see Figure I OH). 
3. Electron Microscopy 
Although most cells of EBs did not show P-cell morphology they were 
polarised and displayed vacuoles and tight junction of an epithelial morphology 
(Figures 12 and 13). Interestingly, some cells displayed secretory granules with a 
distinct halo which is a characteristic of pro-insulin secretory granules of P-cells. 
However, these secretory granules did not show the dark ccntre of granules of adult 
tissue and therefore could possibly be confused with lipid vesicles although these 
tend not to be granular in appearance. To verify that the cells were indeed pro-insulin 
secretory granules it would be necessary to carry out immunogold labelling. 
In summary the differentiation of human ES cells was directed into insulin- 
containing cells, with P-cell-like phenotype based on immunolocalisation and DTZ 
staining. The number of these cells in an EB colony varied with different growth 
factors and their combinations. Some -growth factors such as nicotinarnide and 
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activin A encouraged the cultured cells to become more P-cell -like when compared 
to cells grown in other growth factors. 
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1. INTRODUCTION 
C-Peptide 
Human pancreas development starts as two separate buds with the dorsal 
pancreatic bud appearing firstý at about day 26 of gestation, as an evagination of about 
300 cells in the posterior foregut. This is followed by the formation of the ventral 
pancreatic bud one day later on the opposite side to the dorsal pancreatic bud 
(www. ana. ed. ac. uk). The pancreas organ then forms at about six week of gestation 
when both buds fuse together. The ventral bud form the head of the adult pancreas 
while, the dorsal bud form all other parts of the pancreas, the neck, body and tail 
(www. ana. ed. ac. uk). 
Previous studies have shown that hormone containing cells appear at about 8 
week of gestation in the epithelial of ductal cells of the pancreas (Polak et al, 2000). At 
week 10 gestation a-cells start to differentiate followed by 8-cell which developed at 
about II weeks of gestation. P-cells were shown to be present at about 13 weeks 
gestation (www. ana. ed. ac. uk). At the end of week 17 P-cells start to secrete insulin 
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(www. ana. ed. ac. uk). Each type of cells initiated at very low number of cells 
(www. ana. ed. ac. uk). 
In the human embryonic pancreas, glucagon producing cells, a-cells, are the first 
endocrine cells identified by their hormonal content after eight weeks gestation. Insulin- 
producing P-cells are detected in the ninth and tenth week of gestation by detecting 
either insulin or C-peptide (Peters el al, 2000). Both human insulin and C-peptide 
originate in the pancreatic P-cells as a single polypeptide chain known as pro-insulin 
with a molecular weight of 9000 (Ma el al, 2004). Proinsulin is cleaved proteolytically 
into mature insulin and C-peptide when released into the blood (Ma et al, 2004). 
Because C-peptide has the ability to persist in the plasma longer than insulin and has a 
longer half-life, it can be a more reliable indicator to reflect the secretion of pancreatic 
insulin (Ma et al, 2004; Risdrus et al, 2004). 
Enzyme-linked immunosorbent assay, ELISA, is a widely used method that 
allows rapid measurement of the concentrations of soluble components, mainly proteins, 
in plasma (LindstrOrn et al, 2002; Sj6strand et al, 2002; Risdrus et al, 2004; Liu et al, 
2005) and has been applied extensively for measurements of insulin levels in plasma. 
A new strategy to generate progenitor pancreatic cells and early pancreatic 
endocrine cells without the need for any selective steps of identifying nestin or 
cytokeratin 19 expressing cells was created by Blyszczuk and coworkers (2004). The 
amount of insulin that was secreted from the differentiated cells in vitro, was 
determined by an insulin ELISA assay (Blyszczuk et al, 2004). A group in Japan 
succeeded in lowering the blood glucose in diabetic mice by implantation of primary 
cultured adipocytes, that secrete insulin. The plasma insulin concentration was 
dependent on the implanted cell number and the secretion of insulin and C-peptide from 
adipocytes was measured by an ELISA (Ito et al, 2005). 
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In addition, studies on plasma C-peptide collected from patients with type 11 
diabetes mellitus, cord blood from newborn, from healthy human islets and from 
insulinoma patients have also been analysed by ELISA assay (Paoletta et al, 2002). A 
prospective study of plasma C-peptide and colorectal cancer in men was carried out in 
2004 (Ma et al, 2004). The concentrations of plasma C-peptide, as a stable indicator of 
pancreatic P-cell function, were measured by ELISA (Ma et al, 2004). 
Another clinical research study used different methods to measure different 
human proteins including leptin, insulin and C-peptide. The purpose of the study was to 
compare between different assays using human plasma (Liu et al, 2005). 
C-peptide measurements are also useful for insulin therapy, especially for type 11 
diabetes, monitoring the progress of pancreas or islet cell transplantation, insulinoma 
diagnosis and as a marker for residual pancreatic tissue after pancreatectomy (Ma et al, 
2004; Rudovich et al, 2004; Ito et al, 2005; Liu et al, 2005). 
The aim of this chapter is indirectly assess the amount of insulin secreted from 
human EBs into culture medium following various differentiation procedures using a C- 
peptide ELISA assay. The levels of C-peptide were compared to those produced by 
foetal pancreatic tissue collected from first trimester foetal samples (Table 1) and 
cultured in vitro and correlated with stages of pancreatic development as assessed by 
immunohistochemistry. 
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Table I 
( -I 'c I) I I( I L. 
A tahle indicating the numher of' I'Octal sampIcs used at cach gcstational agc 
for hi vitro culture and histoclicinistry. 
Age/week 
8 
9 
12 
Number of foetal 
samples for in 
vilro cuItu re 
I 
I 
2 
4 
Number of foetal 
samples for 
hislocheinistry 
4 
4 
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11. MATERIALS & METHODS 
1. Materials 
1.1 Human Foetal Sample Collection 
C-Peptide 
Foetuses (first trimester) were obtained with full ethical approval (South 
Sheffield Research Ethics committee, Professor Harry Moore as person responsible). 
Tissue was obtained with informed patient consent after counselling by a research nurse 
independent from the research group and following the Polkinghome guidelines. This 
was normally undertaken at the patient's first visit to clinic. Women underwent medical 
termination with Mefepristone and prostaglandin. 
Following termination, foetal tissue were put into cold DMEM medium and 
transferred to the laboratory within I hour. Foctal age was determined by the last 
menstrual bleeding and subsequently confirmed by the gross anatomy of forearm digits 
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(Moore et al, 2000). Foetuses were obtained at different ages of development from 8 -12 
weeks of gestation. In total 21 foetal samples were obtained for this study. 
The foetal pancreas was immediately recovered by stereoscopic microscope 
dissection in a Class 11 laminar flow hood using gauge 19 needles attached to Iml 
syringes. The foetus (usually intact) was removed from extra-embryonic membranes 
and placed in fresh cold medium in a Petri dish. The peritoneum was slit open and the 
contents removed by sliding a needle along the backbone and then carefully removing 
the entire internal alimentary canal and other associated organs including the liver. The 
pancreas was identified close to the liver by its distinctive lobular and granular 
appearance and removed intact. It was either prepared for culture in vitro, snapped 
frozen in liquid nitrogen and stored at -70 
0 C, or f ixed for I hour in 4% 
paraformaldehyde for later processing for paraffin sections (3 x8 weeks, 4x 10 week 
and 4x 12 weeks). 
1.2 Culture of Foetal Pancreas 
Using forceps and needle, the isolated pancreas was cut into small pieces under 
the dissecting microscope. The small pieces of pancreas were then washed with PBS 
without Ca+2 and Mg+2 and treated with 2 ml of Img/mI collagenase IV solution for 8- 
10 minutes at 37*C in 5% C02 in air. Tissue was also dispersed by scraping with 3mm 
glass beads, centrifuged at 200 g for 3 minutes, the supernatant removed and the pellet 
dissociated by moving them through the pipette up and down. Fresh RPMI 1640 media 
mixed with 10% FCS was added to the pellet and the cell suspension transferred to 
wells of 6-well culture plates and incubated at 37*C in 5% C02 in air. 
Medium was changed every two days. Conditioned medium (0.5ml) was 
collected from different samples on various days to measure the amount of C-pcptide 
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secreted (Table 2). Days of collecting media differed according to the availability of 
each sample. The collected media were stored at -80*C. 
1.3 Culture of EBs 
Conditioned media from cultured EBs, with different growth factors were 
collected after 7 and 14 days (see chapter 11) post passage. Conditioned media from hES 
cells, growing on MEFs, were collected 2-3 days post passage (Table 2). The collected 
media were stored at -80*C. 
1.4 Preparation of Washing Buffer 
From the concentrated (IOX) washing buffer (IX) dilution was prepared by 
mixing 100ml of (IOX) concentrated washing buffer with 900 ml distilled water. The 
solution was then stored in the refrigerator. 
2. ELISA Kit Reagents 
The human C-Peptide ELISA (Linco 20K, Missouri, USA) displayed specificity 
for human C-Pcptide and intact human proinsulin, but not human insulin, and was used 
to measure the C-peptide from the medium collected from different samples such as 
EBs grown with different growth factors, hES cells and human foetal pancreatic tissue 
at different ages in weeks (8w, 9w, I Ow, IIw and l2w) as mentioned in tables I and 2. 
The ELISA kit contained the following reagents: a microtitre plate, adhesive plate 
sealer, IOX washing buffer concentrate of 50mM TBS buffer containing 0.05% Tween 
20, human C-peptide standards (0.2,0.5,1,2,5,10, and 20ng/ml), ELISA C- peptide 
quality controls I and 2, human C-peptide matrix solution, assay buffer of 0.05M PBS 
containing 0-025M EDTA, 1% BSA with 0.08% sodium azide (pH 7.4), a detection 
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Table 2 Foetal tissue samples of' difIlerent ages were used to determine tile 
arnount of C-peptide secreted from them by I'LISA method. Cuiture 
medium was collected on different days after the beginning of' culture. 
Days of collecting media diff'ercd according to the availability and 
conditions. 
Sample Age/week Days ol'collcction after 
beginning CUlture 
1 8 4,9,15 
2 9 4,8,15,25,32,34,37 
3 9 7 
4 10 7,9,11,14,19,25,46 
5 11 3,5.8,12 
6 II 3 
7 12 3,5,9 
8 12 4,9 
9 12 3 
10 12 3,8,15 
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Table 3 
C-Pept I de 
The treatment of' Flis and lil, S samples, used to measure tile amount of 
C-pepticle by tile human C-pepticle F'LISA nictliod. 
Sample EBs EBs His Elis 
Gro"th Nicotinamidc Nicolinamide Nicofinumidc Actk in A 
Factor/s 
i FGI-2 i Actkin., \ f F(11.2 
Days 7 and 14 7and 14 7 and 14 7 and 14 
Collecting 
media 
Times 6 6 6 6 
Repeated 
hES 
2-3 
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antibody of biotinylated. anti-human C-peptide monoclonal antibody, enzyme solution 
of pre-titred streptavidin-horseradish peroxidase conjugate (SA-HRP), 3,3% 5,5'- 
tetramethylbenzidine (TMB)and stop solution of 0.3M HCL. 
3. Methods 
3.1 Quantification Analysis of Human C-Peptide 
Using the ELISA Assay 
3.1.1 Assay Procedure 
Human C-peptide ELISA was applied to the media collected from growing EBs 
with different growth factors, hES cells and pancreatic tissue from human foetuses with 
different ages of 8,9,10,11 and 12 weeks, to determine the concentration of C-peptide 
secreted by them into the media. 
All kit reagents and medium samples were pre-warmed to room temperature. 
The microtitre assay plate was washed three times with 300ýtl IX washing buffer. 20ýd 
detection antibody was added to all wells followed by addition of 101d assay buffer to 
the blank wells only. lOgI from each standard, 0.2,0.5,1,2,5,10 and 20ng/mI, and 
logl from each experimental kit control, QCI and QC2, were then added into wells in 
duplicate. DMEM/FCS medium, 101d, was used in duplicate as a fresh control. Media 
samples, 10ýfl, were added to the rest of washed wells in triplicates. Serum matrix and 
assay buffer, I Old and 40gl respectively, were added to the wells containing the blank, 
standards and experimental kit controls, while 50ýtl assay buffer was added to the wells 
containing the media samples. Moreover, the microtitre plate was then sealed and 
incubated at room temperature, 2- 5*C, while shaking on a microtitre plate shaker for 
about 2 hours. 
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Wells were washed five times with 3001A IX washing buffer. 80gl enzyme 
solution was then added to all wells and the microtitre plate was incubated at room 
temperature shaking on the microtitre shaking plate for 30 minutes. The addition of 80PI 
substrate solution into all wells then took place after 5 washing steps with 300PI IX 
washing buffer. Another incubation step for the microtitre plate at room temperature 
was carried out for 12-19 minutes. The reaction was then stopped by 80PI stopping 
solution followed by a gentle hand shake for the microtitre plate to mix the solution in 
each well. Finally, the reading was measured by spectrophotometer (DU 650, 
California, USA) at an absorbance of 450 nm. 
The experiment was repeated six times in triplicate for each EB sample growing 
k 
with different growth factors. 
4. ELISA Assay Readings 
The assay was repeated six times for most of the samples to show the 
consistency and reliability of the results that were obtained from the assay. The mean 
for each repeated sample was determined by adding the readings obtained for each 
sample divided by the total number of readings for the specific sample. The following 
formula was used: 
Meanforsamplel A+B+C+D+E+F where, 
N 
A, B, C, D, E and F= readings obtained for the same sample at different times. 
N= the total number of readings for a specific sample. 
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5. Immunohistochemistry 
C-Peptide 
The pancreas was prepared from three fbetuses at stages 8-9 week, 10-11 week 
and 12 week gestation. Tissue was fixed in 4% parafon-naldehyde overnight and 
then dehydrated and infiltrated and embedded with paraffin before 5-1 Oýtm sections 
were cut and mounted on microscope slides (Pathology Department, Medical 
School). The sections were deparaffinized and dehydrated, blocked for endogenous 
peroxide activity and antigen enhanced by microwave treatment before 
immunolocalisation. 
Slides were gently rinsed with PBS and incubated with four drops of normal 
rabbit serum (diluted 1: 30) for 30 minutes at 371C. The serum was blotted off and 
50gl of primary antibody diluted (1: 500) was used to cover the section which was 
incubated for I hour at 37'C. The slide was rinsed 3 times with PBS and then 501A 
of enzyme-conjugated secondary antibody (horseradish peroxidase and alkaline 
phosphatase) applied to cover the section which was incubated for a further hour. 
The slide was then rinsed extensively with PBS before incubation with appropriate 
substrate/chromogen (diaminobenzidene, Naphthol-AS-BI-phosphate/fast red TR) 
solution for immunostaining. The slide was rinsed gently with distilled water, 
counterstained with haemotoxylin and eosin solution and mounted with coverslip. 
The primary antibodies used are shown in table 4. 
Secondary horseradish peroxidase and alkaline phosphatase antibodies were all 
from Vector Laboratories. Control was with no primary antibody. 
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Table 4 
U-Pcptide 
The Primary antibodies used for immunohistoclicinistry of l'octuscs 
samples. 
Primary Antibodies Raised in Supplier 
Polyclonal human anti- Rabbit Zynied, ( ISA 
insulin 
monoclonal human anti- MOLISC signia Ltd 
glucagoil 
monoclonal IlUnian anti- MOLISC Novocastra Ltd 
CK19 
monoclonal human anti- C- Mousc Abcam hd 
peptide 
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III. RESULTS 
1. Culture of Foetal Pancreas 
C-Peptide 
The length of the foetal pancreas Tanges from 1-2mm (8 -9 weeks), 2-3mm (10 - 
II weeks) and 4-5mm. (12 weeks). For comparison, the crown-rump of the 10 weeks 
foetus was about 25mm. 
Ducts of the pancreas could be clearly seen by 8 weeks gestation (Figure IA). 
The developing organ was surrounded by a membrane but collagenase digestion for 
about 10 minutes made it easier to dissect out pieces of ductal and stromal tissue for 
incubation (Figure 113). Pancreas from 10-12 weeks had more membrane and required 
longer collagenase digestion. These pieces of tissue were placed in wells of six-well 
plates and rapidly adhered (within 10 minutes) to bottom of the well. In a few hours the 
ductal pieces rounded up (Figure IC). When stained with DTZ within 24 hours of 
dissection, only a few cells stained red for tissue from 8 weeks gestation. 
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Figure I (A) Pancreatic tissue (8 weeks) after collagcnase treatment showing 
ductal morphology. (B) A piece of tissue after needle dissection in 
culture. (C) Tissue after 24 hours in culture has rounded up. At 10 or 
12 weeks some aggregates show intense DTZ staining. N=3. 
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However, some aggregates displayed intense staining at 10 and 12 weeks (Figure I C). 
Within a few days there was rapid outgrowth of mesenchymal-like cells from the 
tissue pieces (Figure 2A) and confluence of these cells surrounding the aggregate was 
achieved within a week. The cells displayed a characteristic cobblestone appearance 
(Figure 213). Epithelial outgrowths of the ductal aggregates also occurred after few days 
(Figure 2A, arrow). These eventually rounded up into characteristic morphology (Figure 
213, arrows). If these aggregates were stained with DTZ then red staining was observed 
inside the epithelial outgrowths (Figures 2B and 2C). 
While the flattened mesenchymal-like continued to proliferate throughout the 
culture period to was more difficult to ascertain if ductal cells proliferated. By the end 
of two weeks there was little indication of proliferation, therefore cultures were 
terminated for DTZ staining and C-peptide analysis. 
2. Analysis of Human C-Peptide Using 
ELISA Assay 
The quantities of C-peptide secreted into the medium from growing the EBs 
with different growth factors and foetal tissues were determined by using a human C- 
peptide ELISA assay. The Standard curve is shown in Figure 3, where the lower limit to 
be detected by the assay is 0.1 ng/m 1. 
C-peptide readings obtained from the cultured EBs grown with different growth 
factors, after 14 days incubation, hES cells and the human foetal tissues at different 
gestational ages from 8 weeks to 12 weeks were shown in tables 5 and 6 respectively. 
Culture medium was recovered from foetal pancreas tissue cultures between 3 and 46 
days of incubation depending upon the sample. In addition, means 
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Figure 2 (A) Pancreas aggregate (10 week foetus) after 5 days in culture showing 
mesenchyrnal cells and ductal outgrowth (arrow). (B) At 10 days ductal 
outgrowth round tip and stain red with DTZ. (C) highcr magnification of (B). 
N=3. 
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Figure 3A graph showing the human C-peptide standards curve as given by 4 
parameter logistic (4-PL) curve-fit software in the PC connected to the 
plate reader. Y axis = Optical Density, while X axis = the C-peptide 
concentrations (ng/ml). Proprietary software with the reader analysed 
the data and created the curve. 
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Table 5 The readings (ng/rnl), means and standards deviations obtained from the 
C-peptide F'LISA 1'()r cultured I'lls with diflerent groýWi I'actors: 
nicotinarnidc, nicotinanlidc i FGF2, nicotinamide I activin A, Activin A 
+ FGI-2, control sample and hFS cell, sample. 
Sample Reading Reading Reading Reading Reading Reading Mean 
1 2 3 4 5 (1 1 SI) 
Control 0.047 0.042 0.046 0.041) 0.0-44 o. o42 0.045 
0.003 
Nicotinamide 0.045 0.047 0.045 0.05 0.046 0.043 0.046 
0.002 
Nicotinamide 0.05 0.046 0.049 0.048 0.041) 0.003 (). 05 1- 
0.006 
+ FG F2 
Nicotinamide 0.048 
+ Activin A 
Activin A+0.040 
FG F2 
hES 0.052 
0.045 0.049 0.047 0.041) 0.051 0.048+ 
0.002 
0.048 0.044 0.041) 0.05 7 0.0 
0.005 
0.049 0.051 
0.002 
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Table 6 The readings obtained from the hunian C-Peptide FHSA for l'Oetal tissue 
sarnples of' different ages (8,9,10, 11 and 12w), w= ýweks and d 
days. 
Sample Colic. (Ilg/1111) A 1114) 11111 0 1* C- 
Ileptide Seereted 
ellitilre (lig/1111/11r) 
Foctal I (9)%N, (4d) 0.053 Not detected 
(8d) 0.055 Not detected 
Foetal 2 (9)\v (4d) 0.062 Not detected 
(8d) 0.058 Not detected 
( 15d) OM04 Not detected 
Foctal 3 (9\%) (7d) 0.08 Not detected 
Foctal 4 (1 0)\N, (7d) 0.104 0.00 1 
(9d) 0.054 Not detected 
I Id) 0.083 Not detected 
(14d) 0.081 Not detected 
(19d) 0.051 Not detected 
(25d) 0.055 Not detected 
(46d) 0.051 Not detected 
I-octal -5 1 I)w (3d) 1.975 0.03 
(5d) 2.189 0.02 
(8d) 1.80 1 (). () I 
(12d) 2.355 0.009 
I ocuil 011 )%% (ýd) 0.03 0.005 
Foctal 7 (12)\ý (3d) 0.245 0.003 
(5d) 0.279 0.002 
(8d) 0.047 Not detected 
Foctal 9( 12)\\ Od ý 0.007 Not detected 
(9d) 1.586 0.009 
Foctal 9 (12)\\ (_5d) 1.31) 0.012 
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Foetal 10 (1 2)w (3d) 1.214 0.02 
(8d) 1.901 0.0 1 
(15d) 1.75 0.005 
('-I lept I (I C 
Continuation from the previous page ofthe readings obtained from the human ('-peptidc 
ELISA for foetal tiSSLies samples ot'difilcrent ages. 
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and standards deviation of cultured EBs with different growth factors were also shown 
in table 5. Whereas C-peptide could not be detected readings obtained in EBs samples 
in culture for 7 days with different growth factor combinations. 
The assay was repeated six times for each EB sample to check the 
reproducibility and reliability of the results obtained from the assay, as shown in table 3. 
In four experiments, using nicotinamide alone, when culture medium and cells were 
taken together from EBs samples at 14 days of culture and freeze-thawed twice to 
release intracellular content, 8-10 EB colonies, the concentration of C-peptide was 0.26 
:L0.2 1 ng/ml (Table 7). 
For foetal samples before week II C-peptide was absent from culture 
supernatant except for one medium sample from a week 10 tissue culture. However 
most samples of medium from week 11 and 12 tissue cultures showed positive levels of 
C-peptide. 
3. Immunohistochemistry of Foetal Pancreas 
By week eight of gestation pancreas displayed ductal epithelium surrounded by 
extensive stromal tissue and ductal cells exhibited clear cytokeratin 19 expression 
(Figure 4A and B). The amount of staining in individual ductal cells was variable at 
week 8 (Figure 413), but the consistency and intensity increased by 10 (Figure 4C) and 
12 weeks. 
in two samples of pancreas at eight week gestation, insulin/C-peptide was 
either absent (Figure 5A), or only present in a few cells mainly of ductal origin rather 
than in the stroma (Figure 5B). It is possible that the pancreas showing no expression 
was from a growth retarded individual as crown-rump measurement was only 19mm 
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Table 7 The readings (ng/ml), means and standards deviations obtained From the 
C-peptide ELISA for 8-10 cultured FIB colonics with n1cotinamide only. 
Sample Reading Reading Reading Rcading Mean 
1 2 3 4 f SI) 
1 0.06 0.06 0.07 0.06 (). ()o 0,0(). s 
2 0.14 0.14 0.14 0.14 0.14 +0.0 
3 0.33 0.32 032 (01 0.32 0.009 
4 0.53 0.53 0.53 0.53 0.53 1-0.0 
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Figure 4 Cytokeratin 19 irnmunolocalisation in week 8 and 10 pancreas. (A) week eight 
pancreas showing ductal epithelium and surrounding stromal cells. CK19 
staining is clearly detected but variable in ductal cells. (13) Higher 
magnification. (C) Week 10 pancreas shows increased intensity of CK19 
staining and less variability. Brown stain was diarninobenzidine with 
haernotoxylin counterstain Controls showed no staining. Ný3 and 4 
respectively. 
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Figure 5 (A) A Pancreas section from most immature week 8 loetus. No 
insulin localisation. (11) Week 8 pancreas showing a sinall arnOLInt 
of insulin immunolocalisation. (C) Week 10 pancreas displaying 
insulin immunolocalisation. Controls showed no staining. 
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which was smaller than normal (usually 25-30mm) and gross morphology of the 
pancreas was immature. An apparently retarded foetus could be mis-classiried as the 
length of pregnancy is determined from the last menstrual period and this method is not 
always accurate especially if menstrual cycles are irregular. However, there could also 
be other abnormalities of the foetus or placenta leading to retarded growth. 
By 10 weeks insulin expression was greater and all samples displayed some expression 
(Figure 6A). There was indication of positive cells moving into the stroma as shown by 
insulin/CK19 co-immunolocalisation (Figure 6B and C). Week 12 pancreas expressed 
more extensive staining for insulin and there were clear indications of morphogenesis of 
islets of Langerhans (Figure 7). Individual cells in the ductal epithelium also showed 
intense insulin staining. 
Glucagon expression was detected in week 10 pancreas (Figure 8A) in ductal 
epithelial cells. This increased by week 12 when some cells in the stroma in putative 
islets were observed (Figure 813). 
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Figure 6 Higher I-nagn i fi cation of 10 weeks pancreas insulin inimunolocalisation. 
(A) insulin expression is mainly confined to ductal cells mainly. (B) co- 
localisation of CK19 (brown) and C-peptide (rcd-brown Naphol texas 
red). (c) the beginning of islet formation. N-4 
C-Peptidc 
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Figure 8 
C-Pcptidc 
 ;. 
Glugagon immunolocalisation in (A) week 10 pancreas and (13) week 
12 pancreas. N=4. 
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IV. DISCUSSION 
C-Peptide 
Because of the relation between C-peptide and insulin, a human C-peptide 
ELISA assay was used in the present study to measure the quantity of human C-peptide 
in cell culture medium. Nonetheless, the assay worked to capture the human C-pcptide 
in the examined samples, EBs and foetal tissues, by monoclonal antibody which is 
found in the microtitre wells. All the unbound materials were then removed by a 
washing step. Finally, the reaction was stopped by adding acid to the samples which 
gives a colorimetric endpoint that can be detected spectrophotometrically at an 
absorbance of 450 nm. 
Immunoreactivity for insulin, glucagon, somatostatin and pancreatic polypeptide 
(PP) was detected at 12-13 weeks gestation when immunohistochernical study of the 
development of endocrine cells within the human embryonic and early foetal pancreas 
was applied (Piper et al, 2004). However, insulin expression was detected closer to the 
end of the human embryonic period (Piper et al, 2004). 
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The results obtained from the human C-peptide ELISA method, (tables 5 and 6) 
showed that EBs samples which were grown in culture with different growth factors 
(nicotinamide, nicotinamide + FGF2, nicotinamide + activin A and activin A+ FGF2) 
for 14 days, did not secrete C-peptide in the media with all readings below the assay 
limit, which was O. Ing/ml or less. This may indicate that growing EB cells in culture 
with different growth factors may need more than 14 days which help the cells to have 
the ability to secrete more C-Peptide into the culture media. 
Foetal pancreas tissue samples at 8 and 9 weeks were also incapable of secreting 
C-Peptide into culture media. However, the level of C-Peptide secreted from samples at 
10 weeks gestation reached about 0.001ng/hr (Ipglhr) with levels increasing to reach 
about 0.0 1 ng/hr at II weeks. The amount of C-Peptide secreted from human foetal 
tissues varied between different wells of samples of the same age. However, this may 
due to the differences in the number of cells in each sample. Each well contained 
different sizes of pancreatic human foetal tissue and the number of cell secreting C- 
Peptide may have differed accordingly. In addition, isolation, dissection and incubation 
steps of the sample tissue in culture may have led to cell death. 
During the incubation period of the foetal pancreas tissue in culture the secretion 
of insulin decreased week by week and this may be due to the environmental differences 
that are found between in vitro and in vivo conditions. 
Moreover, the results obtained from the foetal tissues indicated that, even if the 
human fbetal pancreas developed completely morphologically, the P-cells will not 
secrete huge amounts of insulin until later in development i. e. at more than 12 weeks' 
gestation. 
in conclusion, the EBs which were grown in culture with different growth 
factor/s did not secrete C-peptide into the culture media as detected by ELISA. This 
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may have been due to the short incubation period of the EB cells in culture or the 
method that used to direct their differentiation from ES cells toward insulin secreting 
cells was not successful and needed improving. On the other hand, foetal tissues were 
shown to secrete C-peptide after 9 weeks gestation. 
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1. INTRODUCTION 
RT-PCR 
As discussed in chapter 1, the expression of a number of genes are important 
for pancreas and islet formation in vivo and therefore their expression in culture of 
differentiating embryonic stem cells may indicate development down a pathway 
towards an insulin-secreting cell. A profile of gene expression can therefore be used 
to characterise cell cultures (D'Amour et al, 2006). 
initially, PDX-I, defines a distinct compartment of the endodermal foregut 
that specifies the dorsal and ventral pancreas. Another gene expressed early in 
pancreatic development is the LIM-domain protein Isl-I (ISL-1) which is expressed 
in all types of islet cell in the adult. Isl-I may serve two functions. First, in the 
development of the dorsal mesenchyrnal cell, the presence of which is necessary for 
development of the exocrine pancreas, and second, in epithelial cells where its 
expression is necessary for differentiation of islet cells. Nestin has also been identified 
as a marker of a progenitor stem cell population. Early markers of islet differentiation 
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include genes such as Nkx2.2 (NKX2-2) and Nkx6.1 (NKX6-1) which produce 
homeodomain proteins. Nkx2.2 is expressed in a, P and PP cells of islets, whereas 
Nkx6.1 expression is believed to be restricted to the P cells and is therefore a useful 
marker of this cell type. Ngn3 (NGN3) is also important and leads to increases in 
endocrine cell differentiation factors (such as NeroDI) that push the cell towards a 
differentiated endocrine cell lineage. NeuroDI (NEURODI) is expressed in the 
developing endocrine pancreas, the small intestine, and the nervous system. NeuroD I 
has been shown to act downstream of ngn3 and Ist-1. The expression of Pax 4 (Pax4) 
is also important at this stage. Finally insulin-secreting cells should express genes 
related to their function including glucose transporter genes (Glut-I (SLC2AI) and 2), 
glucokinase (GK) and insulin (IDDM2) (D'Amour et al, 2006). 
Therefore, various combinations of genes related to the pancreatic and P-cell 
pathway have been used to characterise embryonic stem cells induced to differentiate 
to insulin-secreting cell types (D'Amour et al, 2006; Fukazawa et al, 2006). Such cells 
differentiated in vitro should have the ability to transcribe and process insulin, which 
can be detected by the reverse transcriptase polymerase chain reaction, RT-PCR 
(Segev et al, 2004). Hori and coworkers, in 2005, used RT-PCR to show the 
expression of some essential genes for pancreatic endocrine insulin-producing cells 
which were differentiated from human neural progenitor cells (Hori et al, 2005). 
Islet cells differentiation, which was derived from mouse, expressed insulin C- 
peptide, Glut-2 and Pdx-I when RT-PCR was applied on the RNA extracted from 
them. However, differentiated mouse ES cells showed changes in the levels of mRNA 
in the studied genes (Vaca et al, 2006). Islet-like clusters, which were differentiated 
from bone marrow stem cells showed an endocrine genes expression similar to that of 
the pancreatic P-cells. These genes include Pdx-1, insulin 1, glucagon, insulin 11, 
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somatostatin, Glut-2 and Pax-4 which were expressed by PCR (Tayaramma et al, 
2006). 
The chemistry of PCR depends on the complementary nature of the DNA 
bases (Murad el al, 2004). When a DNA molecule is heated to a certain temperature 
the hydrogen bonds that held the two strands together will break down into single 
strands. In addition, when the same solution cools down the hydrogen bonds between 
the bases of the DNA strands will re-nature to form the original DNA double helix 
form (Murad et al, 2004). PCR method includes three main steps. These steps starts 
with denaturation and ending with extension, with an in between annealing step. The 
three steps repeated in number of cycles between 20-45 cycles, and after each cycle 
the amplified target doubled (Murad et al, 2004). The denaturation step, first step, 
required an incubation of the DNA in a high temperature that can break down the 
hydrogen bonds between the double helix into single strands. The oligonucleotide 
primers then, bind to the specific region, to be amplified, on the template (Murad et 
al, 2004). In the second, annealing, step the temperature is reduced, to allow the 
primers to anneal to their complementary target sequences. However, the oligo primer 
anneals toward the 5' end of the template RNA and extend it with DNA polymerase 
to form the complementary cDNA. The best method to generate cDNA is reverse 
transcription of total RNA using Moloney Murine Leukaemia Virus reverse 
transcriptase, MMLV-RT, enzyme with gene specific primers or oligo (dTs) (Freeman 
el al, 1999; Ginzinger, 2002; Nishimura et at, 2006). These oligo primers can be 
either gene specific or not specific. On the other hand, oligo (dT) anneal to the RNA 
3' end and extend it (Freeman et al, 1999). 
The extension step is the third step in the PCR method. This step requires an 
intermediate temperature, where the polymerase binds to each oligo primer and 
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extension occurs. Following the RT reaction, the cDNA is ready to be amplified by 
PCR (Freeman et al, 1999; Murad et al, 2004). 
In this study, some of the genes expressed during pancreatic development 
were analysed (Figure 1) for expression in embryoid bodies cultured with various 
growth factors (Chapter II). 
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MATERIALS & METHODS 
1. Materials 
1.1 Preparation of Solutions 
1.1.1 TAE (Tris-Acetate-EDTA) Buffer (IX) 
RT-PCR 
To 10ml of TAE (IOX) solution was added 90ml of RNase-free water. The 
mixture was shaken well and stored at room temperature. Fresh (IX) TAE was used 
for each electroPhoresis run. 
1.1.2 Formaldehyde Gel Running Buffer (1%) 
In a 1000ml measuring cylinder, 100ml of (IOX) formaldehyde gel buffer was 
mixed with 20ml of (37%) formaldehyde and 880ml RNase-frcc water. 
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2. Methods 
2.1 RNA Extraction Using TRIzol 
After incubating EBs, derived from hES H7 S6, in culture for 14 days with 
different growth factors, cells were washed with (IX) PBS without Ce 2 and Me 2 
then transferred to a centrifuge tube. Cells pellet were collected by centrifugation at 
120OOg for 3 minutes. TRIzol reagent was added to the pellet, 2ml per 2x 106 cells, 
and the suspension was passed through the syringe several times to disrupt the pellet. 
The sample was incubated at room temperature for 5 minutes. Chloroform was added 
to the sample as 0.2m]/ Iml TRIzol reagent and the tube was shaken for about I 
minute. Another incubation time for 2 minutes and 30 seconds at room temperature 
took place. The tube was centrifuged at 120OOg for 15 minutes to remove cellular 
debris. The aqueous phase was removed and an equal volume of isopropanol was 
added to precipitate the RNA. After an incubation time of 15 minutes at room 
temperature, centrifugation was performed at 120OOg for 15 minutes. The pellet was 
left to dry at room temperature for few minutes and finally re-suspended in RNase- 
free water. 
2.2 DNase Treatment of Extracted RNA 
To the extracted RNA, 0.1 volume of (IOX) DNase I buffer (Ambion) was 
mixed with IgI DNase 1 (2 units) (Ambion). The mixture was incubated at 37*C for 
30 minutes then 5ttl of DNase inactivation reagent (Ambion) was added to the tube. 
The tube was incubated at room temperature for 2 minutes then centrifuged at I 00OOg 
for I minute to pellet the DNase inactivation reagent. The aqueous layer was removed 
and the steps were repeated again twice to clean up the RNA from any DNA residue. 
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2.3 Agarose, Gel Preparation 
Agarose gel was prepared by adding agarose powder (1%, 1.2%, 1.5% and 2% 
w/v) to (IX) TAE buffer. The mixture was heated in the microwave oven until no 
granules of agarose powder were visible. The molten agarose was allowed to cool 
down to about 65*C then 0.2gg/ml of ethidium bromide (10mg/ml) was mixed with it 
and poured into the gel tray. The gel was allowed to solidify for about 30 - 40 
minutes. Approximately two litres of fresh (I X) TAE buffer were poured into the tank 
to cover the gel surface to about 2cm above the gel. 
2.4 Formaldehyde Gel Preparation (1.2%) 
Agarose gel powder (0.6g) was dissolved in 5ml (IOX) formaldehyde gel 
buffer then RNase-free water added to the mixture to a total of 50ml. The mixture was 
boiled in a microwave oven until no agarose granules were present then left to cool to 
about 65*C. Formaldehyde (37%) was added to the gel, mixed and poured to the gel 
tray to solidify. 
2.5 Preparation of Loading Buffer 
Loading buffer for RNA samples was prepared in a ratio of 1: 2, RNA sample 
to loading buffer, by mixing 3[d of extracted RNA sample with 3 RI RNase-free water 
and 6ptl loading buffer. The mixture was heated to 65*C for 10 minutes then chilled on 
ice for few seconds. Samples were, finally, loaded into appropriate wells. 
2.6 Electrophoresis 
The electrophoresis apparatus was placed on a flat surface and leveled using 
the in-built adjustable legs. 
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The samples were taken out from the freezer, thawed then centrifuged in a 
microcentrifuge at 120OOg for few seconds. From each sample, IgI of cDNA were 
mixed with 21d loading dye and 7gl RNase-free water then loaded into the sample 
well. Into one well, 2gl of both high molecular weight (I Kb) DNA marker (Bioline) 
and (100bp) DNA ladder (Fermentas), used to estimate the size of cDNA fragments, 
was mixed with 2gl loading dye and 6gl RNase-firee water then loaded into the well. 
The electrophoresis tank was closed and connected to a power supply. The samples 
migrate from the cathode, negative electrode, to the anode, positive electrode. 
Electrophoresis was carried out at a constant voltage of 100 V with a current of 250 
MA for about 60 minutes or as required. 
The electrophoresis was monitored, by following the migration of the loading 
dye. When the dye reached to about the edge of the gel, the power supply was 
switched off. The gel tray was removed and placed on the surface of an ultraviolet 
transluminator 254 nm (Genius). The gel was then photographed using a video 
camera connected to a digital graphic printer (Sony). 
2.7 Synthesis of First Strand cDNA 
In a nuclease- free microcentrifuge tube, 2ýd oligo (dT) of 0.5gg/gl was added 
to 5gg of total RNA and up to 29[tl of RNase-free water as a final volume. The tube 
was heated at 70*C for 8 minutes then quick chilled on ice for 10 minutes. During this 
time a master mix was prepared in a separate tube on ice for a final volume of 40gl by 
mixing 8gl Moloney Murine Leukaemia Virus reverse transcriptase, MMLV RT, (5X) 
buffer (Promega), IgI MMLV RT enzyme (Promega), 21d dNTP's mix (25mM; 
Promega) and I til RNase inhibitor (Promega). 
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The sample tube was removed from the ice, mixed by vortex and centrifuged 
by pulse. The master mix was added to the sample tube and the mixture incubated at 
37*C for 2-3 hours. The reaction was then stopped by heating at 95*C for 2 minutes. 
2.8 Analysis of the Extracted RNA 
2.8.1 Quantification of RNA by Spectrophotometer 
The quantity of extracted RNA was determined by a spectrophotometcr 
(Beckman DU 650). RNA samples were diluted with RNase-free water in a final 
volume of I 001d in a euvette and readings were taken. 
The optical density (OD) of each RNA sample was measured at two 
wavelengths, 260nm and 280nm in triplicates. The 260 nm/ 280 nm ratio was 
calculated to determine the purity of RNA, where the desired range of ratios was 
between 0.9 - 1.5. The RNA concentration was calculated in gg/gl using the following 
formula: 
I OD = 40gg (for single stranded RNA)/ gl 
therefore, RNA concentration (gg/gl) = OD@260 X 40 X Dilution Factor (100X) 
The diluted RNA was stored at -800C. 
2.8.2 Analysis of the Quality of Extracted RNA 
The quality of the extracted RNA was analyzed by agarose gel elecrophoresis 
in order to evaluate the suitability of the RNA for PCR and to ensure that the 
extracted RNA is of high molecular weight and with minimal degradation. 
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2.9 RT-PCR Technique 
RI -1VR 
RT-PUR %Aas used in the pre-sent study and was performcd in a Tgraclient PCR 
machinc (Biometra). For the optimi/ccl proccclUrcs a gradient PUR ýýere used. 
In a final volume ol'301il aliquots the following was added: 
Chemicals 
loxhul't, cl. 
(dTTP, MIT, dGTII and All') 
50mM MgCT 
100pm/pl I'Orward primer 
100pni/pl reverse primer 
0.3units Taq polyrnerase 
cDNA milplatc 
Suppliers 
AlliblOll 
Ambion 
Anibion 
Metabion 
Mctabion 
Ambion 
IZNasc-l'rcc ýNatcr up to 30pl. In control sampics RNase-Frec \\alcr \us uscd Insicad ol 
cDNA template, where no positive controls were used. 
The PCR conditions used N%as as I'Ollows: 
Process 
initial Denaturation 
Denaturation 
Annealing 
Extension 
Teitil). 'Hole 
95'(' 30 scconds 
*(, x) x' 1 illin (22--40) Cycles 
72'(' 1 mill - 
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Final extension 72*C 5 min 
Hold 4*C for as long as required 
the annealing temperature selected according to the primers in use. 
RT-PCR 
The amplified products were then loaded into the agarose gel wells, 
electrophoresis was then applied, gel visualized on a UV transluminator and 
photographed. 
2.10 Primers Selection 
Primers which were selected in this study where chosen according to their 
importance in the development of endocrine progenitor pancreas. The genes used to 
apply in this study were selected according to their importance in the development of 
pancreas (Table 10). 
All the primers used in this study had been validated by colleagues in the 
laboratory for in other investigations.. 
2.11 Primers Design 
All primers in this study were designed to have about 45-55% GC content and 
with at least two GC base pairs at the last 3' end. To prevent the formation of 
secondary structure no more than three of the same bases were repeated through each 
primer. In addition, there was no more than two degree difference between the 
annealing temperature for each primers pairs, forward and reverse. 
By using Genbank database (httpH: www. ncbi. nlm. nih. gov) specific gene DNA 
sequences were obtained to determine the highly conserved regions and homologous 
genes. Primer pairs and the predicted products were BLAST searched to exclude 
nonsp- 
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Table 10 The human primers used in PCR and characterization. Tm: annealing 
temperature, bp: base pair and #: number. 
Gene of Accession Primers Sequences Product Tm # of 
interest Number (5' Y) size (bp) Cycles 
Pax-4 NM006193 F-ATG AAC CAG CTT GGG GGG CTC T 1161 58 30 
R-CTC CTT CCC ACT CCC TGC CTC A 
p-actin NM001101 F-ATC TGG CAC CAC ACC TTC TAC AAT 838 60 28 
GAG CTG CG 
R-CGT CAT ACT CCT GCT TGC TGA TCC 
ACA TCT GC 
Ngn-3 NM020999 F-TAG AAA GGA TGA CGC CTC A 768 52 38 
R-GAA GCA GAA GGA ACA AGT G 
P Fk x -6.1 NM006168 F-AAC AAT ATC CTG AGC CGG CC 629 55 38 
R-CGA GTC CTG CTT CTT CTT GG 
GK NM000162 F-CTG TGA CTG AAC CTC AAA CCC C 621 58 38 
R-AAG GAG AAG GTG AAG CCC AGG 
Oct-4 NM00270 F-CGA CCA TCT GCC GCT TTG AG 576 60 28 
R-CCC CCT GTC CCC CAT TCC TA 
Isl-1 NM002202 F-GGC CAA TAT TTC CCA CTT AGC 520 55 35 
R-GGC CCT CTC CAC CAC ATC 
Nestin NM006617 F-CCG CTA AGG TGA AAA GGG GTG TG 416 58 28 
_R-AGC 
GGA GGC ATT ACT TTA TTC AGG 
Glut-1 NM006516 F-CAT GTG CTT CCA GTA TGT GG 312 52 28 
R-GTC AGG TTT GGA AGT CTC AT 
Glut-2 NM- L09674 F-GCA GCT GCT CAA CTA ATC AC 265 60 38 
R-TCA GCA GCA CAA GTC CCA CT 
Pdx-1 NM000209 F-CCC ATG GAT GAA GTC TAC C 262 52 35 
R-GTC CTC CTC CTT T17 CCA C 
Insulin NM000207 F-GCC TTT GTG AAC CAA CAC CTG 261 58 35 
R-GTT GCA GTA GTT CTC CAG CTG 
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ecific primers and products. All the primers were obtained from metabion (Germany). 
The presence of genomic DNA, gDNA, was checked in all extracted RNA 
samples, between the DNase treatment and cDNA synthesis. 
2.12 Optimization Procedure 
By using aT gradient PCR machine (Biometra), the annealing temperatures 
for each primer pairs were optimized to obtain good PCR products. 
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III. RESULTS 
1. RNA Extraction 
RT-PCR 
25 - 30 EB colonies were generated by culture conditions with each different 
growth factor treatment (Activin A+ FGF2, Activin A, Nicotinamide + FGF2, 
Nicotinamide + Activin A and Nicotinamide) (chapter 11) for 14 days and used for 
extraction of RNA. 
The extracted RNA was of good yield and high quality as determined, from the 
readings measured, by spectrophotometer. In addition, the purity was also determined 
by the 260 nm/280 nm absorbance ratio which was ranged between 1.5 and 1.8. 
The final concentration of extracted RNA was diluted to 5[tg/[tl. The extracted 
RNA showed minimal degradation as visualized on 1.2% formaldehyde agarose gel as 
well as on 0.7% agarose gel (Figures 2 and 3). 
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Figure 2 Formaldehyde agarose gel (1.2%) shown the quality of RNA 
extracted from different FBs grown with different growth 
Factors. N= Nicotinanildc, AA ý Activin A and 2= FGF-I. This 
experiment was repeated tlour times lor each FIB sample grown 
with different growth factor/s. 
Figure 3 An agarose get (0.7%) sho%%Ing the RNA extracted from diffei-oit 
EBs gro%kn with different growth factors. Ný Nicotinamidc, AA 
- Activin A. The experiment was repeated ten times I'Or cach EB 
sample grown with different growth factor/s. 
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2. RT-PCR Technique 
RT-PCR 
The RNA samples which were amplified with RT-PCR technique, using all the 
primers which were listed in Table 1, indicated positive expression for some genes such 
as Pdx-1, insulin, Pax-4, GK and nestin which were expressed in almost all EB samples 
grown with the different growth factor combinations. 
On the other hand, Glut-2, Ngn3 and Nkx6.1 showed only slightly positive 
expression with all EB samples grown with different growth factors, while Glut-I , Oct- 
4 and lsl-I showed negative results, no bands were expressed, in all EB samples grown 
with different growth factors (Figure 4). 
The PCR experiments were repeated at least four times for each gene to obtain 
consistentand accurate results. 
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Figure 4 PCR products from different El3s, 117 S6, grown with difTerent growth 
factors. (A) Control (EBs grown in FBs medium, no growth factor/s was 
added, for the 14 days) (B) Activin A+ FGl-'-', (C) Activin A, (D) 
Nicotinarnide + FGF2, (E) Nicotinamide + Activin A and (1-') 
Nicotinamide. 
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IV. DISCUSSION 
RT-PCR 
Islet-like clusters which were differentiated from bone marrow stem cells 
showed an endocrine gene expression similar to that of the pancreatic P-cclls. These 
genes include Pdx-1, insulin 1, glucagon, insulin 11, somatostatin, Glut-2 and Pax4 
which were expressed by PCR (Tayaramma et al, 2006). 
insulin and PDX-1 genes were detected by reverse transcriptase, RT-PCR from 
14 days cultured mouse ES cells (Vaca et al, 2006). 
RT-PCR study by Fujikawa and colleagues was used to generate insulin- 
producing cells from rat ES cells using a modified protocol of nestin positive cells. By 
using RT-PCR method they showed that transcriptional factors found in endocrine and 
pancreatic lineages such as PDXI, NKX2.2, NKX6.1, PAX6, nestin and insulin I and It 
were expressed, in vitro, in the rat ES cells. However, the undifferentiated ES cells did 
not express insulin message (Fuj ikawa et al, 2005). 
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Moreover, RT-PCR was used to detect pancreatic genes from murine thymus 
(Palumbo el al, 2006). Isolation of proinsulin-producing epithelial cells which were 
derived from cultured murine thymus expressed Pdx-1, Glul-2 and insulin I and 11 as 
shown by RT-PCR (Palumbo et al, 2006). 
The expression of endocrine hormone genes and proteins of human islet-like 
structures from pancreatic precursor cells was analyzed in culture by RT-PCR (Bodnar 
et al, 2006). The amplified genes included insulin, glucagon, somatostatin, pancreatic 
polypeptide (Bodnar et al, 2006). 
In addition, RT-PCR was performed to assess the expression of some genes 
involved in the P-cell differentiation pathway which were differentiated from hES cells 
such as GK, PDX-1, ISL-I, NKX6.1, GLUT-] and 2 and PAX-4 (Baharvand et al, 2006). 
Human foetal pancreases between gestational ages 8-21 weeks were shown to 
express PDX-1, insulin, cytokeratin 19, NGN3, glucagon, somatostatin, ISL-I, 
NEURODI, NKX2.2, NKX6.1 and PAX6 during early development of the pancreas 
(Jiang et al, 2007; Gannon el al, 2008; Lyttle et al, 2008). While Sarkar and coworkers 
showed expression of insulin, glucagon, somatostatin, ghrelin and pp in the 
development of human foetal pancreases between gestational ages of 9-23 weeks when 
they used gene expression profiling (Sarkar et al., 2008). Moreover, PDX-1, GLUT- 
2(SLC2A2) and GK were implicated in playing an important role in the development of 
human foetal pancreases (Kaneto et al, 2007). 
In the present study PDX-1 gene was found in all EBs samples grown with 
different growth factors, this may indicated that all the growth factors which were 
selected in this study were encouraging the EB cells toward insulin containing cells but 
after maturation, especially with cells grown in nicotinamide where they display higher 
intensity of PCR product. 
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On the other hand, NGN-3 and nestin genes are mostly expressed in neural 
precursor cells as well as in progenitor cells. NGN-3 regulates the function of both ISL-I 
and PAX-4 genes in early stages of pancreas development. Thus, the presence of NGN- 
3, even if it was very little as showed from the bands in all EB samples, may indicate 
that the chance for expression of more ISL-I, which is always found in adult pancreas, 
PAX-4 and insulin later in development. 
NKX6.1 gene was not expressed in all EB samples grown with different growth 
factors except EBs with nicotinamide + FGF2. NKX6.1 gene is usually expressed at the 
termination of pancreas development. 
Insulin was expressed in about all EB samples especially in those cells grown 
with nicotinamide + FGF2 that showed a sharp band when repeating the experiment 
four times. This may be in accordance with the presence of some developed cells to 
become insulin-like cells, especially in nicotinamide + FGF2, that start secreting small 
amounts of insulin but with incubating all EBs cells, longer than two weeks, in culture 
they may secrete more amount of insulin. 
Oct-4 gene was not expressed in any EB samples grown with different growth 
factors. Oct-4 is expressed in undifferentiated cells and while the EBs cells start 
expressing other genes this means that the cells were differentiated towards a cell line so 
there was no Oct-4 in these differentiated cells. 
Glut-I and Glut-2 glucose transporter genes may not be expected to be 
expressed in immature insulin-like cells, and only in cells that become glucose 
responsive, which are mature insulin secreting P-cells. 
On the other hand, the similarities in gene expression patterns observed in the 
developing pancreas and central nervous system (CNS) can confuse conclusions about 
the differentiation of real insulin-secreting cells from ES cells when the only assay is 
139 
Chapter IV RT-PCR 
the expression of gene markers. For example, somatostatin, pancreatic polypeptide, 
Nkx6.1, and Glut-2 all have been detected in differentiated cells by RT-PCR, 
microarray analysis, or immunocytochemistry, from which it was concluded that insulin 
-like cells have been fon-ned. Although these genes are indeed expressed in pancreatic 
endocrine cells, they are also expressed in the CNS. 
In conclusion, as most of the 14 days cultured EBs, which were derived from H7 
S6 hES cells, showed positive expression for some genes e. g. Pdx-1, Ngn3, Pax4, 
Nkx6.1, Insulin and GK this may indicate the presence of insulin-like cells in culture 
but they may remain immature. 
To improve the amount of mature insulin-containing cells in culture, a longer 
incubation, for more than 7 days, with different growth factor/s may be recommended, 
while this may give the possibility to more cells to differentiated towards insulin 
containing cells. 
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1. INTRODUCTION 
Proteomics 
The proteorne is the expression of the total protein profile of a cell. Proteomics 
is the large-scale study of proteins, particularly their structures and functions. The 
development of proteomic technology gives the chance to determine genetic variants at 
the protein level within cells or tissue (Valmu el al, 2006) and it gives a much better 
understanding of an organism than genetic analysis alone. Firstly, the level of 
transcription of a gene gives only an approximate indication of level of expression as a 
protein. The mRNA might be produced but degraded rapidly or translated inefficiently 
in both cases resulting in a small amount of protein. Also many proteins undergo post- 
translational modifications that can affect their activity or composition and transcripts 
give rise to more than one protein, through the process of alternative splicing. 
Proteomics is also important for identifying biomarkers, such as markers that indicate a 
particular disease or for identifying stages of development. 
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To determine the number of proteins in a sample and their composition and 
identity they must be first extracted from the sample and then individually separated. 
Protein separation can be performed using two-dimensional gel electrophoresis (213 
PAGE), which separates proteins first by their isoelectic point (PI) and then by their 
molecular weight. Protein spots in a gel can be visualized using a variety of chemical 
stains (or fluorescent markers) and can be semi-quantified by the intensity of the stain. 
image analysis software can be used to make comparisons between gels of two different 
samples. 
Once proteins are separated and quantified, they can be analysed to determine 
their precise composition. Individual spots are cut out of the gel and cleaved into 
peptides with proteolytic enzymes. The peptides can then be identified by mass 
spectrometry. However, spots may contain a mixture of proteins. Protein mixtures can 
also be analyzed without prior separation and are oflen injected onto a high pressure 
liquid chromatography column (HPLQ that separates peptides based on 
hydrophobicity. HPLC can then be coupled directly to a time-of-flight mass 
spectrometer using electrospray ionization. It is very useful in producing ions because it 
overcomes the problem of molecular fragmentation when macromolecules are ionized. 
John Bennett Fenn was awarded a Nobel prize in 2002 for development of electrospray 
ionization. Pcptides eluting from the column can be identified by tandem mass 
spectrometry (MS/MS). The first stage of tandem MS/MS isolates individual peptide 
ions, and the second breaks the peptides into fragments and uses the fragmentation 
pattern to determine their amino acid sequences. A particular type of MS/MS is called a 
Q-Tof (quadrupole time of flight) and has two analysers. The first is a quadrupole 
analyscr that is used as an ion guide in MS mode, but as a resolving analyser in MS/MS 
mode. The second analyser is a reflectron time-of-flight analyscr placed at an angle to 
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the quadrupole. The final detector is a microchannel plate detector for high sensitivity. 
in MS/MS mode, the two analysers are used together for structural studies by 
monitoring fragmentation patterns in molecules. The fragmentation patterns of peptides 
are particularly well documented and the information of an unknown peptide can be 
compared with databases. 
There are a number of proteomic studies on the human adult pancreas (Hu, et al 
2004; Shen et al, 2004) and on the human adult islets (Ahmed, et al 2005). But there is 
no proteomic study on the differentiate protein expression between two different ages of 
foetal pancreas. By studying the developmental stages of the pancreas will increase our 
knowledge of pancreatic development and perhaps lead to a greater understanding in 
how the basic mechanism of endocrine homeostasis is maintained and to how a disease 
state may arise when one or more of the mechanisms are disrupted. 
The aim of this chapter was to determine the proteome profile of the human 
foetal pancreas between weeks 10 and 12 when islet formation was shown to first occur 
(Chapter 111). 
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MATERIALS & METHODS 
1. Materials 
1.1 Foetal Pancreas 
Proteomics 
Collection of foetal pancreas was as described in Chapter 111. The age of the 
foetus was estimated from last menstrual bleeding and then determined by forearm 
digit morphology. The foetal pancreas was recovered by microscopic dissection. A 
small sample was prepared for immunobistochemistry as described in chapter III and 
the rest placed on aluminum foil and snapped frozen in liquid nitrogen and then stored 
at -700C. 
2. Methods 
These experiments were carried out in conjunction with Dr Chi Wong, 
Proteomics Facility, Centre for Stem Cell Biology. 
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2.1 Two-Dimensional Gel Electrophoresis 
The isoelectric point (pl) is the pH at which a molecule or surface carries no 
net electrical charge. A protein at its pI will therefore not migrate in an electric field at 
this point and molecules of the same pI will become focused. When combined with 
separation according to the size of the molecule, molecular weight, MW, (2nd stage 
MW separation) a spot of protein with molecules of the same pl and MW occurs. This 
process is called two dimensional gel electrophoresis (2D-PAGE). 
2.1.1 Sample Preparation 
Foetal pancreas was cut into small pieces and proteins were extracted using 
the Grinding kit (Amersham. Biosciences) in lysis solution (6M urea, 2M thiourea, 
40mM DTF, 2% wIv CHAPS, 0.5% v/v IPG buffer, protease inhibitor cocktail 
(Sigma)). After grinding for I minute the sample was centrifuged at 5OOg for 3 
minutes and the solution transferred to a fresh microcentrifuge tube. PlusOne 2D 
Clean up kit (Amersharn Biosciences) was used according to the manufacturer's 
instructions to desalt and remove DNA/RNA contaminants from the lysis solution. 
The final protein pellet was resuspended in 6M urea in 2% CHAPS, and the protein 
concentration was determined by the BCA (Bicinochoninic acid) assay (Smith et al, 
2007). 
2.1.2 Isoelectric Focusing 
Samples (200gg of total proteins) were passively hydrated into 18cm 
immobiline DryStrips pH 4-7 (Amersham Biosciences, UK), ovemight at room 
temperature. The proteins were resolved under the following conditions: 50OVhr 
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gradient, lOOOVhr gradient, 8000 V step-n-hold, for a total of 32500kVhr using the 
IPGphor system (Amersham Biosciences). The resolved proteins were reduced in 
loml of equilibration buffer (6M urca, 30% v/v glycerol, 2% w/v SDS and 0.25% w/v 
bromophenol blue in 50mM Tris-HCI p1l 8.8) containing I OOmM DTT for 15 minutes 
followed by alkylation for 15 minutes in 10ml of equilibration buffer containing 350 
mM iodoacetamide. 
2.1.3 2 nd Dimension Gel Electrophoresis 
The Ettan DALT 6 electrophoresis system (Amersham Biosciences) was 
assembled according to manufacturer's instructions. Focused and equilibrated 
pancreatic protein strips were placed on top of a pre-cast 12.5% homogenous SDS- 
PAGE gel (24 x 24 cm, Amersharn Biosciences), scaled with 2% molten agarose and 
ran at 250C at 5 W/gel for 30 minutes, then at 18 W/gel for 4 hrs. These gels were 
fixed overnight with 40% methanol in 7% acetic acid. The fixed gel were stained with 
Brilliant Blue Colloidal concentrate (Sigma, UK) for 2 hours, destained for I minutes 
with 25% methanol in 10% acetic acid and washed in 25% methanol until the gel 
background was clear. 
2.2 Gel Analysis 
Stained gels were scanned with the flat bed ImageMaster Scanner and 
LabScan software (Amersham Biosciences). Gel images were normalized and 
differential protein expression were analysis using the ImageMaster 2D Platinum 
software (Amersharn Biosciences). 
Gel spots were cut and transferred to a 0.5ml siliconiscd tube using the GclPal 
spot cutter (Genetix, UK). Excess water was removed and spots destained with 300ýd 
of 50mM NH3HCO3 containing 25% acetonitrile (ACN) were added to the gel spot 
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for 30 minutes at 37"C. The gel pieces were dried under vacuum in a speed Vac 
(Eppendorf) for 15 minutes, rehydrated in 20gl of 200ng/ml modified trypsin solution 
(Promega, UK) in 5OmM NH3HCO3 solution and incubated overnight at 370C. 
Peptides were recovered by transferring the solution to appropriately labeled fresh 
microcentrifuge tubes. To recover the peptides from the gel pieces a four stage 
extraction procedure was used. Firstly, 15pi of 25mM N1131IC03 solution were added 
to the gel pieces, incubated for 15 minutes at 370C and transferred to labeled tubes. 
Secondly, 20ptl of ACN was added to the gel pieces and incubated at 370C for 15 
minutes followed by drying for 3 minutes by vacuum centrifugation. The dehydrated 
gel pieces were rehydrated with 40gl of 5% formic acid, incubated for 15 minutes at 
370C and then transferred to labeled tubes. The second step was then repeated for the 
final peptide extraction. The pooled peptide extractions were dried under vacuum 
centrifuge for 4 hours, resuspended in 12pl of 3% ACN containing 0.1% formic acid 
and transferred to recovery vials. 
2.3 MSMS Analysis 
Recovery vials containing peptides were placed into the liquid 
chromatography system, CapLC (Waters, UK). Peptides were first desalted through a 
5mm C18 PepMap pre-column (Dionnex, LC Packing, UK) and then separated 
through a 15CM C18 PepMap column (Dionnex, LC Packing, UK) under the 
following conditions: 5% - 85% B (95% ACN and 0.5% formic acid) over 45 
minutes, 85% B for 2 minutes, 85%-5% B for I minutes, 5% B for 12 minutes. The 
eluent from the reverse phase column directly sprays into the QTOFA mass 
spectrometer (Waters, UK). The Q-TOFýL was controlled by MassLynx v4 (Waters), 
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parent ions were acquired and analyzed by data dependent analysis (DDA) that saves 
the data as peak list. 
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Z-spray 
Ion Source 
Probe 
Ouadrupole Hexapols, 
Analyser Transfer Lens 
MCP 
Detector 
Figure I (A) Electrospray: the ion source (11) Capl. C (Waters Coporation) 
liquid chromatography system: mass analyscr and (C) Q-TOF micro 
(Waters Corporation) MS/MS analyzer: detector system (D) Diagram 
of mass spectrometer. 
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Peak list data were analyzed by Mascot (Matrixsciences, UK) under the 
following criteria: MSDB database, taxonomy: mammals, variable modifications: 
carbamidomethyl C and oxidation M; peptide tolerance: ± 0.5 Da; MSMS tolerance: ± 
0.5 Da. 
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III. RESULTS 
Proteomics 
Immunohistochernistry of insulin and glucagons showed the same pattern as 
described in chapter III indicating the samples were of the developmental age expected. 
Pancreas from at least three week 10 foetus were required for obtaining 
sufficient protein for spot resolution on the 2D PAGE for MS analysis. Two pancreases 
from week 12 samples were sufficient. 2D PAGE gels of pooled protein samples of 
week 10 and week 12 foetuses are shown in Figures 2 and 3. As expected the protein 
profiles showed differences. 
Expression of 81 and 132 proteins from week 10 and 12 foetal pancreas, 
respectively were detertnined and analysed. Of these, 13 proteins were found only in 
week 10 foetal pancreas (Table 1), and 75 proteins found only in week 12 pancreas 
(Table 1). However, the samples did share common proteins such as house keeping 
proteins (heat shock proteins, alcohol dehydrogenase [NADP+]) and structural protein 
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Figure 2 2D PAGE gel of protein extracted from week 10 tbetuses. Obtained from 
three foetal pancreases of 10 weeks gestation which were pooled 
together. 
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Figure 3 2D PAGE gel of protein extracted from week 12 foetuses. Obtained frorn 
two foctal pancreases of 12 week gestation which were pooled together. 
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Table 1 Differential expression of proteins between foetal pancreas at week 10 
and week 12. Individual ions scores > 40 indicate identity or extensive 
homology (p<0.05). MW: molecular weight, pl: isoelectric focusing 
point, Mowse Score: molecular weight search, and #: number. 
Theoret ical 
Triosephosphate TIM, Triose-phosphate P60174 26522 6.5 67 
isornerase isornerase. 
Translation elongation EF-Tu, P43. S62767 49509 7.3 71 
factor EF-Tu 
Superoxide dismutase P00441 15926 5.7 86 
[Cu-Znl I 
Proteins Synonyms Primary MW P1 I Mowse 
accession # Score 
Protein disulfide disulfide isornerase ER-60, P30101 56761 218 
isornerase A3 ERp60,58 kDa microsomal 
protein, p58, ERp57,58 
kDa glucose regulated 
protein. 
Nucleophosmin NPM, Nucleolar P06748 32603 4.6 36 
phosphoprotein B23, 
Nurnatrin, Nucleolar protein 
N038. 
Macrophage capping actin-regulatory protein P40121 39949 5.9 49 
protein CAP-G. 
Keratin 6C P48666 60032 56 
Keratin 6A Cytokcratin 6A, CK 6A, P02538 60008 8.1 45 
K6a keratin. 
Heterogeneous nuclear hnRNP 11. P31943 49099 5.9 116 
ribonucleoprotein H 
Hemoglobin y-chain Q68NI19 16092 6.6 219 
variant Hb. M-Circleville 
Heat shock cognate Heat shock 70 kDa protein P11142 70827 5.4 511 
71 kDa protein 8. 
F-actin capping protein CapZ alpha-2. P47755 32904 5.6 39 
ct-2 subunit I I 
Calreticulin CRP55, calregulin, HACBP, Q9UDG2 I 470 19 I 7 
ERp60, gT60. 
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Continuation from the previous page of the differential expression of proteins between 
foetal pancreas at week 10 and week 12. Individual ions scores > 40 indicate identity or 
extensive homology (p<0.05). 
Theoretical 
Proteins Synonyms Primary MW PI Mowse 
accession N Score 
Annexin A5 Annexin V, lipocortin V, P08758 35787 4.9 262 
cndoncxin 11, calphobindin I 
CBP-I, placental 
anticoagulant protein 1, 
PAP-1, PP4, 
thromoboplastin inhibitor, 
vascular anticoagulant- a, 
VAC-ct, anchorin CIT. 
Annexin A6 Annexin VI, lipocortin VI, P08133 75724 5.5 179 
P68, P70, protein 111, 
chromobindin 20,67 kDa 
calelectrin, calphobindin-11, 
CPB-11. 
Collagen ct-2 (VI) chain P12110 108269 5.8 56 
precursor I 
Proliferation associated Cell cycle protein P38-3G4 Q9UQ80 43787 7.1 136 
protein 2G4 homolog, hG4-1. 
14-3-3 protein y Protein kinase C inhibitor P61981 28171 4.8 209 
protein -1, KCIP-1. 
Peroxiredoxin 2 Thioredoxin peroxidase 1, P32119 21873 5.7 114 
thioredoxin-dcpendent 
peroxide reductase 1, thiol- 
specific antioxidant protein, 
TSA, PRP, natural killer cell 
enhancing factor B, NKEF- 
B. 
Heat shock protein beta- Heat shock 27 kDa protein, P04792 22768 6.0 84 
1 (need more analysis) HspB 1, HSP 27, stress- 
responsive protein 27, 
SRP27, estrogen-rcgulated 
24 kDa protein, 28 kDa heat 
shock protein. 
Iron responsive element Citrate hydrolyase, P21399 98398 6.2 52 
binding protein I aconitase. 
Heat shock protein HSP 84, IISP 90. P08238 98398 6.2 330 
HSP90-P 
Elongation factor 1-8 EF- 1 -8, antigen NY-CO-4. P29692 31203 4.9 53 
Lamin BI LMNBl, LMN2, LMNB. P20700 66368 5.1 617 
Acylamino acid releasing AARE, Acyl-peptide P13798 81274 5.3 54 
enzyme hydrolase, APH, 
Acylaminoacyl-peptidase, 
oxidized protein hydrolase, 
PH, DNF15S2 pro in. 
Gelsolin, plasma Actin-depolymerizing PC6396 85679 5.9 88 
factor, ADF, grevin, AGEL. 
1 
Caldesmon CDM. Q05682 93232 5.6 1 go 
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Continuation from the previous page of the differential expression of proteins between 
foetal pancreas at week 10 and week 12. Individual ions scores > 40 indicate identity or 
extensive homology (p<0.05). 
Theoretical 
Proteins Synonyms Primary MW PI Mowse 
accession 9 Score 
Aldehyde dehydrogenase Aldehyde dehydrogenase, P00352 54712 6.3 695 
IAI cytosolic,. ALDII class 1, 
retinal dehydrogenase 1, 
ALHDII, ALDII-E I. 
T-complex protein 1, TCP- I -cc, CCT-a. P17987 60325 5.8 507 
a-subunit 
T-complex protein 1, y- TCP I ring complex protein P49368 60402 6.1 74 
subunit TriC5, TCP-1- y, CCT- y. 
T-complex protein 1, E- TCP-I-e, CCT-e. P48643 59653 5.4 427 
subunit 
Dihydropyrimidinase DRP-2, collapsing response Q16555 62275 5.9 123 
related protein-2 mediator protein 2, CRMP- 
(2 diff spots) 2, N2A3. 
Dihydropyrimidinase DRP-3, Unc-33-like Q 14195 61945 6.4 204 
related protein-3 phosphoproteins, ULIP 
protein, collapsing response 
mediator protein 4, CRMP-4 
Bifunctional purine OK/SW-cl. 86, P31939 64447 6.8 250 
biosynthesis protein phosphoribosylaminoimidaz 
PURK olecarboxamide 
formyltransferase, EC 
2.1.2.3, AICAR 
transformylase, IMP 
cyclohydrolase, EC 
3.5.4.10, inosinicase, IMP 
sy thetase, ATIC. 
Fibrinogen beta chain Fibrinopeptide B P02675 55910 8.7 184 
precursor 
a-internexin cc-Inx, 66 kDa Q16352 55390 5.3 281 
ncurofilament protein, 
neurofilamcnt-66, NF-66. 
Serine/threonine protein 65 kDa regulatory subunit P30153 65092 5.0 53 
phosphatasc 2A A, alpha isoform, (PP2A, 
subunit A, PR-alpha 
isoform), (PP2A, subunit A, 
Rl-alpha isoform), medium 
tumor anti gcn-assoc: iated 61 
kDa protein. 
Probable protein Disulfide isomerase ER-60, P30101 56764 6.0 798 
disulfide isomerase A3 Erp6O, 58 kDa microsomal 
protein, p58, Erp57,58 kDa 
glucose regulated protein. 
HSC70-interacting Hip, putative tumor P50502 41313 5.2 98 
protein suppressor ST13, 
progesterone receptor- 
associated p48 protein. 
Heterogeneous nuclear hnRNP F. P52597 45653 5.5 104 
ribon icleoprotein F 
_Esýý 
PRPH. P41219 
_O 
1 5.4 1 144 
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Continuation from the previous page of the differential expression of proteins between 
foetal. pancreas at week 10 and week 12. Individual ions scores > 40 indicate identity or 
extensive homology (p<0.05). 
Theoretical 
Proteins Synonyms Primary MW PI I Mowse 
accession # Score 
Cytokeratin 8 Keratin 8, cytokeratin 8, K8, P05787 53525 5.5 648 
CK8. 
Cytokeratin 19 Cytokeratin 19, keratin 19, P08727 45870 5.2 549 
K19, CK19. 
cc =centractin Centratin, centrosome- P61163 42595 6.2 98 
associated actin homolog, 
actin-RPV, ARPI. 
NG, NG- Dimethylargininase 2, 095865 
dimcthylarginine dimethylarginine 
dimchtylarninohydrolase dimcthylaminohydrolasc 2, 
2 DDAHII, G6a, S-phase 
protein. 
Rho GDP-dissociation Rho GDI 2, Rho-GDl beta, P52566 
inhibitor 2 Ly-GDl. 
Ubiquitin carboxyl- UCH-Ll, Ubiquitin P09936 
terminal hydrolase thiolesterase L I, neuron 
isozyme LI cytoplasmic protein 9.5, 
PGP 9.5, PGP9.5. 
>2fold increase 
expression in week 12 
*Alpha-2-fieremans Fetuin A, a-2-Z-globulin, P02765 39306 5.6 144 
Schmid glycoprotein Ba-cE-2-glycoprotein, 
R02743. 
*Serum albumin P02768 69348 5.9 
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such as actin and tubulin, and channel proteins such as chloride intracellular channel 
protein 1. 
There were significant differences in the relative proportion of signalling and 
structural proteins between pancreas at week 10 and week 12 (Figure 4). The proteins 
were grouped into functional categories based on the information provided in the 
UniProt Knowledge base (European Bioinformatics Institute, UK). 
Proteins found in both weeklO and week12 pancreases are also present in the 
adult human islet protein database (Ahmed et al, 2005). They include calrcticulin, 
superoxide dismutase (Cu-Zn), translation elongation factor EF-Tu, protein disulfide 
isomerase A3 precursor, triosephosphate isomcrase, Tumor rejection antigen (TRAI 
protein), transitional endoplasmic reticulum, ATPase, heat shock protein IISP 90-P, heat 
shock cognate 71 kDa, 78 kDa glucose-rcgulated protein precursor, heat shock 70 kDa 
protein 1,60 kDa heat shock protein, keratin 8, keratin 18, keratin 19, aldehyde 
dehydrogenaselAl, ATP synthase P-chain, Tubulin cA, brain specific, protein 
disulfide isomerase A6 precurosor, cc-enloase, P-actin, elongation factor 1-8, guanine 
nucleotide binding protein P-subunit, annexin A5, and glutathione S-transferase P. 
Specific examples of differences in protein expression patterns of 2D-PAGE arc 
shown in Figure 5A-E. The protein/peptide spot or isoforms of the protein varied 
between week 10 and 12 samples. For example, serotransferrin is0forms increased in 
expression in week 12 with the protein caldesmon completely absent in week 10 
samples (Figure 5A). Likewise, the alpha-2-liercman Schmid (11S) glycoprotein, had a 
number of isoforms that were expressed at elevated levels in week 12 as compared to 
week 10 while other isoforms were relatively unchanged (Figure 513). Cytokcratin 
proteins also displayed differences between week 10 and 12 samples. Cytokeratin 19 
and 8 were absent at week 10 but present at week 12 while other proteins of similar 
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Figure 4 Pie chart of proportion of the different functions of proteins/peptides 
detected by mass spectroscopy in pooled samples of 10 and 12 week foetal 
pancreas after 2D-PAGE analysis. Based on the peptide sequence, the 
function of the protein was assigned according to the information provided 
by Uniprot knowledgebase database, European Bioinformatic Institute 
(www. ebi. ac. uk). 
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Figure'-S Examples of differential spot analysis between week 10 and 12 pancreas 
2D PAGE showing some proteins detected at both developmental stages 
and proteins present or absent (open circle lor position). The whole gel 
was closely examined Jor diftlercnccs and spots recovered for analysis. 
(A) Caldesmon and serotransfierrin (13) Alpha-2-11S proteins (C) CK19 
(D) CK I, CK8, actin and protein disullide isomerase A3 (E) Vimentin. 
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molecular weight were not significantly different including cytokeratin I and actin 
(Figure 5C and D). In contrast vimentin was present in week 10 sample but absent at 
week 12 compared with surrounding proteins (Figure 5E). 
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IV. DISCUSSION 
Proteomics 
Proteornics is the study of the protein expression profile of ccils/tissues at the 
time of sampling. To date a number of proteomic studies on adult human pancreas (flu 
et al, 2004; Shen et al, 2400) and adult islets (Ahmed et al, 2005) have been performed. 
The results on foetal human pancreas here have shown that there are a number of 
proteins that were also found in the adult pancreas, indicating that the use of proteornics 
is a proven technique in the study of foetal tissues. 
There were significant differences in the relative proportion of signalling and 
structural proteins between pancreas at week 10 and 12 (Figure 4). This may reflect that 
the foctal pancreas at week 10 comprises mainly structural proteins, while at week 12 
there were significant increases in signalling proteins and these may correspond to the 
increase in islet development and activity. 
The use of the proteornics technique has shown that it can be used in the 
identifying differences between the foetal developmental stages. It has shown common 
162 
Chapter V Proteomics 
proteins between all different stages of pancreas as well as compared with the adult 
pancreatic proteome. A number of these proteins including calreticulin, superoxide 
dismuatase (Cu-Zn), Translation elongation factor EF-Tu, protein disulfide isomerase 
A2, triosephosphate isomerase, TRAI protein, translational ER ATPase, heat shock 
protein 90-cc, heat shock protein cognate 71 kDa protein, 78 kDa glucose regulated 
protein, cytokeratin 10, heat shock 70 kDa protein 1,60 kDa heat shock protein, 
aldehyde dehydrogenase IAI, ATP synthase b-chain, protein disulfide isomerase A6, 
cytokeratin 8, cytokeratin 18, cc-enloase, cytokeratin 19, actin, EFI-5, annexin A5 and 
GST-P were all expressed in adult human islets (Ahmed et al, 2005). It is unclear to 
whether all these proteins are involved in insulin synthesis and secretion. 
No pancreatic enzymes were found in the foetal pancreas and may be due to 
their relatively low concentration in week 10 and week 12 foetal pancreases. 
The protein, alpha-2-Hereman Schmid (HS) glycoprotein, has a number of 
isoforms that were expressed at elevated levels in week 12 as compared to week 10 
(Figure 5b). The function of cc-HS glycoprotein is uncertain but is found to be a natural 
inhibitor of insulin stimulated insulin receptor tyrosine kinase activity (IR-TK). The 
insulin receptor is found on cell surface and may play a physiological role in regulating 
insulin sensitivity, a condition of type 11 diabetes. Alpha-HS glycoprotein has been 
shown to inhibit autophosphorylation of the insulin receptor (Matthews el al, 2000) 
indicating that it may play a role in the regulation of insulin signaling and has been 
implicated in insulin resistance (Maegawa et al, 1991). It is interesting there was an 
increase in alpha HS glycoprotein corresponds with the insulin secretion and activity in 
week 12 pancreas. 
Keratins 1,6a, 6C, 8,9,10,18 and 19 were found in the pancreatic tissues 
between the two samples. While keratins I and 10 were most likely to be contaminants 
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because they showed greater similarity to bovine keratins so they might get it from the 
media (FCS), keratins 6,8,9,18 and 19 may play an important role in pancreatic 
development. 
Keratins are usually expressed in pairs, for example, keratin I and 10, keratin 8 
and 18/19, and can be tissue-specific and differentiation-specific manner (Bouwens, 
1998). The intermediate filament protein, cytokeratin 19 (CK19), is also of interest as it 
has been associated with pancreatic stem cells (Kang et al, 2005). Bouwens et al have 
shown, by immunohistochernistry, that CK19 is present in human foctal pancreatic 
epithelial cells and islet cells from week 12 to 16 (Bouwens el al, 1997). They have also 
shown that acinar and islet cells progressively losses the CK19 expression but the islet 
cells remains weakly antigenic until the end of gestation. Immunohistostaining showed 
that CK19 was also expressed on epithelial cells lining the ductal structures of week 7 to 
week 12 foetal pancreas (Chapter 111) and by week 10 cells around the ductal region 
start to synthesize insulin and appear to migrate away from the ductal structures by 
week 12 (Chapter III). However, the week 10 2D gels failed to identify CK19, but this 
may be due to smaller amount of the ductal structures in week 10 as compared to week 
12 foetal pancreas. 
When the proteins were categorized according to their functions, it revealed that 
there were little change in the relative proportions of proteins involved in transport, 
metabolism, catabolism, protein folding/protein complexes, cell adhesion/motility, cell 
growth/ maintenance/ proliferation, protein modification and others (Figure 4A and B). 
There were a relatively high proportion of structural proteins in week 10, which were 
expected as the major proportion of the pancreas consists of supporting and not 
specialized cell types. 
164 
Chapter V Proteomics 
Comparing the foetal protein data with those of the adult pancreas revealed that 
a lot of the foetal pancreatic proteins were not found in the adult pancreas. This may 
indicate that the proteins in the foetal pancreas may be involved in pancreatic 
development whilst those of the adult may be involved in pancreatic maintenance 
(Ahmed et al, 2005). 
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GENERAL DISCUSSION 
Immunofluorescent Localisation of Insulin-Containing Cells 
Derived from Human Embryonic Stem (hES) Cells 
A principal aim of this study was to generate insulin-secreting cells from human 
embryonic stem (hES) cells. If this process could be made efficient and robust then such 
cells might be used in the future for regenerative cell therapies to treat type I diabetes. In 
this disease, insulin-secreting cells of the islets of Langerhans are progressively lost from 
the pancreas due to a degenerative auto-immunity. Various growth factors were used to 
direct the differentiation of hES cells towards insulin-containing cells in a defined tissue 
culture protocol involving embryoid body (EB) formation. The factors were selected on the 
basis of their importance in the process of pancreatic differentiation in mammals and on the 
findings of previous studies in vitro. EBs formation were considered as a good step to start 
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the differentiation of cells, where cells in EBs can mimic those in the islets by way of cell 
to cell communication (Segev et al, 2004). 
Some spontaneous differentiation of hES cells in culture towards insulin producing 
cells was observed, however the number of cells expressing insulin was very low. A 
significantly greater number of cells apparently expressing insulin was obtained when 
culture medium was supplemented with nicotinamide alone, nicotinamide + FGF2, 
nicotinamide + activin A and activin A+ FGF2 compared with medium without growth 
factor supplements or various other combinations of growth factors (Chapter II). These 
findings are supported by a number of reports indicating that nicotinamide, FGF2 and 
activin A all have a positive effect on the generation of insulin-secreting cells from ES 
cells. 
The addition of nicotinamide as a growth factor to the cultured ES cells has been 
reported to be important in the differentiation of cells into insulin producing cells (Santana 
el al, 2006) although there are few studies of using nicotinamide alone as a supplement 
with culture medium. In the mouse model, Vica and co-workers (2007) showed that 
undifferentiated mouse ES cells treated with nicotinamide alone exhibited an 80% decrease 
in cell proliferation but produced a progenitor cell phenotype that co-expressed insulin, C- 
peptide and Glut-2. These cells after transplantation into diabetic mice, normalized blood 
glucose levels over a 7-week period. But exactly how nicotinamide exerts an action on ES 
cells to influence insulin-secreting cell differentiation remains unclear. Nicotinamide can 
act to remove free radicals that can attack cell membranes; is a component of the coenzyme 
NAD; and may act on DNA repair pathways (Knip et al, 2000). However, none of these 
processes are thought to be specific to pancreatic differentiation or ES cells. High doses of 
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nicotinamide seem to have a protective effect on P-cell survival and function in animal and 
during in vitro studies (Knip et al, 2000), and of relevance to the present study, 
nicotinamide stimulated formation of cultured foetal human islet-like cell clusters (Sandler 
et al, 1989). This protective action of nicotinamide suggests that it may prevent 
degeneration or apoptosis of insulin-expressing cells once they have formed rather than 
directly acting on hES differentiation. Thus nicotinamide may increase the number of cells 
surviving in culture and in this way indirectly support FGF2 and activin A. 
FGF2 play a role during definitive endodermal development to pancreas and 
therefore is more likely to have a specific action on hES cell differentiation. However, it 
may not necessarily improve the survival of cells expressing insulin once they are 
generated. For example, Segev and colleagues demonstrated that nicotinamide and FGF2 
together increased the insulin content in culture of differentiated P-cell-like cells from 
mouse ES cells after the formation of EBs (Segev et al, 2004). 
As hedgehog signaling inhibits tissue morphogenesis and cell differentiation during 
early stages of pancreas organogcnesis, it is required to maintain adult endocrine cell 
functions (Hebrok, 2002). However, FGF2 has the ability to repress endodermal hedgehog 
signals and allows the expression of pancreatic Pdx-I and insulin genes (Hebrok et al, 
1998; Dilorio et al, 2003). 
Transforming growth factor P, TGFP, signaling pathway is involved in many 
cellular processes like cell growth, proliferation, differentiation apoptosis and cellular 
homeostasis (Riedy et al, 1999; Florio et al 2000). Activin A is a member of TGFP 
proteins. Furthermore, TGFP and activin A are important proteins during the development 
of human embryo (Riedy et al, 1999; Florio et al 2000). 
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Activins are required for the specialization of pancreatic precursors and inactivation 
of activins enhance expansion of epithelial pancreatic cells and decrease the number of 
differentiated P-cells (Zhang et al, 2004). 
Activin A was also included as a supplement in the present experiments to enhance 
the differentiation of hES cells towards insulin secreting P-cell-like cells. Activin A may 
act to prevent self - renewal of hES cells and promote differentiation particularly to 
endoderm. Recently, it was shown by D'Amour and colleagues that activin A has the 
ability to direct the differentiation of hES cells towards endocrine progenitor cells even if 
they are in low numbers (D'Amour et al, 2006). However unlike these investigators, EB 
culture was used instead of an adherent culture method. It has been postulated that for 
efficient endoderin differentiation of hES cells it is better to avoid EB fonnation, as this 
may hinder uniform exposure of cells on the interior of the aggregates to medium and 
factors (D'Amour et al, 2006). This may be one reason why the proportion of insulin 
expressing cells in EB culture was relatively low compared to the D'amour protocol. 
In the current investigation, dithizone (DTZ) was used to check the presence of 
insulin containing cells in culture, which had been differentiated from hES cells. While this 
stain is not specific to insulin-secreting cells (as it detects zinc content rather than insulin) it 
still remains a good method of monitoring putative P-cells because of its ease of use. The 
results obtained from DTZ staining showed different percentages of cells stained red in 
human EBs colonies with the various growth factors and their combinations. Comparable 
cultures were then followed by immunostaining to confirm the presence of cells expressing 
insulin in culture. A similar procedure was used by others to detect insulin -secreting cells 
(Shiroi et al, 2005; DAmour et al, 2006). However it must be taken into account that 
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insulin containing cells may result from insulin absorption from culture medium and it is 
important to also detect C-peptide or hormone for other endocrine cells (Le glucagon). 
Blyszczuk concluded that nestin and C-peptide expression was important throughout the 
pathway of development of P-cell-like cells from ES cells to establish the presence of 
endocrine progenitor cells (Blyszczuk et al, 2004). Some investigators contend that 
differentiation of ES cells into insulin-secreting cells need development through a neuronal- 
like differentiation with cells expressing nestin followed by insulin later in differentiation 
(Brolen et al, 2005; Santana et al, 2006). 
Thus, DTZ staining was used in this study as a preliminary check for the presence 
of potential insulin-producing cells in EBs colonies. This was followed by immunostaining 
for nestin, glucagon (to detect progenitor immature insulin-producing cells), C-peptide and 
insulin (to detect mature insulin producing cells) to confirm the differentiation of hES cells 
towards an endocrine lineage. 
In summary some cells expressed the characteristics of insulin-expressing cells after 
hES differentiation to EBs but incubation periods longer than 14 days may be required in 
future to produce cells with greater insulin content and secretory capacity. 
2. Measurement of C-Peptide Secretion In vitro from ES- 
Derived Cell and Foetal Pancreatic Cells 
To quantify the amounts of insulin secreted from the cultured hES cells grown with 
different growth factors, a human C-peptide ELISA was used and comparisons made with 
cultures from fbetal pancreatic tissue recovered from 8-12 weeks gestation. Although the 
ELISA assay was reproducible and consistent, it was not very sensitive, so that even when 
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C-peptide was detectable it was at the lower end of the standard curve. A similar ELISA 
assay was used by D'Amour and colleagues, who differentiated hES cells into endocrine 
precursor cells and measured C-peptide levels (D'Amour et al, 2006). 
After various incubation periods, foetal pancreatic cultures exhibited islet-like cell 
clusters, which were very similar to those described previously by others for both foetal and 
adult pancreatic tissue (Sandler et al, 1989; Gao et al, 2003). Clusters of cells budded from 
tissue outgrowths showing ductal epithelial morphology and staining relatively intensely 
with DTZ stain. However these foetal cultures showed very limited proliferative capacity. 
The amount of C-peptide detected in culture supernatants was generally greater in foetal 
tissues of older gestational age indicating that pancreatic tissue before weeks 11-12 of 
foetal age secreted very little insulin. This observation was consistent with the immuno- 
histological staining of pancreatic tissue of equivalent developmental age (chapter III), 
indicating far fewer C-peptide/insulin positive cells present before 10 weeks while more 
insulin positive islet clusters by 12 weeks of age. However, prolonged incubation of tissue 
also resulted in a decrease of C-peptide in the culture supernatant when removed at regular 
intervals. This demonstrated a gradual failure of C-peptide/insulin secretion by cells in 
culture possible due to the environmental differences between in vitro and in vivo 
conditions. Several factors may be important for developing and maintaining islet -like cell 
buds in vitro. In the present study, culture medium was supplemented with foetal calf 
serum, which promoted cell attachment and outgrowths. However, it had been reported 
previously that serum suppresses islet buds in culture of adult pancreas tissue samples (Gao 
et al, 2003). Extracellular matrix components may also be important since Matrigel aided 
adult pancreatic cultures (Gao et al, 2003). 
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While immunostaining indicated that some cells that differentiated from hES cells 
into EBs under various growth factor conditions expressed C-peptide and were 13 cell-like it 
was unclear what quantity of C-peptide/insulin they might secrete. Hence by using the 
ELISA technique it was considered it might be possible to determine the amounts of C- 
peptide such differentiated cells secreted in comparison with equivalent amounts of fbetal 
pancreatic tissue in culture. However the amounts of C-peptide in supernatants of EBs were 
undetectable (not significantly different from zero control). 
In conclusion, it was possible to detect a proportion of cells exhibiting C-peptide/ 
insulin expression that differentiated from human EBs in culture, but in comparison to 
foetal tissue there was no indication of C-peptide in culture supernatant suggesting that 
hormone secretion was absent. On the other hand C-peptide levels in foetal tissue cultures 
generally increased with the gestational age of the sample. 
To ensure of the presence of some insulin like cells from the EBs cells, derived 
from hES cells, grown with different growth factors, endocrine gene expression by RT- 
PCR for some selected genes like Pdx-1, Ngn3, GK, Glut- I and 2 and insulin was applied. 
3. Pattern of mRNAs Expression Related to P-cell 
Development from hES Cells 
After differentiation of hES cells in culture it was important to show that these cells 
expressed genes that would be present in cells of the pancreatic cell lineage and B- cells 
including insulin, glucagon, somatostatin, pancreatic polypeptide, ghrelin, Pdx-1, Ngn-3, 
Nkx2.2 and Pax-4 (D'Amour et al, 2006). 
During human fbetal pancreas development, Pdx-I expression decreased slowly 
from the early development of pancreatic progenitors until they reached mature P-cells, 
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where the expression of this gene increased again (Broldn et al, 2005; D'Amour et al, 
2006). In the present study, after incubation of hES cells in culture for two weeks, Pdx-1 
and insulin genes were observed as concentrated sharp bands in almost all examined 
samples grown with different growth factors, especially nicotinamide and nicotinamide + 
FGF2, respectively. These results may indicate that all the growth factors selected in this 
study encouraged the EB cells toward insulin-containing cells. 
On the other hand, other genes like Ngn-3, Nkx6.1 and Pax-4 were also found to be 
expressed during early stages of the development of the pancreas as well as in the 
progenitor endocrine cells (D'Amour et al, 2006; Shiroi et al, 2005). However, as these 
genes expressed in the progenitor cells of the pancreas there were selected to be examined 
in the cultured EBs grown with different growth factors for 14 days in the present study. 
The expression of these genes in the cultured EBs confirms the pathway of differentiation 
of the hES cells from endocrine progenitor cells towards later mature P-cell-like cells. 
4. Protein Expression Patterns During Development of 
the Foetal Pancreas Between 10 and 12 weeks Gestation 
Protein analysis was applied in this study to compare human foetal pancreases at 
two different gestational ages, 10 and 12 weeks, where this may help in understanding the 
pancreatic development at the protein level. However, to date there is no similar work that 
uses proteomic profiles to explain the development of the pancreas. 
The development of proteomic technology gives the chance to express genetic 
variants at the protein level (Valmu et al, 2006). Recently, proteomic profiling by using 
serum markers was used to diagnose pancreatic cancer at early stage (Chen et at, 2007; 
Pappas et al, 2007). 
173 
Chapter VII General Discussion 
Quantitative protein analysis of some pancreatic proteins extracted from pancreatic 
cancer patients and normal control was detected (Chen et al, 2006). With proteomic 
technology used by Chen group for the diagnosis of early pancreatic cancer 116 
differentially expressed proteins were detected from human patients (Chen et al, 2007). 
Proteomic analysis was employed to identify cellular proteins that interact with the 
core protein of Hepatitis C virus (HCV) (Kang et al, 2005). Cytokeratin 8, cytokeratin 19 
and cytokeratin 18 were identified as intermediate microfilament proteins that involved in 
the infection processes of the HCV disease (Kang et al, 2005). 
In the present study, proteins which where expressed in 10 weeks fbetuses where 
more likely to be structural proteins, while the ones expressed in 12 weeks foetuses seems 
to be signalling proteins and this is may be due to the developmental and activity of the 
pancreas at late stages. 
However, it has been found that there were proteins which displayed expression in 
12 weeks foetuses, but not 10 weeks, and were found in adult pancreas as well (Ahmed et 
al, 2005). There were no pancreatic enzymes in the foetal pancreas and this is may be due 
to their relatively low concentration in week 10 and week 12 fbetal pancreas. 
By comparing foetal proteins with those of adult pancreas it has been indicated that 
most of the foetal pancreas proteins do not appear in the adult pancreas. Thus, most of 
foetal pancreas proteins are involved in the development of pancreas where in adult they 
more likely to be involved in the maintenance of pancreas function. 
By using a proteomics approach in the future it may be possible to identify proteins 
that can characterise each stage of pancreatic development. 
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The EB, a three dimensional structure, , has been used in many different studies to 
direct the differentiation of ES cells towards different lineages (Perkins et al, 1998; Soria et 
al, 2000; Assady et al, 2001; Lumelsky, 2001; Conley et al, 2004; Kim et al, 2007; Peiffer 
et al, 2007). In the EB colony, cells have the chance to communicate and react with each 
other as they do in vivo. 
Differentiation of ES cells by forming EB towards endothelial. cells was done by 
Kim group (Kim et al, 2007). The purpose of their study was to compare between 
endothelial cells isolated from the centre of the EB colony and the cells isolated from the 
outgrowth of the EB colony. They reached to the conclusion that cells which were isolated 
from the centre of the EB colony showed higher number of endothelial cells than the cells 
isolated from the outgrowth of the EB colony (Kim et al, 2007). 
Differentiation of the ES cells and human pancreatic P-cells towards different cell 
lineages has also been carried out by the formation of a monolayer differentiated cells 
(Schuldiner et al, 2000; Lachner et al, 2004; Kamer el al, 2007). However, in this case all 
the cultured cells have the chance to be exposed to the same amount of growth factor/s in 
use, C02 and light during their incubation period in culture. 
Using different growth factor/s may help in directing the differentiation of ES cells 
into a specific cell line (Schuldiner et al, 2000; Loebel et al, 2003; Cho et al, 2008). In 
addition, these growth factors can be used at different stages during the incubation of the 
cells in vitro (Hori et al, 2002; Bai et al, 2005; Beattie et al, 2005). For example, in the 
present study the growth factors were used from day one of the formation of EB colony and 
continued to the end of day 7 when media were changed to a normal EB medium (Chapter 
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11 section 1.2.3) for another 7 days. These growth factors can also be used after few days of 
the differentiation, the fonnation of EB colony (Houard et al, 2003; Segev et al, 2003). 
On the other hand, a selection/purification process by selecting specific cells from 
the cultured differentiated cells may generate a pure pool of one cell type of differentiated 
cells. Moreover, selected cells can then be encouraged, by using different growth factor/s, 
to keep their differentiation until they reach to the maturation step (Blyszczuk el al, 2003; 
Baharvand et al, 2006). 
In summary, the differentiation in vitro of human ES cells into insulin containing, P- 
cell-like has been successfully achieved. Moreover, the growth factors, nicotinamide FGF2 
and activin A were shown to significantly increase the proportion of such cells in culture. 
However, cultures displayed an absence of C-peptide in the supernatant, indicating that 
these P-like cells fail to secrete insulin. By comparison cultures of an equivalent numbers of 
cells from foetal pancreatic tissue exhibited detectable levels of C-peptide in culture 
supernatant at later gestational ages (week 10-12). Overall these findings suggest that P-like 
cells generated from hES cells are non-functional. Further studies are required to 
determined their precise phenotype and further optimize the culture conditions to generate 
true P-cells from hES cells. 
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Appendix 
Table 3 Mests between small and large EBs colonies for each growth factor of cells 
stained with Dithizone (DTZ). The tabulated t value of 2.45 (p = 0.05) rises 
to a tabulated value of 5.96 (p = 0.001). 
A. 
Nicotinamide Small colonies Large colonies 
Replicate 1 802(643204) 815 (664225) 
Replicate 2 483(233289) 1189(1413721) 
Replicate 3 450(202500) 620(384400) 
Replicate 4 600(360000) 800(640000) 
Sum of x 2335 3424 
n. (repeated times) 4 4 Total (= sum of 
the 4 replicate 
values) 
Mean Qotal/n) 583.75 856 
sum X2 (E X) 1438993 3102346 Sum of the squares 
of each replicate 
value 
(z X)r- 5452225 11723776 Square of the total 
(E X)* 
1363056.25 2930944 
Ed 2 4089168.75 171402 I: d2 =1 jr2 - 
2 1363056.25 57134 Cr 
2= Ed 2 /n 1 
22 
02 
340764.062 + 14283.5 355047.562 CFd 
2iS 
the variance 
eyd ! 
n: + of the difference 
nj 112 between the means 
(yd 595.859 -": 
4 
Cyd 
2 (the 
standard deviation 
of the difference 
between the 
1 means) 
xl-x2 -0.457 ,. 
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B. 
Nicotinamide + Small colonies Large colonies 
Activin A 
Replicate 1 (176400)420 1090(1188100) 
Replicate 2 901 (811801) 1110(1232100) 
Replicate 3 660(435600) 998(996004) 
Replicate 4 615(378225) 1345(1809025) 
Sum of x 2596 4543 
n (repeated times) 4 4 Total (= sum of the 
4 replicate values) 
Mean (totaUn 649 1135.75 
Sum X, (1: X') 1802026 25864078 Sum of the squares 
of each replicate 
value 
(z X), 6739216 20638849 Square of the total 
(E X). 
1684804 5159712.25 
Ed 2 117222 20704365.8 Xd2 xl:. t2 
CY 
2 39074 6901455.27 a2= Ed 2/ nI 
712 02 
2 63.82 1735132.32 9768.5 + 17253 ad 2iS the v anance 
+ 2 of the difference 
nj n2 between the means 
ad 1317.244 : -- 
ý ad 2 (the 
standard deviation 
of the difference 
between the 
means) 
xl-X2 -1.478 I. 
tv 
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C. 
Nicotinamide + Small colonies Large colonies 
FGF2 
Replicate 1 1200(1440000) 1010(1020100) 
Replicate 2 (986049)993 1500(2250000) 
Replicate 3 805(648025) 1583(2505889) 
Replicate 4 1150(1322500) 1594(2540836) 
Sum of x 4148 5687 
n (repeated times) 4 4 Total (= sum of the 
_4 
replicate values) 
Mean (total/n) 1037 1421.75 
SUM x2 (Z X2) 4396574 8316825 Sum of the squares 
of each replicate 
value 
(E X)2 17205904 32341969 Square of the total 
(E X). 
4301476 8085492.25 
Ed 2 95098 231332.75 
Jd2 =I: X2 - 
(I xý 
Cr 
2 31699.33 77110.92 Cr 
2= Ed 2/ nI 
022 2 n2 
7924.83 + 19277.73 27202.56 2is ad the variance 
+ , 7d of the difference nj n2 between the means 
CFd 164.93 =q Cyd 2 (the 
standard deviation 
of the difference 
between the 
means) 
l=xl-x2 -2.333 
I 
&V . 
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D. 
Activin A+ FGF2 Small colonies Large colonies 
Replicate 1 220(48400) 580 (3.36400) 
Replicate 2 435(189225) 510(260100) 
Replicate 3 210(44100) 910(828100) 
Replicate 4 108(11664) 352(123904) 
Sum of x 973 2352 
n (repeated times) 4 4 Total (-- sum of the 
4 replicate values) 
Mean (totajUn 243.25 588 
SUM X2 (y X2) 293389 1548504 Sum of the squares 
of each replicate 
value 
(E XY 946729 5531904 Square of the total 
(1: X). 
236682.25 1382976 
Ed 2 -56706.75 165528 Id2 zj X2 - 
(Z xý 
P2 
2 
Cr 18902.25 55176 
1 
2/ 
cr2=Ed n-I 
22 
02 971 
4725.563 + 1382976 1387701.56 crd2 is the variance 
+ i7d 
2 of the difference 
nj n2 between the means 
CFd 1178.01 =q (Td 
2 (the 
standard deviation 
of the difference 
between the 
means) 
xl-x2 -1.1 ,. 
tv f 
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E. 
Activin A Small colonies Large colonies 
Replicate 1 19(361) (1444)38 
Replicate 2 10(100) 66(4356) 
Replicate 3 24 (576) 7(49) 
Replicate 4 13 (169)_ 19(361) 
Sum of x 1206 130 
n (repeated times) 4 4 Total (= sum of the 
4 replicate values) 
Mean ýtotal/n) 301.5 32.5 
SUM X2 (E X2) 1206 6210 Sum of the squares 
of each replicate 
value 
(z X), 1454436 16900 Square of the total 
(z X). 
363609 4225 
Ed 2 -362403 1985 Ed 21 x2 - 
(1: xý 
n 
CY 
2 
-120801 661.67 cr 
2= Zd2/ n-I 
02 
2 
e7l 
2 -30200.25 + 165.417 -30034.833 Cyd 
2is the variance 
+ 2 c7d of the difference 
nj n2 between the means 
Crd 173.31 =q CFd 2 (the 
standard deviation 
of the difference 
between the 
means) 
xl-x2 1.55 
&V - 
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F. 
Control Small colonies Large colonies 
Replicate 1 2(4) 9(81) 
Replicate 2 0 6(36) 
Replicate 3 0 2(4) 
Replicate 4 4(16) 0 
Sum of x 6 17 
n (repeated times) 4 4 Total (= sum of the 
4 replicate values) 
Mean (total/n) 1.5 4.25 
Sum X2 (F. X') 20 121 Sum of the squares 
of each replicate 
value 
(z X), 36 289 Square of the total 
(E X). 
9 72.25 
Ed 2 4 48.75 
Zd2 2Z ý2 
CY 2 1.33 16.25 Cr 2= Ed 2/ n-I 
02 
2 971 2 0.333 + 4.063 4.396 Cyd 
2iS 
the variance 
+ 2- t7d of the difference 
nj n2 between the means 
Cyd 2.097 =4 Cyd 2 (the 
standard deviation 
of the difference 
between the 
1 means) 
,. x1-x2 -1. 
31 
4V 
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Table 
Based on observed means. 
The mean difference is significant at the . 05 level. 
95% Confidence 
Interval 
Mean 
Difference (I- Std. Upper Lower 
(1) Growth Factor (J) Growth Factor J) Error Sig. Bound Bound 
Tukey Nicotinamide Nicotinamide+Activin -3.8750 2.10489 . 454 -10.2077 2.4577 HSD A 
Nicotinamide + 
-12.8750(*) 2.10489 . 000 -19.2077 -6.5423 FGF2 
Activin A +FGF2 8.5000(*) 2.10489 . 003 2.1673 14.8327 
Activin A 17.6250(*) 2.10489 . 000 11.2923 23.9577 
control 18.1250(*) 2.10489 . 000 11.7923 24.4577 
Nicotinamide+Activin Nicotinamide 3.8750 2.10489 . 454 -2.4577 10.2077 A Nicotinamide + 
-9.0000(*) 2.10489 . 002 . 15.3327 -2.6673 FGF2 
Activin A +FGF2 12.3750(*) 2.10489 . 000 6.0423 18.7077 
Activin A 21.5000(*) 2.10489 . 000 15.1673 27.8327 
control 22.0000(*) 2.10489 . 000 15.6673 28.3327 
Nicotinamide + Nicotinamide 12.8750(*) 2.1 D489 . 000 6.5423 19.2077 FGF2 Nicotinamide+Activin 9.0000(*) 2.10489 . 002 2.6673 15.3327 A 
Activin A +FGF2 21.3750(*) 2.10489 . 000 15.0423 27.7077 
Activin A 30.5000(*) 2.10489 . 000 24.1673 36.8327 
control 31.0000(*) 2.10489 . 000 24.6673 37.3327 
Activin A +FGF2 Nicotinamide -8.5000(*) 2.10489 . 003 -14.8327 -2.1673 
Nicotinamide+Activin 
-12.3750(*) 2.10489 . 000 . 18.7077 -6.0423 A 
Nicotinamide + 
-21.3750(*) 2.10489 . 000 -27.7077 -15.0423 FGF2 
Activin A 9.1250(*) 2.10489 . 001 2.7923 15.4577 
control 9.6250(*) 2.10489 . 001 3.2923 15.9577 
Activin A Nicotinamide -17.6250(*) 2.10489 . 000 -23.9577 -11.2923 
Nicotinamide+Activin 
-21.5000(*) 2.10489 . 000 -27.8327 -15.1673 A 
Nicotinamide + 
-30.5000(*) 2.10489 . 000 -36.8327 -24.1673 FGF2 
Activin A +FGF2 -9.1250(*) 2.10489 . 001 -15.4577 -2.7923 
control . 5000 2.10489 1.000 -5.8327 6.8327 
control Nicotinamide -18.1250(*) 2.10489 . 000 -24.4577 -11.7923 
Nicotinamide+Activin 
-22.0000(*) 2.10489 . 000 -28.3327 -15.6673 A 
Nicotinamide + 
-31.0000(*) 2.10489 . 000 -37.3327 -24.6673 FGF2 
Activin A +FGF2 -9.6250(*) 2.10489 . 001 -15.9577 -3.2923 
Activin A -. 5000 2.10489 1.000 -6.8327 5.8327 
Games- Nicotinamide Nicotinamide+Activin -3.8750 2.37876 . 595 -11.6797 3.9297 Howell A 
Nicotinamide + 
-12.8750(*) 2.56653 . 002 -21.3329 -4.4171 FGF2 
Activin A +FGF2 8.5000(*) 2.40071 . 031 . 6211 16.3789 
Activin A 17.6250(*) 1.65224 . 000 11.4110 23.8390 
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control 18.1250(*) 1.64140 . 000 11.9050 24.3450 
Nicotinamide+Activin Nicotinamide 3.8750 2.37876 . 595 -3.9297 11.6797 A Nicotinamide + 
-9.0000(*) 2.61861 . 038 -17.6114 -. 3886 FGF2 
Activin A +FGF2 12.3750(*) 2.45631 . 002 4.3181 20.4319 
Activin A 21.5000(*) 1.73205 . 000 14.9815 28.0185 
control 22.0000(*) 1.72171 . 000 15.4757 28.5243 
Nicotinamide + Nicotinamide 12.8750(*) 2.56653 . 002 4.4171 21.3329 FGF2 Nicotinamide+Activin 9.0000(*) 2.61861 . 038 . 3886 17.6114 A 
Activin A +FGF2 21.3750(*) 2.63857 . 000 12.7034 30.0466 
Activin A 30.5000(*) 1.98206 . 
000 23.0286 37.9714 
control 31.0000(*) 1.97303 . 000 23.5233 38.4767 
Activin A +FGF2 Nicotinamide -8.5000(*) 2.40071 . 
031 -16.3789 -. 6211 
Nicotinamide+Activin 
-12.3750(*) 2.45631 . 002 -20.4319 -4.3181 A 
Nicotinamide + 
-21.3750(*) 2.63857 . 000 -30.0466 -12.7034 FGF2 
Activin A 9.1250(*) 1.76208 . 010 2.4920 15.7580 
control 9.6250(*) 1.75191 . 007 2.9862 16.2638 
Activin A Nicotinamide -17.6250(*) 1.65224 . 000 -23.8390 -11.4110 Nicotinamide+Activin 
-21.5000(*) 1.73205 . 000 -28.0185 -14.9815 A 
Nicotinamide + 
-30.5000(*) 1.98206 . 
000 -37.9714 -23.0286 FGF2 
Activin A +FGF2 -9.1250(*) 1.76208 . 010 -15.7580 -2.4920 
control . 
5000 . 18898 . 
202 -. 2161 1.2161 
control Nicotinamide -18.1250(*) 1.64140 . 000 -24.3450 -11.9050 
Nicotinamide+Activin 
-22.0000(*) 1.72171 . 000 -28.5243 -15.4757 A 
Nicotinamide + 
-31.0000(*) 1.97303 . 000 -38.4767 -23.5233 FGF2 
Activin A +FGF2 -9.6250(*) 1.75191 . 007 -16.2638 -2.9862 
Activin A -. 5000 . 18898 . 202 -1.2161 . 2161 
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